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Cardiac and orthopaedic diseases are significant causes of morbidity and mortality in 
dogs and are therefore critical areas for veterinary research. More information regarding 
the pathophysiology of these diseases, and the developm nt of novel therapeutics are 
sorely required and adult stem cells (ASCs) are a promising source of cells for both 
investigation of these diseases in vitro and also potentially therapeutics in the longer 
term.  
ASCs are a readily available source of multipotent cells which bypass the ethical issues 
surrounding embryonic stem (ES) cells. ASCs have been described in several tissues of 
the body, and typically differentiate along specific cellular routes related to original 
source location. This thesis investigates whether ASCs can be isolated and cultured from 
the dog from two specific locations; cardiac, producing cardiac stem cells (CSCs); and 
the bone marrow, producing mesenchymal stem cells (MSCs). These cell sources will be 
extensively characterised at their baseline for morph logy, culture behaviour and gene 
marker expression. Following characterisation each cell source will be subjected to 
differentiation techniques to examine canine ASC multipotent differentiation potential.   
CSCs were isolated from cultured atrial cardiac explant tissue taken from dogs 
post-mortem, with owners’ consent. These cells were able to survive successive passages 
in serum free media and formed large spherical cell clusters, termed ‘cardiospheres’. 
CSCs were capable of clonal expansion under controlled culture conditions, 
demonstrating their ability for self-renewal. Characterisation of these cells demonstrated 
the expression of CSC markers; c-Kit, GATA 4 and Flk-1 and no expression of cardiac 
lineage markers including cardiac troponin T and I, Nkx2.5, the cardiac ryanodine 
receptor and the β1-adrenergic receptor. 
Primary canine MSCs were isolated from bone marrow aspirates using ficoll separation 
and cultured on tissue culture plastic. Canine MSCs clo ely resembled MSCs described 
from other species, such as the human and mouse, and were found to express CD44 and 
STRO-1 and were negative for CD34 and CD45.  
CSCs and MSCs were exposed to published cardiac dire ted differentiation protocols 
and differentiation then analysed using cellular moph logy and gene expression. Canine 
 iv 
CSCs appeared to differentiate partially along cardiac lineages with upregulation of 
cardiac troponin T and Nkx2.5, and down regulation of c-Kit and endothelial lineage 
markers. Canine MSCs demonstrated some morphologica ch nges during cardiac 
differentiation, and demonstrated up-regulation of Nkx2.5 and Flk-1 but no significant 
alteration in other markers examined. This suggested that cardiac directed differentiation 
was not as successful with canine MSCs compared to CSCs and conflicting with 
published data using rodent MSC models.  
Murine MSCs were used as a positive control cell line for cardiac directed 
differentiation, based upon published literature. Critically there were key marker 
expression differences between baseline murine and canine MSCs, including the 
expression of cardiac markers such as cardiac troponin T and I, and the Ryanodine 
receptor.  Furthermore, expression analysis of cardiac genes changed with time in 
culture and passage number and no significant alteration was seen when cells were 
subjected to the cardiac differentiation protocol; thereby bringing into question the data 
regarding successful cardiac differentiation using murine MSCs. 
Canine MSCs were further differentiated toward a chondrocyte lineage to investigate the 
use of MSCs for orthopaedic research. Canine MSCs were successfully differentiated 
toward articular type cartilage, with demonstration of extracellular matrix secretions, an 
upregulation of collagen type II with downregulation of collagen type I and the 
development of SOX9 expression in differentiated cells.  
This thesis builds the groundwork for future ASC research in the dog.  Successful 
isolation and culture of two ASC sources from the dog is demonstrated. Cardiac and 
cartilage directed differentiation was successful using primary sourced cells, but 
differentiation was found to be limited to highly specific routes for each stem cell 
source. The results presented here highlight the importance of analysing baseline stem 
cells extensively prior to differentiation and in particular, before making comparisons 
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Generall  Introductii on  
 
1.1 Stem Cells 
 
Stem cells are defined by having two characteristic properties: the ability for self-
renewal, giving rise to more stem cells and the ability to differentiate into cell lineages 
from all three germ layers of the embryo under appro riate conditions (the endoderm, 
mesoderm and ectoderm) (Bajada et al., 2008).  This differentiation has led to the cells 
being termed pluripotent - with the ability to divide into all cell types, or termed 
multipotent - with the ability to differentiate into multiple cell types of a limited number. 
 
Stem cells are tightly controlled by a combination of intrinsic (intracellular) programs, 
and extracellular, micro-environmental signals. Recent work utilising techniques such as 
micro-patterning and cellular microarray have greatly increased known information of 
these cellular control systems. For instance, pluriotency is tightly controlled by the 
expression of genes such as Oct 4, Nanog and SOX2. Alongside this, the local 
environment to the stem cell, often termed the ‘niche’ has a large impact on the 
differentiation of the cell   (Underhill and Bhatia, 2007). 
 
 2 
Stem cells hold great promise for the field of regenerative medicine and tissue 
engineering, however currently there are very few true clinical applications, largely due 
to difficulties in optimising cell culture, and targeting cultured cells to specific tissue 
sites in vivo.  
 
Ultimately the study of stem cell differentiation ad the production of viable new tissue 
specific cells would enable the treatment of many diseases, such as neurological 
disorders, diabetes mellitus, orthopaedic disease and c rdiac disease. 
 
1.1.1 Defining Stem Cells  
 
Stem cells have been defined as cells which are capable of self-renewal, and which have 
the ability to differentiate into multiple cell lineages. Stem cell marker profiles 
examining gene expression have been used to try to define stem cells in vitro. This 
technique has also proven useful in determining what st ge of differentiation the cell 
may have reached. Cellular morphology, such as ability to form spheres, and behaviour 
in culture, including clonal expansion have also been used in combination with marker 
expression panels to attempt to define stem cells. However, this is a developing and 
challenging area; defining the marker or groups of markers which can be reliably used to 
define a cell as a stem cell is still being investigated. This is made more complicated by 
the possibility of interspecies differences and differences between different stem cell 
populations and stages of differentiation. 
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There are three key types of stem cells described; embryonic, adult and induced 
pluripotent stem cells. These differ in both origin a d differentiation potential, but all 
have the possibility for usage in the future of regenerative medicine. 
 
1.2 Stem Cell Classifications 
 
1.2.1 Embryonic Stem Cells  
 
In the 1970s embryos of normal mice, transplanted to an extra-uterine site, were found 
to form teratocarcinomas (Stevens, 1970). Cell lines d rived from these tumours were 
termed embryonal carcinoma cell (ECC) lines, and were found to have morphological, 
biochemical and immunological properties in common with pluripotent embryonic cells. 
The behaviour of these cells closely resembled the behaviour of cells taken from the 
inner cell mass of the embryonic blastocyst (Martin et al., 1977). ECC lines were also 
able to participate in the development of normal adult mice, forming chimeras when 
injected into blastocysts (Martin, 1981).  
 
Evans and Kaufman took blastocysts from 129SvE mice, and cultured them in groups of 
6 within small drops of tissue culture medium under pa affin oil. Over 48 hours the 
blastocysts attached to the tissue culture plastic petri dishes and trophoectoderm grew 
out and differentiated into giant trophoblast cells. The inner cell mass subsequently 
grew, surrounded by endoderm, and was selectively picked and cultured. Actively 
proliferating colonies which resembled the ECC cells were picked out and passaged. 
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These cells grew rapidly in culture, supplemented with leukaemia inhibitory factor (LIF) 
and/or on feeder cell layers of mitotically inactive mouse embryonic fibroblasts (MEFs) 
and were maintained for over 30 passages in vitro (Evans and Kaufman, 1981). These 
were what would classically come to be defined as embryonic stem cells (ES cells). 
Desbaillets et al took this work further, and found that single undifferentiated ES cells 
separated into corresponding cell lineages dependent upon culture techniques: Single 
cells grown on methylcellulose semisolid medium (MC) became erythroid, lymphoid, 
myeloid and endothelial cell lineages; ES cells grown on non-adhesive tissue culture 
plates in standard culture medium became erythroid, en othelial, neuronal and glial cell 
lineages; and hanging drops of 400-600 cells suspended on petri dish lids for two days, 
and subsequently transferred into suspension became lymphoid progenitors, 
spontaneously contracting cardiomyocytes, skeletal myocytes, vascular smooth muscle 






Figure 1.1. Generation of multiple cell lineages from ES cells using alternative culture 
techniques. Undifferentiated ES cells are disassociated into single cells and plated using 
three different methods, creating the initiation for differentiation into the three germ cell 
lineages. Adapted from (Desbaillets et al., 2000). 
 
In 1998 Thomson et al described ES cells derived from human blastocysts, (human 
embryonic stem cells, hES cells) (Thomson et al., 1998). This work followed more than 
a decade of research in murine ES (mES) cells, and posed the opportunity to study 
developmental events which could not be studied in the intact human embryo, including 
comparisons of development and function of tissues between mice and humans. Initially 
culture of hES cells required a MEF feeder layer. Over the subsequent years more 
advanced systems of culturing hES cells were found, which did not need the MEF feeder 
layers which were a potential source of cell contamin tion. Instead the cells were grown 
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in medium with and without serum replacement, plus a combination of growth factors 
such as LIF, Transforming growth factor β1 (TGFβ1), basic fibroblast growth factor 
(bFGF) and fibronectin matrix. The hES cells in this system still maintained their ES cell 
properties of self-replication and pluripotency (Richards et al., 2002, Amit et al., 2004, 
Bajada et al., 2008). 
 
Crucially, mES and hES cells are initially derived in different ways; mES cells are 
derived from culture of the inner cell mass from pre-implantation embryos. They express 
genes characteristic of the early blastocyst including Oct 4, SOX2 and stem cell surface 
markers SSEA 1 and SSEA 3, and can be grown on both a feeder layer, or without a 
feeder layer in the presence of LIF, removal of which promotes differentiation (Ginis et 
al., 2004). Interestingly, mES cells cannot differentiate into trophectoderm (Edwards, 
2002). mES cells retain high telomerase levels, show karyotypic stability,  and retain the 
ability to contribute to chimeras and teratomas after repeated passage (Burdon et al., 
2002).  
 
In contrast hES cells are derived from the inner cell mass of the post-implantation 
embryo (Thomson et al., 1998). These ES cells have many similarities to their mouse 
counterparts; they express stem cell surface markers SSEA 3 and the pluripotency gene 
Oct 4, as well as SSEA 4 (Mummery et al., 2003, Ginis et al., 2004). Interestingly, hES 
cells must be cultured in the absence of serum, which would otherwise promote 
differentiation (Thomson et al., 1998) and unlike mES cells these cells also have the 
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ability to differentiate into trophoblast-like cells and do not require the presence of LIF 
(Niwa et al., 2000, Schneider et al., 2010). 
 
To date more than 400 human cell lines have been derive , giving great opportunity to 
gain access to hES cells (Beqqali et al., 2009). An international study characterised and 
compared 59 hES cell lines and found that they all h d a similar expression pattern for 
several hES cell markers including SSEA 3 and 4, Oct 4 and Nanog, despite their 
different genetic background and derivation technique. However the cell lines were not 
identical; different expression levels in lineage markers were seen, and some gene-
dependent variation was seen for imprinted genes (Adewumi et al., 2007). ES cells have 
been predominantly isolated from the human and mouse, however they have also been 
isolated from different species such as dogs (discussed later), and rabbits, rats and 
monkeys (Thomson et al., 1995, Wang et al., 2007, Buehr et al., 2008, Li et al., 2008). 
 
1.2.2 Adult Stem Cells 
 
Although ES cells were the first truly pluripotent s em cells to be identified and 
characterised, it was hypothesised that a mechanism existed whereby organs could repair 
and replenish cells as they died. The hypothesis wa confirmed when it was 
subsequently demonstrated that many developed tissues possessed a reservoir of somatic 
stem cells, which still retained some of the characteristics of their ES cell predecessors, 
including the capacity to self-renew but had a more limited differentiation capacity, 
termed multipotent (Fuchs et al., 2004, Beltrami et al., 2007). 
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Non-embryonic stem cells are lower in the stem cell hierarchy. Their multipotent 
function allows them to differentiate into a limited number of cell types generally 
common to the tissue of origin and generally assigned to one of the three germ cell 
layers of the embryo (Bajada et al., 2008). Many tissues within the body have been 
found to contain adult stem cells (ASCs), including liver, bone marrow, brain and heart 
(Beltrami et al., 2007).  
 
Cells with a multipotent differentiation potential taken from adult tissue were first 
studied by Becker in the 1960s; irradiated mice were injected with bone marrow cells 
and the subsequent colonies that formed in the spleen counted. This work suggested that 
the cell colonies formed were in proportion to the number of cells injected, and that each 
colony was derived from a single cell (Becker et al., 1963). Following this the first 
successful bone marrow transplant was performed between a patient suffering acute 
lymphoblastic leukaemia, and 6 of his immediate relatives, creating a patient with an 
haematopoietic chimera (Mathe et al., 1963). ASCs were subsequently formally 
described in the 1970s, where multiple cells from within the haematopoietic 
compartment were found to have derived from a common precursor – a stem cell 
(Fialkow, 1973). Bone marrow derived stem cells arenow split into two classes, 
haematopoietic as previously discussed and mesenchymal, found to differentiate into 
multiple connective tissue types (Owen, 1988). 
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1.2.3 Induced Pluripotent Stem Cells 
 
Due to the therapeutic and ethical issues surrounding ES cells (discussed in ES cells for 
Therapeutics), a viable alternative has been sought. In 2006 Takahashi and Yamanaka  
described a method whereby differentiated cells could be re-programmed to an 
embryonic-like state by insertion of 4 factors; Oct 4, SOX2, c-Myc and KLF4 and 
termed them induced pluripotent stem (iPS) cells (Takahashi and Yamanaka, 2006). The 
factors were inserted into both mES cells and adult mouse fibroblasts using a retroviral 
vector which subsequently over expressed the inserted factors. The following year, the 
same group described the successful production of iPS cells generated using human 
fibroblasts (Takahashi et al., 2007). iPS cells are crucial advancement in the 
development of patient specific stem cells important for both  individual cellular 
therapeutics and the study of patient specific diseases in vitro. iPS cells were optimised 
in further studies, proving that DNA methylation, gene expression and chromatin state 
of the iPS cells were similar to that of ES cells (Wernig et al., 2007), and were also able 
to produce functional germline chimeras (Okita et al., 2007). However, insertion of the 
oncogene c-Myc increased tumorogenicity in the chimera and progeny mice and was 
therefore not an ideal factor in the iPS induction system; therefore in 2008 Nakagawa et 
al, devised a method to produce functional iPS cells without c-Myc, and found that 
chimeric mice derived from the c-Myc negative iPS cells did not develop tumours 
during the period of the study (Nakagawa et al., 2008). 
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Another concern with the generation of iPS cells habeen the use of retroviral vectors, 
which renders the cells unusable in a therapeutic se ting.  In 2009 two new techniques 
were described. Firstly, a piggyBac technique, which enables insertion of the four 
original factors into both mouse and human embryonic a d adult fibroblasts, generating 
iPS cells. The genes required for iPS transition are inserted into a transposon (a section 
of DNA which moves as a block within the genome) named piggyback; first discovered 
in moths and butterflies, this transposon has an innate ability of reliably and efficiently 
inserting itself into the genomes of mice and humans (Kaji et al., 2009, Woltjen et al., 
2009). Secondly, the insertion of the 4 factors using Sendai Virus, an RNA virus which 
effectively produced iPS cells which could then be further selected against to remove 
virus carrying cells using simple antibody-mediated negative selection (Fusaki et al., 
2009). 
 
1.3 Stem Cell Niche 
 
Stem cells are thought to reside within a ‘niche’; a biological microenvironment, specific 
to the cell, helping to promote and maintain the stm cells’ innate characteristics 
(Urbanek et al., 2006). This environment provides the necessary signals required to drive 
appropriate cell differentiation. In ES cells, the niche is well defined, being part of the 
embryo itself. However, since the discovery of adult stem cells within various tissues 
different tissue specific niches have been described.  When attempting to culture adult 
stem cells, trying to mimic the specific cell’s niche as closely as possible will promote 
cell self-renewal, and limit differentiation. Niches xist to protect the stem cells, and not 
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only include the stem cells, but a host of differentiated cell types which secrete a rich 
mix of extracellular matrices and other factors. There is considerable variation within 
different stem cell niches: for instance muscle stem c lls (satellite cells) exist in relative 
isolation on the basal lamina of the muscle fibre bundle, and only become active when 
myofibres are damaged, whereas intestinal stem cells reside at the base of the intestinal 
crypts and are constantly active, producing replacement paneth cells, goblet cells, 
absorptive villus cells and extraendocrine cells (Fuchs et al., 2004). 
 
1.4 Stem Cells and Disease 
 
The development of stem cells has provided new opportunities for the study of the 
pathophysiology of disease and introduced the prospect of using stem cells for 
regenerative medicine, tissue engineering and therapeutics. This is a developing field 
and much research is still ongoing to optimise these uses.   
 
1.4.1 Embryonic Stem Cells in Therapeutics  
 
Using ES cells in therapeutics is potentially fraught with problems. Teratoma formation 
was described very early in the literature, and dueto the innate ability of ES cells to 
differentiate into all three germ layers of the body (i.e. any tissue within the body), strict 
methods of controlling differentiation in vivo are crucial before they can be used 
successfully (Martin, 1981, Barile et al., 2007). 
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The potential use of ES cells within treatment regimes requires large scale production of 
a homogeneous population of differentiated cells. A previously discussed, currently  
> 400 hES cells have been derived worldwide (Beqqali et al., 2009). Although the 
significant majority of the cell lines are similar, some important differences have been 
demonstrated (Adewumi et al., 2007). Directed differentiation of ES cells to a specific 
lineage creates a mixed population of cells, each at their independent level of 
differentiation. Ultimately, differentiated cells derived from an ES cell source must be a 
homogeneous population prior to any form of transplantation to limit the significant risk 
of teratoma formation (Odorico et al., 2001, Laflamme et al., 2007, Beqqali et al., 2009).  
 
Ethically, the use of ES cells has been questioned. To obtain ES cells, they must be 
harvested from a fertilised embryo. In all species, but most importantly in the hES cell 
lines, the ethics of this has been questioned, as these fertilised embryos would have the 
potential of forming a living creature (Bajada et al., 2008). Debate will continue to 
surround this sensitive subject, with the moral statu  of the embryo (Towns and Jones, 
2004) and the potential use of saviour siblings as a source of higher matched ES cells 
(Spriggs and Savulescu, 2002) fuelling the arguments for and against.  
 
Finally, implanting differentiated ES cells for specific treatment into a host would cause 
an immunological reaction akin to that found in transplant patients. Recipients of the ES 
cells would require immunosuppressive therapy to all w a more successful outcome of 
the implant, which in itself makes the treatment protocol more hazardous (Swijnenburg 
et al., 2005). 
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1.4.2 Adult Stem Cells in Therapeutics  
 
ASCs have been described in multiple organs within t e body (Beltrami et al., 2007). It 
is unknown if these cells are stem cells left over from embryonic development or 
whether they are a separate cell type. They have multipotent differentiation potential, 
usually toward cell types found at their tissue of origin. These cells are not capable of 
teratoma formation, and there are no ethical objections to their use as their origin is from 
fully developed animals, without the requirement for destruction to obtain tissue. 
However, one limitation in the use of ASCs is that the isolation of this cell population 
generally requires surgical procedures and cells are often obtained in small numbers. 
These cells may hold the most realistic potential for therapeutic use, as they can be used 
autologously and can be given with patient consent but scalability will need to be 
addressed. The discussion of individual ASC populations can be found in Chapters 4 to 
7.  
 
1.4.3 Induced Pluripotent Stem Cells in Therapeutics  
 
iPS cells are capable of pluripotent differentiation (Hu et al., 2010) and circumvent some 
of the key issues relating to ES cells. Derived from adult somatic cells, these cells do not 
have the same ethical concerns surrounding usage of embryonic tissue. Furthermore, the 
ability to derive truly autologous stem cells should limit the patient’s immunological 
reaction should these cells be transplanted back into the original donor. However, given 
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that these cells are otherwise essentially similar to ES cells, they still have the ability to 
form teratomas. Furthermore, c-Myc is a known oncogene and therefore use of any 
transformed cells carrying this gene would be impossible. However, it is hoped that 
patient specific iPS cells will allow the study of disease in vitro more readily.  
 
1.5 The Canine Perspective 
 
The pet dog contributes to a significant amount of cases seen in small animal veterinary 
practice. The use of dogs as a subject allows us to study canine specific diseases more 
closely, advancing the understanding of the biology f veterinary disease. Furthermore, 
canine research may contribute to the development of ovel therapeutics which could 
improve treatment regimes for other veterinary species. The dog is not only a patient in 
its own right, but also inadvertently an ideal model for the study of human diseases. 
Large animal models of disease are a requirement for any translation of basic science 
into therapeutics and practice (Dixon and Spinale, 2009). Many diseases are known to 
affect both species, and in the western world the dog and human are exposed to many 
similar environmental factors of disease. The dog is a larger species than many 
commonly used rodent models, and also has greater longevity thereby allowing for age 
influence. Furthermore the pedigree dog is a relatively inbred model allowing for genetic 
influences on disease to be studied. Isolating stem c ll populations from the dog will 
allow for in vitro disease modeling and may also act as an animal sparing process in 
drug discovery. The dog has been the prevalent species in transplantation research and is 
therefore known to be an essential model for human tr slation (Kirk, 2003). Dog 
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lifespan allows for longer term follow up on both cellular transplantation and gene 
therapy, and similarities can be seen in the molecular and physiological basis of disease, 
including cancer (Schneider et al., 2010). 
 
1.5.1 Canine Embryonic Stem Cells 
 
Canine ES (cES) cells were first developed by Hatoya et al in 2006 and demonstrate 
some similarities with hES cells (Table 1.1). Pre-implantation embryos were collected 
from Beagle bitches at day 11-16 of first oestrus. Inner cell masses were removed from 
blastocysts and cultured on MEFs in the presence of LIF whereby they formed colonies. 
Both enzymatic and mechanical dissociation of the inner cell mass was performed; 
enzymatic dissociation resulted in immediate differentiation, however mechanical 
dissociation created two ES-like cell lines which survived 8 passages, had stem cell 
morphology and expressed stem cell markers such as SSEA 1, Alkaline Phosphatase and 
Oct 4 and were negative for SSEA 4. The cES cells could be cultured in embryoid 
bodies which differentiated into several cell types including neuron-like, fibroblast-like, 
melanocyte-like, and myocardium-like cells (Hatoya et al., 2006). Following this cES 
cells were derived from a Golden Retriever bitch, grown on MEFs and were found to 
express stem cell markers SSEA 1, Alkaline Phosphatase, Oct 4, Nanog and SOX2, and 
were again negative for SSEA 4. The cES cell line derived was maintained for 10-12 
passages, but continuous passages were increasingly d fficult.  Co-culture of these cells 
with murine bone marrow cells created a population of CD34 and GATA 2 positive 
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cells, indicating differentiation toward the haematopoietic lineage (Schneider et al., 
2007, Schneider et al., 2008).  
 
Hayes et al generated several blastocyst-derived cell lines, of which one, FHDO-7 could 
be maintained for 34 passages and expressed Oct 4, Nanog, Alkaline Phosphatase and 
telomerase, and a cluster of microRNAs found in human and mouse ES cells. FHDO-7 
cells grew on MEFs in the presence of LIF and could form embryoid bodies which gave 
rise to ectoderm, mesoderm and endoderm derived cells (Hayes et al., 2008). All cES 
cell lines up to this point were unable to differentiate in vivo and therefore unable to 
form teratomas in immunodeficient mice. In 2009 a fourth group derived cES cells from 
pre-implantation embryos and found that days 12-14 post luteinising hormone (LH) 
surge was the optimum time for embryo collection which concurred with the previous 
studies consistently stating that late stage, or ‘hatc ed’ blastocysts from days 13-14 post 
LH surge are most efficient. These cES cells were grown on MEFs in the presence of 
both LIF and human bFGF. Oct 4, Nanog, SOX2 and SSEA 3 and 4 were all expressed, 
with SSEA 1 found at very low levels. These cells could be maintained for 30 passages 
and were capable of forming embryoid bodies which could subsequently be 
differentiated into cell lines from all three germ layers. Crucially, it was found that these 
cES cells could form teratomas in NOD/SKID mice (Vaags et al., 2009). Most recently 
canine ES cells have been found capable of synaptically- ompetent neuronal 
differentiation, giving an indication of their specifi  differentiation potential (Wilcox et 





Table 1.1. Comparison of ES cell characteristics betwe n species. 
Marker Mouse ES Cell Human ES Cell Dog ES Cell 
SSEA 1 + - +/- 
SSEA 3 +/- + + 
SSEA 4 - + +/- 
TRA-1-60 - + + 
TRA-1-81 - + + 
Alkaline Phosphatase + + + 
Oct 4 + + + 
Feeder cell required Yes Yes Yes 
LIF required Yes No Yes 
Embryoid bodies in vitro Yes Yes Yes 
Teratomas in vivo Yes Yes Yes/No 
Adapted from (Schneider et al., 2010) 
 
cES cells can only be derived from  ex vivo collection of embryos; in vitro production is 
rendered technically difficult due to the canine specific pre-ovulatory increase in 
progesterone and ovulation of immature oocytes, therefore creating a large obstacle for 
the development of an i vitro fertilization and maturation system (Songsasen and Wil t, 
2007, Schneider et al., 2008). 
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1.5.2 Canine Adult Stem Cells 
 
Different ASC sources have been described in the dog. Mesenchymal stem cells (MSCs) 
predominate in the literature however follicular stem cells have also been described 
(Kadiyala et al., 1997, Kobayashi et al., 2010, Vieira et al., 2010, Zucconi et al., 2010). 
Furthermore, cloned Beagles have been generated from adipose derived MSCs from an 
original cloned dog demonstrating germline competence (Oh et al., 2011). As the field 
of ASCs develops more tissue specific stem cells are likely to be discovered in the dog. 
Cardiac and mesenchymal canine adult stem cells are discussed in further detail in 
Chapters 4-7.  
 
1.5.3 Canine Induced Pluripotent Stem Cells 
 
Canine iPS cells have been developed only relatively recently. Shimada et al reported 
the production of canine iPS cells using retroviral t nsduction of the four classic iPS 
genes (Oct 4, c-Myc, KLF4 and SOX2) into canine embryonic fibroblasts. The cultured 
cells were grown in the presence of LIF and TGFβ1 and growth inhibitors of MEK and 
GSK3-β, as described by Li et al, and were capable of differentiation into all three germ 
layers; mesoderm, ectoderm and endoderm (Li et al., 2009, Shimada et al., 2010). More 
recently it has been shown that canine iPS cells derived from canine adult dermal 
fibroblasts and adipose stromal cells require LIF and bFGF for formation and growth, 
but do not require the inhibition of MEK and GSK3-β. These iPS cells were also capable 
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of differentiation along all three germ layers (Lee t al., 2011, Luo et al., 2011). 
Interestingly it was shown that reprogramming of adipose derived cells was twice as 
efficient as that of fibroblasts, suggesting that original cell source may be relevant for 
successfully reprogramming, even though on microarray analysis both sources of 
reprogrammed cells were similar in expression profile to each other and canine ES cells 
(Lee et al., 2011). iPS cells are a rapidly developing field and the generation of canine 
iPS cells will allow for greater study of veterinary diseases in vitro.  
 
This general introductory chapter is followed by Chapter 2 which describes general 
cellular and molecular techniques which are common to all sections of the thesis. 
Following this is Chapter 3, which is a specific introductory chapter for the cardiac work 
contained in Chapters 4, 5 and 6. Chapter 7 contains its own introduction relating to 
cartilage differentiation of stem cells, and this is followed by a final discussion chapter, 
Chapter 8, encompassing the whole thesis. 
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CHAPTER 2 
Materii all s and Methods 
 
2.1 Tissue Culture Plastic Coating 
 
Tissue culture plates and flasks (Helena Biosciences, UK) were coated with bonding 




Tissue culture flasks (Helena Biosciences, UK) were coated with a fibronectin/collagen 
coating comprising; 100 mL basal medium, 10 mL Bovine Serum Albumin (BSA) 
(1 mg/mL), 1 mL Collagen 1 (Bovine, 2.9mg/mL. BD, USA. Catalogue number; 40231), 
1 mL Fibronectin (Human, 1 mg/mL. BD, USA. Catalogue number; 40008A). 100 µL 
per cm2 was added to tissue culture flasks and incubated at 37 °C, 5% CO2 overnight. 
Following this excessive coating was removed and flasks allowed to air dry in tissue 





Poly-D-Lysine (Sigma, UK) was diluted to 0.1 mg/mL using 1 x Phosphate Buffered 
Saline (PBS) (Gibco, UK). 100 µL was added to the base of each well of a 24 well plate 
(Costar, UK) and incubated at room temperature for 5 minutes. Poly-D-Lysine was 
discarded and each well was subsequently washed twice ith PBS, following which the 




Gelatin type A (Sigma, catalogue number G6144) was prepared as a 1% solution by 
adding 1 mg into 100 mL of PBS and autoclaved to produce a sterile solution. Gelatin 
was used at either a 1% or 0.1% dilution and was applied directly to the base of the flask 
or well on multi-well plates and incubated at 37 °C, 5% CO2 for 15 minutes before 
discarding the gelatin solution. Flasks/plates could be used immediately or stored at 4 °C 
for 1 month. 
 
2.2 Cell Counting 
 
Harvested cultured cells were made up to a known volume using appropriate media. 
10 µL of cell solution was added to an equal volume of trypan blue (Sigma, UK) and 
counted using a haemocytometer (Menzel-Glaser, Germany). 
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2.3 RNA Extraction, Cleanup and Quantification 
 
2.3.1 RNA Extraction from Cell Pellets 
 
Total RNA was isolated according to the protocol outlined in the RNeasy® Mini Kit 
(Qiagen, UK). Cell pellets totaling less than 5 x 106 cells were disrupted using 350 µL of 
Buffer RLT, and transferred to a Qiashredder tube (Qiagen, UK) and centrifuged at full 
speed for 2 minutes. 350 µL of 70% ethanol was mixed with the homogenized lysate and 
then transferred to a RNeasy spin column (Qiagen, UK) and centrifuged at >8,000g for 
15 seconds. Flow through was discarded and 700 µL of Buffer RW1 was added to the 
column, and again centrifuged at >8,000g for 15 seconds. Flow through was discarded 
and 500 µL of Buffer RPE (containing ethanol) was added to the column and centrifuged 
at >8,000g for 15 seconds. Flow through was discarded and a second 500 µL of Buffer 
RPE was added to the column and centrifuged at >8,000g for 2 minutes. Flow through 
was discarded and the spin column was transferred to a new collection tube and 
centrifuged at >8,000g for 1 minute to remove residual ethanol. 50 µL of DEPC treated 
RNase free water (Ambion, UK) was added to the centre of the spin column membrane 
and incubated at room temperature for 10 minutes before being centrifuged at >8,000g 
for 1 minute to elute RNA. The RNA was subsequently cleaned up using the DNase 1 
protocol (see below).  
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2.3.2 RNA Extraction from Tissue 
 
Tissue sections harvested from recently euthanized animals were placed immediately 
into RNAlater (Ambion, UK) and stored at -20 °C. For RNA extraction, sections were 
subsequently dissected into 1-2mm3 sections weighing approximately 5-10 mg and 
placed into lysing Matrix D tubes (MPBio, Germany) with 300 µL buffer RLT from the 
RNeasy® Fibrous Tissue Mini Kit (Qiagen, UK). The samples were then homogenized 
using FastPrep (Thermo Scientific, UK) for 40 seconds at level 6 and placed on ice for 
10 minutes. Tissue lysate was then transferred (carefully leaving behind protein froth) 
into a new eppendorf and 590 µL of DEPC water added plus 10 µL of Proteinase K. The 
solution was mixed and placed at 55 °C for 10 minutes before being centrifuged at 
10,000g for 3 minutes at room temperature. Supernatant was transferred to a new 
eppendorf leaving behind a debris pellet, and 0.5 volume of 100% ethanol was added 
and mixed. 700 µL of mixture was transferred to an RNeasy mini-column and 
centrifuged at >8,000g for 15 seconds. Flow through was discarded and remaining lysate 
mixture was added to the column and spun again. 700 µL of Buffer RLT was added to 
the column and the column centrifuged at >8,000g for 15 seconds. Flow through was 
discarded and 500 µL of Buffer RPE was added to the column and centrifuged at 8,000g 
for 15 seconds and flow through discarded again. A further 500 µL of Buffer RPE was 
added to the column, and the column centrifuged at 8,000g for 2 minutes. The column 
was transferred to a new collection tube and centrifuged for 1 minute to evaporate 
excess ethanol. 50 µL of DEPC treated water was added to the column and subsequently 
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centrifuged at >8,000g for 1 minute to elute the RNA. The RNA was subsequently 
cleaned up using DNase 1 protocol (see below).  
 
2.3.3 RNA Cleanup 
 
RNA was DNAse treated to eliminate genomic DNA contamination using the protocol 
outlined in the RNase-Free DNase Set (Qiagen, UK). RNA solution was made up to 
87.5 µL using DEPC treated water, and 10 µL of Buffer RDD and 2.5 µL of DNase 1 
stock solution were added. The mixture was incubated at room temperature for 
10 minutes before commencing RNA cleanup. 350 µL of Buffer RLT plus 250 µL of 
100% ethanol was added to the solution and transferred to a spin column and centrifuged 
at >8,000g for 15 seconds. Flow through was discarded and 500 µL of Buffer RPE was 
added and the tube centrifuged at >8,000g for 15 seconds. Flow through was discarded 
and a further 500 µL of Buffer RPE was added before being centrifuged at >8,000g for 
2 minutes. The spin columns were then transferred to a new collection tube and 
centrifuged at >8,000g for 1 minute to evaporate ethanol. 35 µL of DEPC treated water 
was placed in the centre of the column membrane and incubated at room temperature for 
10 minutes before a final centrifuge spin at >8,000g for 1 minute to elute RNA. 
 
2.3.4 Total RNA Quantification 
 
Eluted RNA was quantified and quality checked using 260:280 nm absorption ratios on 
the Thermo Scientific Nanodrop ™ machine (Thermo Scientific, USA). 
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2.4 Semi-Quantitative  RT-PCR  
 
2.4.1 Primer Design 
 
Primer pairs for canine and murine markers were design d based on published genome 
sequences (NCBI) and the Primer3 software (http://primer3.sourceforge.net/). Individual 
primers are displayed in the chapters of relevance. All primers where possible were 
designed as intron spanning. In the case of canine primers they were designed to allow 
for multiplexing with GAPDH primers. Nkx2.5 primers were taken from Vaags et al 
(Vaags et al., 2009) and GADPH primer sequences were used as a housekeeping control 
gene and were generously donated by Dr. Karen Tan. 
 
2.4.2 Primer Preparation 
 
All primers were ordered through MWG Eurofins, and were HPSF quality. Upon arrival 
primers were diluted to 100 pmol/µL and stored at -20 °C. Melting temperatures for each 
primer pair were optimized upon arrival using RT-PCR (see below).  
 
2.4.3 Reverse Transcription 
 
Extracted RNA was reverse transcribed using the protocol outlined in the Omniscript® 
Reverse Transcription kit (Qiagen, UK) using Random Nanomers (Sigma-Aldrich, 
 26 
USA) at an optimised final concentration of 2.5 µmol/L, and an RNase inhibitor 
(Promega, UK. Catalogue number N2511). A Reverse Transcription (RT) master mix 
was prepared as described in Table 2.1. 
 
Table 2.1. Reverse transcription master mix components and volumes. 
Master Mix Component 1 x (µL) 
10 x Buffer 2 
RNase inhibitor  0.25 
dNTP 2 
DTT 2 
Random Primers 2 
Omniscript RT Enzyme 1 
 
 
Total RNA was made up to a final volume of 10.75 µL using DEPC treated water and 
incubated at 65 °C for 5 minutes, before chilling on ice. 9.25 µL of RT master mix was 
then added to the RNA and incubated at 40 °C for 1 hour before storing newly formed 
cDNA at -20 °C. For semi-quantitative analysis all samples had the same total RNA 
input at RT step. 
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2.4.4 Polymerase Chain Reaction 
 
Polymerase chain reaction (PCR) master mixes were pr pared for all canine experiments 
(murine experiments are outlined in Chapter 6) using the Promega Go-Taq PCR kit 
(Table 2.2). 
 
Table 2.2. PCR master mix components and volumes.  
Master Mix Component 1 x (µL) 
DEPC Treated Water 32.05 
dNTP 1 
MgCl2 4 
5 x GoTaq Buffer 10 
GAPDH Forward Primer 0.1 
GAPDH Reverse Primer 0.1 
Target Forward Primer 0.25 
Target Reverse Primer 0.25 
GoTaq polymerase 0.25 
 
 
48 µL of PCR master mix was added to 2 µL of sample cDNA in a PCR reaction tube 
(Axygen, USA). PCR cycles were run using the Bio-rad iCycler. The following protocol 
was found to be optimal for the reactions: An initial denaturation step of 95 °C for 
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5 minutes. This was followed by 35 cycles of denaturation at 95 °C for 1 minute, 
annealing at primer specific temperatures for 1 minute and extension at 72 °C for 
1 minute. The program was completed with a final extension step of 72 °C for 
10 minutes. Samples were stored at 4 °C until analysis. Gene target primers were run at 
a final concentration of 0.5 pmol/µL with GAPDH multiplexed within the reaction at a 
final primer concentration of 0.2 pmol/µL, thus creating an internal positive control. 
Negative controls of RNA and water were run alongside to confirm absence of genomic 
DNA contamination.  
 
2.4.5 Agarose Gel Preparation and PCR Product Analysis 
 
PCR products were run on a 2% agarose gel. This was prepared by adding 2 g of agarose 
(Sigma, UK) with 100 mL of 1 x Tris Acetate EDTA (TAE) (Gibco, UK) and melted 
using a microwave. 10 µL GelRed 10,000X (Biotium) was added to the 100 mL elted 
agarose and the agarose was poured into a setting tray with inserted comb and allowed to 
set at room temperature. 6 µL of PCR product was added to 2 µL of 6 X Blue/Orange 
Loading Dye (Promega, UK) and mixed before loading into the gel. A 100 base pair (bp) 
ladder (Promega, UK) was run as a size control alongside samples. The samples were 
run though the gel using electrical current (Bio-Rad, UK) to create band separation and 
visualised using the BioRad Molecular Imager GelDoc system. 
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2.4.6 Gel Band Excision and Cleanup 
 
PCR products were run on a 2% agarose gel as describ d above, and the bands 
visualised using a UV transilluminator. Bands at the expected product size were excised 
from the gel and DNA extracted and purified using the Wizard® SV Gel and PCR 
Clean-up System (Promega, USA). Purified DNA products were stored at -20 °C. 
 
2.4.7 PCR Product Sequencing 
 
PCR products were extracted as described previously. DNA concentration was 
determined using the Thermo Scientific Nanodrop ™ (Thermo Scientific, USA). 
Sequencing reactions were prepared using 3-10 ng of PCR product in 5 µL RNAse free 
H20 (Ambion, UK), and 3.2 pmol of either forward or reverse primer in 1 µL of RNAse 
free water. Reactions were sequenced with BigDye®Terminator kit (Applied 
Biosystems, UK) and run on the ABI 3730 DNA Analyzer (Applied Biosystems, UK). 
Sequencing was analysed using the Sequence Scanner v1.0 (Applied Biosystems, UK) 
and compared to the canine genome (NCBI). 
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2.5 Quantitative RT-PCR 
 
2.5.1 Primer Design 
 
Primers for target genes and probes were designed using the LightCycler® Probe Design 
Software 2.0 (Roche). Where possible intron spanning primers were selected. A 
Eukaryotic 18s rRNA endogenous control VIC/MGB probe and primer were utilised as 
housekeeping internal control primers (Applied Biosystems, UK. Catalogue number: 
4319413E). 
 
2.5.2 Primer and Probe Preparation 
 
Primers were ordered from MWG Eurofins (HPLC purified). Individual FAM probes 
were ordered from Roche Applied Science, UK. Upon arriv l primers were diluted to 
50 µmol/L (50 pmol/µL) using DEPC treated water. A 10 X primer/probe stock solution 
was prepared by adding 1 part forward primer, 1 part reverse primer, 1-part probe and 
7-parts water. This was stored at -20 °C and protected from light.  
 
2.5.3 Reverse Transcription  
 
RNA was extracted and cleaned up as previously describ d. cDNA was generated using 
the Roche Hi-Fidelity cDNA synthesis kit (Roche, UK). A master mix was prepared as 
desribed in Table 2.3. 
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Table 2.3. Reverse transcription master mix for cDNA for quantitative RT-PCR 
reactions. 
Master Mix Component 1 x (µL) 
Buffer (5x) 4 
RNAse inhibitor 0.5 
dNTP 2 
DTT 1 
RT enzyme 1.1 
 
Total RNA was made up to a final volume of 9.4 µL using DEPC treated water and 2 µL 
of random primers was added to this. This was heated to 65 °C using the Bio-rad iCycler 
and then allowed to cool before adding 8.4 µL of master mix to each reaction. The 
samples were then transferred to the Bio-rad iCycler for the cycle programme described 
in Table 2.4. 
 
Table 2.4. Programme settings for reverse transcription step for quantitative RT-PCR.  







Samples were then pooled and aliquots (if large volumes were prepared) stored at -20 
°C. 
 
Individual quantitative RT-PCR reactions are described in the relevant chapters. Data 
processing was performed using Microsoft® Excel.  
 
2.6 Western Blot Analysis 
 
2.6.1 Cell Harvesting and Cell Lysis 
 
Cells were harvested from culture using 0.05% trypsin/EDTA (Invitrogen, UK) and 
pelleted by centrifugation at 1200 rpm for 5 minutes at room temperature. Supernatant 
was discarded and pellets re-suspended in 1 mL of PBS. Cell suspension was again 
centrifuged at 1200 rpm for 5 minutes and supernatant discarded. Pellets were disrupted 
using 2 x cell pellet volume of NP40 lysis buffer (1% NP40; 150mM KCl; 25mM 
pH 7.4 Hepes; 5mM DL-Dithiothreitol (DTT); 50mM NaF and 1x Protease Inhibitor 
Mix (all Sigma, UK)) on ice for 15 minutes. The mix was centrifuged at 14000 rpm for 
15 minutes at 4 °C and the lysate was extracted and snap frozen before storing at -80 °C.  
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2.6.2 Bradford Assay 
 
Bradford standards were prepared by dilution of neat Br dford stock (10mg/mL) (Bio-
Rad, UK) in a 2:3 ratio with water creating a 4 mg/L stock, followed by 5 serial 
dilutions through to a 0.125 mg/mL solution. 5 µL of each standard was added to 200 µL 
of Bradford reagent (Bio-Rad, UK) in duplicate across a white 96 well plate (Corning, 
UK). 2 µL of sample protein lysate was added to 200 µL of Bradford reagent in a 
separate well and the absorbance was recorded usinga platemeter (Victor3, Perkin 
Elmer, USA) with a standard curve with R2 value plotted using the Bradford standard 
data. The absorbance of the protein lysate of interes  was plotted against the curve 
indicating mg/mL of the extracted protein.  
 
2.6.3 SDS Polyacrylamide Gel Electrophoresis 
 
 Quantification of protein concentration was performed using Bradford Assays and 
proteins were resolved on the basis of their molecular weight using SDS polyacrylamide 
gel electrophoresis (SDS PAGE). Proteins resolved by the SDS PAGE were transferred 
to a nitrocellulose membrane (Amersham™ Hybond™, GE Healthcare UK) and blocked 
using 5% skimmed milk (Fluka, Switzerland) in 0.1% PBS/Tween (0.1% Tween in 
PBS). Blot probing is described in further detail in Chapter 4; Cardiac Stem Cells.  
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2.7 Immunofluorescence Analysis 
 
Cells were grown on 4 well chambered slides (Corning, UK) under cell specific 
conditions until slides were approximately 50% confluent. Medium was aspirated and 
slides washed in PBS, which was subsequently discarded. Slides were briefly air dried 
and then fixed directly in 4% paraformaldehyde for 20 minutes, followed by two PBS 
washes and subsequently placed in 100% ethanol for 5 minutes, followed by two PBS 
washes to permeabilise the cells. Blocking buffer (10% normal goat serum (Invitrogen, 
UK); 0.1% Tween 20 (Sigma UK), in 1x PBS) was applied for 1 hour at room 
temperature, and slides were incubated with primary antibody of interest, diluted in 
PBST (0.1% normal goat serum; 0.1% Tween 20 in PBS) and incubated overnight in a 
humidified chamber at 4 °C. Following this, two washe  with PBS for 5 minutes were 
performed, followed by incubation with the secondary ntibody of choice, for 1 hour at 
room temperature in a dark humid chamber. Nuclear counterstaining was performed 
using DAPI mount (Vectastain) after three 5 minute washes in PBS. Coverslips were 
placed over the mount, and edges sealed using nail varnish. Images were taken using the 
fluorescent microscope (Zeiss, Axiovert 40) and analysed using the Zeiss Axiovision 4.7 
software. Slides were stored at -20 °C. Specific details of immunofluorescence can be 
found in individual results chapters.   
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2.8 Cardiac Directed Differentiation using Co-Cultu re 
 
Indirect co-culture was performed to allow analysis of both mesenchymal stem cells 
(MSCs) and cardiac stem cells (CSCs) whilst in co-culture with an autologous source of 
stem cells. The general experimental procedure was similar for both cell populations and 
is described below. Individual results for CSCs andMSCs can be found in Chapters 4 
and 5 respectively.  
 
2.8.1 Isolation and Culture of Cardiac Stem Cells and Mesenchymal Stem Cells 
 
Cardiac explants and bone marrow were taken from dogs recently euthanized by 
pentobarbital overdose. CSCs and MSCs were cultured from these tissues and grown 
concurrently to produce viable stem cells of each source. Individual detail of CSC and 
MSC isolation and culture can be found in materials and methods of Chapters 4 and 5 
respectively.  
 
2.8.2 Harvest of Cardiac Stem Cells and Mesenchymal Stem Cells 
 
At approximately 4 weeks after harvesting explants both CSCs and MSCs were ready 
for collection. Detailed description of cellular harvests for CSCs and MSCs can be found 
in the materials and methods of Chapters 4 and 5 respectively, however briefly; 
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1. Cardiac Stem Cells: Media from explant flasks was pooled to collect all free 
floating phase bright cells. Flasks were then gently rinsed using PBS and this 
added to the media to pool cells. Cell suspension was centrifuged at 1200 rpm for 
5 minutes at room temperature to pellet cells. Cells were re-suspended in PBS 
and counted as previously described.  
 
2. Mesenchymal stem cells: MSC media was removed from the flasks and 
discarded and the cells washed in PBS. 0.05% Trypsin/EDTA was added to the 
flasks and the flasks subsequently incubated at 37 °C, 5% CO2 for 10 minutes to 
loosen cells. 10 mL of MSC media was added to the flasks and the cell 
suspension removed. Cells were centrifuged at 1200 rpm for 5 minutes at room 
temperature to pellet the cells, and then re-suspended in PBS and counted.  
 
Both CSCs and MSCs were then re-centrifuged at 1200 rpm for 5 minutes at room  
temperature before being re-suspended in co-culture Diff rentiation Enabling Media 
(DEM); DMEM (high glucose, with L-Glutamine, Catalogue number 41965, Invitrogen 
UK), 10% foetal bovine serum (FBS), 10% ITS+ premix (BD Biosciences, UK), 
10% Na Pyruvate (Gibco, UK), 10% MEM-NEA (Gibco, UK), 1 x Ascorbic Acid 
(Sigma, UK), 0.1 mmol/L 2-Mercaptoethanol (2-ME), 100 U/mL Penicillin G  and 
100 µg/mL Streptomycin (both Invitrogen, UK). 
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2.8.3 Plate Set-up for Co-Culture Experiment 
 




Figure 2.1. Plate plan for CSC and MSC indirect co-culture. One 24 well plate could be 
used for one timepoint, including two dogs. On each plate were control wells of both cell 
sources cultured alone, and co-culture wells of both CSCs and MSCs with the alternative 
cell source grown in transwell inserts above. All wells were coated with 1% gelatin prior 
to initiation.  
 
Collagen-Coated Transwell® - COL Inserts, 0.4 µm diameter were purchased from 
Corning Lifesciences, USA (Catalogue number; 3495). A single 24 well plate containing 
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12 Collagen transwell inserts was used for each time point (day 6 and day 10), with two 
dogs on one plate. The base of each well was coated wi h 1% gelatin to improve cell 
binding. Four individual permutations of experiment were run, each with triplicate wells; 
1. Mesenchymal stem cells alone 
2. Mesenchymal stem cells at the base of the well, with cardiac stem cells grown on 
a transwell insert above 
3. Cardiac stem cells at the base of the well, with mesenchymal stem cells grown on 
a transwell insert above 
4. Cardiac stem cells alone 
 
2 x 104 cells were seeded into base wells of the 24 well plate (growth area 1.9 cm2) in 
600 µL of DEM media, with 1 x 104 cells seeded onto transwell inserts (growth area 
0.33 cm2) in 100 µL DEM media.  Plates were then placed at 37 °C, 5% CO2.  
 
Following plating, remaining cells were re-centrifuged at 400g, for 10 minutes at 4 °C to 
pellet cells. Cells were then washed in chilled PBS and re-centrifuged as above. The 
PBS was discarded and the cell pellet snap frozen and stored at -80 °C as day 0 control 
cells.  
 
Medium was refreshed at days 3 and 8 post initiation. In the base wells 300 µL of DEM 
media was carefully removed and 400 µL of fresh DEM media replaced and from the 
transwell inserts 50 µL of spent media was carefully removed and 80 µL of fresh DEM 
medium was replaced.  
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2.8.4 Time Point Harvest 
 
Triplicate wells were harvested from each plate at two time points, day 6 and 10. 
Transwell inserts were removed and discarded and images were taken of the cell 
monolayer. Medium was removed and the cells washed in PBS. 0.05%.  Trypsin/EDTA 
was added to each well and the plate placed at 37 °C, 5% CO2 for 5-10 minutes. 
Following this 1 mL of warm DEM media was added to each well and the cell 
suspension transferred to a 15 mL Falcon tube. The cells were then centrifuged for 10 
minutes at 400g at 4 °C to form a pellet. Media wasremoved and discarded and 1 mL of 
chilled PBS was added and the cells washed before being centrifuged again at the same 
settings to re-pellet the cells. PBS was discarded an  the pellet snap frozen, before 




Cell pellets were removed from -80 °C storage and thawed. RNA was extracted from 
each pellet using the RNeasy Mini Kit and cleaned up using the DNase 1 Kit as 
described previously. RNA was quantified using the Nanodrop machine to calculate 
total RNA and quality. At this point RNA from each triplicate was pooled into one 
combined sample which was again quantified using the Nanodrop machine to calculate a 
combined total RNA. This RNA was used for reverse tanscription, using 150 ng of total 
RNA (except for cardiac stem cells at day 6, where 50 ng was used due to low total 
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RNA) and the Omniscript RT kit as described previously. cDNA was stored at -20 °C 
until use.  
 
Semi-quantitative RT-PCR was performed using the prpared cDNA and all canine 
primers (see individual chapters), analysing day 0, 6 and 10 time points for both 
co-cultured cardiac and mesenchymal stem cells and the stem cell only controls.  
 
2.9 Image Capture and Processing 
 
Cell morphology images and immunofluorescence were viewed using the Zeiss Axiovert 




Heart Dii sease and the Need for Stem 
Cell ll  Research  
 
3.1 Cardiac Disease and the Dog 
 
In pet pedigree dogs cardiac disease is the third biggest cause of mortality after cancer 
and ‘old age’ and is therefore of significant importance in veterinary practice. Cardiac 
diseases in dogs are predominantly seen in two major c tegories; cardiomyopathies and 
valvular degeneration, with congenital causes of disease generally very rare (Egenvall et 
al., 2006, Adams et al., 2010).  Risk of death from cardiac disease increases with age of 
patient, and is also highly breed specific. For example, large breed dogs, such as Great 
Danes and Irish Wolfhounds are at major risk of developing dilated cardiomyopathy 
(DCM) whereas the Cavalier King Charles Spaniel has a significant risk of developing 
myxomatous mitral valve disease (MVMD) (Egenvall et al., 2006). Managing cardiac 
disease morbidity in the dog has been the focus of significant pharmaceutical research, 
with the key goal being the improvement of quality of life first and foremost, followed 
by increased longevity. Treatment protocols have ben released for both DCM and 
MVMD which alleviate some of the symptoms of heart f ilure, however no treatment 
regime will halt disease progression (Borgarelli et al., 2001, Tidholm et al., 2001, 
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Haggstrom et al., 2009). The need for the study of cardiac diseases in the dog is 
therefore evident, and the use of stem cells for this is an exciting prospect, not only for 
study of disease processes in vitro, but also for their future therapeutic potential in vivo. 
 
Cardiac disease is the number one killer of the human population globally and in 2005 
approximately 17.5 million people died from cardiovascular disease, representing 30% 
of all deaths worldwide. Many similarities can be drawn between humans and dogs, and 
through the study of cardiac disease in both species w  may generate beneficial 
information which can be transferred across to human edicine and vice versa, thus 
allowing for the dog to become a model for human disease.  
 
3.1.1 The Genetic Influence in Cardiac Disease  
 
Genetic causes of cardiac disease are an important area of study in order to allow for 
future limitation of inherited traits contributing to the development of disease. It is 
known that there is a strong genetic influence in canine cardiac disease; this is 
highlighted in pedigree dogs, where specific conditions are more common in certain 
breeds. As already mentioned, MVMD is most common in Cavalier King Charles 
Spaniels with high heritability, and the likelihood of polygenic traits influencing the 
disease (Lewis et al., 2010). Boxers are predisposed to arrythmogenic right ventricular 
cardiomyopathy (ARVC) (Oyama et al., 2008), and Doberman Pinschers to DCM (Wess 
et al., 2010). Even though the evidence for genetic association is very strong in pedigree 
dogs no specific genetic mutations have yet been fou d.  
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Study of genetic influences of cardiac disease may be enabled by the isolation and 
culture of stem cells from affected patients, allowing for disease study in vitro on a cell 
population carrying the genetic flaw (Beqqali et al., 2009). In human cardiovascular 
disease many of the genetic mutations have already been characterised and rodent 
models created (Figure 3.1). These models, although useful, are not an ideal direct 
comparison and therefore studying cell populations from pedigree dogs affected by each 
individual condition would enable a more direct and relevant analysis for veterinary 




Figure 3.1. Human genetic mutations causing cardiovascular disease. Mutations in ion 
channel and cellular proteins lead to diseases of channels or contractility 
(channelopathies and cardiomyopathies respectively). Green represents the known 
genetic mutation found in the human, with blue the corresponding mouse model. 
LQTS-Long QT Syndrome; DCM-Dilated Cardiomyopathy; HCM-Hypertrophic 
Cardiomyopathy; SCN5A-Sodium Channel, Voltage-gated, type V, Alpha subunit; 
KCNQ1-Potassium Voltage-gated Channel, KQT-like Subfamily, Member 1; 
KCNE1/2-Potassium Voltage-gated Channel, Isk-related family, Member 1/2; 
HERG-Potassium Voltage-gated Channel, Subfamily H (eag-related), Member 2 ; 
CTT-Cardiac Troponin T; β-MHC-β-Myosin Heavy Chain; MyBP-C-Myosin Binding 
Protein-C. Taken from (Beqqali et al., 2009). 
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The study of genetically flawed cardiomyocytes deriv d from stem cells would allow for 
new therapeutics to be tested on the cultured cell populations, giving an initial idea of 
the affect these drugs may have on the patients. Furthermore, the use of stem cells in this 
way in vitro may act as an animal sparing source of testing material in pharmacological 
research. Cardiomyocytes derived from ES cells have been found to demonstrate similar 
responses to cardiac and non-cardiac drugs in vitro as have been seen i vivo, thus 
highlighting the potential of stem cells for future drug development (Braam et al., 2010). 
The use of stem cells therapeutically is also being investigated, with some positive 
effects seen with the direct application of stem cells, predominantly MSCs, into 
damaged hearts (this is discussed in more detail in Chapter 5).  
 
3.2 The Heart is Not a Post-Mitotic Organ  
 
The heart was long thought to be a terminally differentiated organ with no capacity for 
renewal and repair. Interestingly the Zebrafish is capable of cardiac repair and is a model 
for cardiac damage due to its ability to fully regenerate the damaged heart within 
2 months after a 20% ventricular resection (Poss et al., 2002, Lepilina et al., 2006). The 
process by which this happens is a matter of great interest as it may elucidate areas for 
research in mammalian models. In humans recent evidence has shown that the heart 
does have regenerative capacity, albeit at low levels. Using Ki-67 staining and genetic 
fate mapping it has been shown that regeneration in the heart is increased following 
injury, and therefore suggests that cardiac renewal is possible, but not part of the normal 
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ageing process (Beltrami et al., 2001, Hsieh et al., 2007). In contrast it has been shown 
using carbon-14 dating that renewal is constantly occurring, and is at its highest level in 
humans under 25, and decreases to under half the original level by the age of 75 
(Bergmann et al., 2009). Furthermore, it has now been shown that females have a 
superior ability for cardiomyocyte renewal than males, with myocyte replacement 
occurring 15 times in a lifetime in a female compared with just 11 in a male (Kajstura et 
al., 2010). It would be fair to extrapolate from these results and assume that the dog also 
has a level of cardiomyocyte turnover, and that the presence of stem cells within the 
heart may contribute to normal remodelling and repair.  
 
3.2.1 Difficulty in Culturing Primary Cardiomyocytes 
 
Stem cells have offered an option to study cardiac seases in vitro which until recently 
had been made challenging by the difficulty in culturing primary cardiomyocytes. Yield 
is notoriously low, and long-term subculture is very difficult and leads to phenotypic 
changes, including loss of sarcomeres by 10 days in culture and loss of myofilaments 
with increasing passage (Li et al., 1996, Bird et al., 2003). This has meant that use of 
primary cardiomyocytes in vitro was severely limiting and unreliable for direct 
translation in vivo and therefore stem cells have become a promising altern tive option.  
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3.3 Differentiation of Stem Cells to Cardiomyocytes  
 
3.3.1 Derivation of Cardiomyocytes from Embryonic Stem Cells 
 
ES cells have been used to derive cardiomyocytes which can then be used for functional 
analysis, pharmacological studies, and also for transplant studies. Crucially the 
signalling pathways and the culturing conditions between undifferentiated and 
differentiating ES cells are not identical between mice (mES) and humans (hES). 
Spontaneous differentiation of ES cells towards a specific lineage is poor, specifically 
for hES cells (Puceat, 2008). The conventional approach to induce cardiac 
differentiation was devised using mES cells and involved  the formation of embryoid 
bodies, which were then ‘hung’ from tissue culture plates, and from which differentiated 
cells derived from endoderm, mesoderm and ectoderm were isolated (Desbaillets et al., 
2000). Subsequent plating of the mesodermal cells rsulted in areas of spontaneous 
contraction appearing within 1-4 days for mES cells (Boheler et al., 2002, Sachinidis et 
al., 2003).  An increase in the percentage of cells differentiating toward the cardiac 
lineage can be achieved by exposing the ES cells to bone morphogenic protein 2 
(BMP 2) prior to the formation of hanging drops (Puceat, 2008) or BMP 2 and TGFβ in 
combination (Behfar et al., 2002); alternatively up-regulation of cardiogenic genes can 
be seen in embryoid bodies treated with the reprogramming cytokine tumour necrosis 
factor-α (TNF-α) initially added to try to limit neoplastic growth (Behfar et al., 2007). 
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hES derived mesodermal cells isolated from the embryoid body can also differentiate 
into cardiomyocytes, producing areas of spontaneous beating, but require the presence of 
serum. Directed differentiation can be further promoted toward the cardiac lineage with 
combinations of growth factors. An efficient system utilising Activin A and bone 
morphogenic protein 4 (BMP 4) has been described, which results in a 71-95% 
conversion of mesodermal ES cells to beating cardiomyocytes (Laflamme et al., 2007). 
Alternatively co-culture of hES cells with the murine endodermal cell line, END-2 in the 
absence of serum also creates spontaneously beating c rdiomyocytes (Mummery et al., 
2003, Passier et al., 2005). 
 
Canine ES cells have only been described in the last 5 years, and are therefore much 
further behind in terms of research than human and mouse ES cells. However, canine ES 
cells are capable of differentiating along all three germ layers; mesoderm, endoderm and 
ectoderm (Hayes et al., 2008, Vaags et al., 2009). More specific differentiation has been 
found toward neuronal cells and haematopoietic stem c lls (Schneider et al., 2007, 
Wilcox et al., 2011). Only two references to specific cardiac differentiation currently 
exist. Hatoya et al demonstrated the most successful cardiac differentiation using the 
embryoid body technique, and found beating cells after 1-2 weeks (Hatoya et al., 2006) 
whereas Vaags et al analysed gene expression following a similar differentiation 
technique which demonstrated a slight increase in cardiac specific markers GATA 4 and 
myosin light chain 2v (Vaags et al., 2009).  
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3.3.2 Derivation of Cardiomyocytes from Adult Stem Cells 
 
The heart had long been thought of as a terminally differentiated organ, with a limited 
capacity for repair. However, the discovery of adult stem cells instigated the search for a 
population of progenitor cells specific to the heart. Following work demonstrating 
mitosis and cytokinesis in human hearts under normal conditions it was found that the 
heart did indeed have a natural population of stem-c ll like cells (Anversa and Kajstura, 
1998, Beltrami et al., 2001, Nadal-Ginard et al., 2003) Messina et al identified and 
characterised a cell population from both the mouse and human heart with properties of 
CSCs. The isolated cells grew as self-adherent clusters, which they termed 
‘cardiospheres’. These cells were capable of both self-renewal and could differentiate in 
vitro and in vivo into the major specialised cell types of the heart; cardiomyocytes, 
endothelial cells and smooth muscle cells (Messina et al., 2004). Stem cells derived from 
the bone marrow have also been driven toward cardiac lineages in vitro using various 
techniques, and may present a more accessible source of stem cells for cardiac 
differentiation than CSCs (Makino et al., 1999, Fukuda, 2001). More detailed 
descriptions of cardiac differentiation from adult stem cells are found in individual 
chapters.  
 
3.3.3 Derivation of Cardiomyocytes from Induced Pluripotent Stem Cells 
 
The development of iPS cells has taken stem cell bio ogy into a new era, with the 
possibility of creating patient specific treatments. Mauritz et al and Narazaki et al both 
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described the production of functional murine cardiomyocytes from iPS cells – the 
differentiated cells displayed functional characteristics similar to that of ES cell derived 
cardiomyocytes. Mauritz et al generated murine iPS cells containing all four iPS 
transcripts (Oct 4, c-Myc, KLF4 and SOX2), which expressed high levels of endogenous 
Oct 4, Nanog and SSEA 1. These were cultured initially on MEF feeders in the presence 
of LIF before generating embryoid bodies which were subsequently plated. The iPS cells 
began spontaneously contracting from around day 12 of plating, and the beating cells 
were found to be expressing markers for cardiomyocyte lineages including GATA 4, 
Nkx2.5 and those for differentiated cardiac cells including α-myosin heavy chain, 
cardiac troponin T and connexin 43.  The beating cells were analysed for their 
functionality using microelectrode arrays for electrical impulses, and intracellular 
calcium measurements using confocal laser microscopy, and were found to be behaving 
as functional cardiomyocytes (Mauritz et al., 2008). Nazaraki et al generated murine iPS 
cells including all four transcripts, and then induced a population of mesodermal cells 
expressing Flk-1 (vascular endothelial growth factor receptor-2). The purified Flk-1 
population was capable of differentiation into endothelial cells and cardiomyocytes 
(Narazaki et al., 2008). Zhang et al generated a human iPS cell line using Oct 4, Nanog, 
SOX2 and Lin 28 transgenes, without the requirement for he oncogenic c-Myc gene. 
They then differentiated these cells using the embryoid body method and created 
functional cardiomyocytes, which were responsive to β-adrenergic stimulation shown by 
an increase in spontaneous contraction rate and a decrease in action potential duration 
(Zhang et al., 2009). Moretti et al found using genetic fate mapping, that iPS cells 
positive for islet 1 were capable of spontaneous differentiation along the three main 
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cardiac routes in both mice and humans without teratom  formation (Moretti et al., 
2010). Following on from this work, murine chimeras have been generated from iPS 
cells derived with and without the presence of c-Myc, using human genes, which were 
capable of forming functional normally developed hearts (Martinez-Fernandez et al., 
2009, Nelson et al., 2009). Most recently it has been found that the addition of small 
molecule Wnt inhibitors can increase the efficiency of cardiac differentiation of human 
iPS cells (Ren et al., 2011). In all differentiation experiments the iPS cells were 
compared to an ES cell line from the same species, and behaviour in culture and 
differentiation patterns were found to be similar between the two. 
 
Canine iPS cells have only recently been described, ut have been found to be capable 
of differentiation along all three germ lines using embryoid body techniques (Shimada et 
al., 2010, Lee et al., 2011, Luo et al., 2011). This data compares favourably with that 
produced for human and mouse iPS cells and will likely pave the way for future research 
into more specific differentiated tissues such as cardiomyocytes.  
 
3.3.3.1 Epigenetic Memory and Direct Re-programming 
 
iPS cells have traditionally been created using fibroblasts as the original somatic cell 
used for reprogramming. However, early stage research has suggested that iPS cells 
retain some epigenetic memory of their tissue of origin. For example, mouse iPS cells 
created using early bone marrow lineage cells were found to produce higher numbers of 
haematopoietic colony forming cells compared to using fibroblast cells as the 
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transformed cell (Kim et al., 2010). Furthermore it has been found that by altering the 
traditional genes inserted into the genome to those which are more tissue specific it is 
possible to directly re-programme somatic cells to a new tissue whilst by-passing the 
pluripotent stage. Vierbuchen et al have found that the insertion of three factors, Ascl1, 
Brn2 and Myt1l, could directly reprogramme adult fibroblasts into functional neurons in 
vitro (Vierbuchen et al., 2010). Excitingly, it has also been found that adult murine 
fibroblasts could be directly re-programmed to the cardiac lineage by the insertion of 
three key developmental factors; GATA 4, MEF2C and Tbx5. These reprogrammed 
cells demonstrated marker expression similar to cardiomyocytes and contracted 
spontaneously. Furthermore, insertion of the three factors directly into cardiac 
fibroblasts increased transcriptional activity compared to fibroblast derived 
cardiomyocytes, suggesting a combined epigenetic memory influence (Ieda et al., 2010). 
 
3.3.4 Isolating Cardiac Precursors 
 
A recent study has found that it is possible to isolate and select for cardiomyocytes 
derived from ES cells and iPS cells from within the mixed population of cells post-
differentiation based upon high mitochondria content. Importantly, these cells were not 
capable of forming teratomas, and thus this technique may increase the ability to select 
for cardiomyogenic cells more specifically, and increase safety of using them in vivo 
(Hattori et al., 2010). 
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3.4 Stem Cell Derived Cardiomyocytes in Disease Mod els and Therapy 
 
3.4.1 Embryonic Stem Cells and Cardiac Disease 
 
Transplant studies have shown the improved repair of infarcted tissue following 
injection of stem cell derived cardiomyocytes. Laflamme et al found that hES cell-
derived cardiomyocytes injected into infarcted immunodeficient rat hearts formed 
myocardial grafts in the presence of a cocktail of pr -survival factors, which attenuated 
ventricular dilation and preserved regional and globa  contractile function compared to 
controls receiving non-cardiac hES cell derivatives (Laflamme et al., 2007). Van Laake 
et al also found that injection of hES cell-derived cardiomyocytes into both healthy and 
myocardial infarcted murine hearts formed a graft, nd in the case of the infarcted 
hearts, initially caused a significant improvement i  cardiac function measured by 
magnetic resonance imaging (MRI). However, the improvement was not sustained at 
12 weeks, although the graft was still present (van L ake et al., 2007). In many of the 
hES cell cardiomyocyte studies there appeared to be a transient improvement in cardiac 
function, but this was not sustainable long term; increased numbers of injected hES cell 
cardiomyocyte derived cells did not increase longevity of increased function, but did 
produce larger grafts within the myocardium. It was noted that over a ten week period 
gap junctions appeared to form within the graft, however connections from the graft to 
the host myocardium were rare. Often the grafts were surrounded by an extracellular 
matrix, although this did not preclude any electrical oupling. Given that mouse and 
human heart rates vary considerably (mouse 400-600 bpm, human 60-100 bpm) it may 
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be that electrical coupling was physiologically impossible. No arrhythmias were found 
in the host hearts, but until this system is trialed in larger animal models, which have 
slower heart rates, it cannot be assumed that none w uld occur (van Laake et al., 2008) .  
 
Canine ES cells are still in their early phase of research and therefore have not yet been 
utilized for the treatment of cardiovascular diseases. Canine ES cells are challenging to 
produce, and as yet have not fulfilled all the criteria of an ES cell, such as teratoma 
formation and therefore the basic science of these cells will need to be investigated 
further before they can be considered for therapeutic use.  
 
In general, concerns regarding the use of ES cell derived transplants remain, including 
the ethical issues surrounding the production of ES cells, the production of teratomas, 
and also an immunogenic response to engrafted cellswithin same species, and even 
genetically identical subjects (Swijnenburg et al., 2005). 
 
3.4.2 Adult Stem Cells and Cardiac Disease 
 
Two main sources of ASCs have been investigated for the treatment of cardiac disease. 
Firstly cardiac stem cells (CSCs), found in the heart itself. Implantation of adult cardiac 
stem cells (CSCs) has been found to improve cardiac fun tion following myocardial 
infarction in mice (Smith et al., 2007, Matsuura et al., 2009), and in rats following 
implantation of human adult c-Kit positive CSCs (Beltrami et al., 2003). Secondly 
MSCs, located both in the bone marrow and adipose tissue have been used to treat 
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cardiac disease (Silva et al., 2005, Plotnikov et al., 2007). These cell sources are the 
main focus of this study and shall be described in more detail throughout the specific 
chapters. Alternative sources for cellular therapy have been described with limited 
success including primary foetal cardiomyocytes (Sakai et al., 1999) and skeletal 
myocytes (Jain et al., 2001, Menasche et al., 2001, Ghostine et al., 2002). 
 
3.4.3 Induced Pluripotent Stem Cells and Cardiac Disease 
 
The injection of murine iPS cells intramyocardially into immunodeficient mice 
generated the growth of teratomas, as would normally be expected of iPS cells. 
However, when injected subcutaneously and intramyocardially into immunocompetent 
mice no teratomas formed, and furthermore the iPS cells stably engrafted into the heart 
itself (Nelson et al., 2009). This may indicate that in future, patient specific iPS cells 
may be used to target damaged myocardium.  
 
Cardioactive therapeutics have been tested on cardiomyocytes derived from human iPS 
cells. The iPS cells were found to respond to the cardiac drugs similarly to both ES cell 
derived cardiomyocytes and human cardiomyocytes. The use of iPS cells in this field 
would allow not only for cardiac drug screening i  vitro but more importantly would 
allow for patient specific testing, individualizing and tailoring drugs to the patients 
themselves (Yokoo et al., 2009). 
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Canine iPS cells have been labelled with a fluorescent reporter gene and iron oxide and 
injected autologously into the left ventricular myocardial wall, allowing cells to be 
tracked using PET/CT and MRI scanning and allowing for further development of 
autologous transplantation of canine iPS cells. Furthermore canine iPS cells were 
differentiated toward endothelial cells and used in mouse models of hindlimb ischaemia 
and induced myocardial infarction. After 14 days there was a significant improvement in 
neo-vascularisation in the hindlimbs of treated mice, and an improvement of systolic 
function following delivery of iPS cells to border zones of infarcts at both 14 and 
28 days. However, in both experiments the delivered iPS cells were found to have a 
significant death rate by week 6 post-implantation (Lee et al., 2011). This preliminary 
data implies that canine iPS cells may play a role in the repair of infarcted tissue, and 




Cardiac disease is of huge importance in dogs, and plays a large part within small animal 
veterinary practice. Furthering the understanding of the physiology behind many of the 
diseases would enable the development of new treatment protocols. Stem cells may pave 
the way for these discoveries, and may in fact have a direct therapeutic role themselves. 
ES cells have several limiting issues, such as teratom  formation, and production of 
canine ES cells has proved difficult. Canine iPS cells have only recently been described, 
therefore the basic science of these cells must be identified prior to their use for cardiac 
research. This therefore leads to the further investigation of adult stem cells for the 
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investigation and treatment of cardiac disease. Preliminary findings using stem cells 
therapeutically have shown a short term benefit, but further work investigating the basic 
science of these cells, and the species specific dif erences needs to be performed before 
longer term therapeutic applications. Canine cardiac stem cells and mesenchymal stem 
cells will be discussed in more detail in Chapters 4 and 5 respectively. This is followed 
by Chapter 6 describing murine mesenchymal stem cells as a comparison to canine cells.  
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CHAPTER 4 
Canii ne Cardii ac Stem Cell ll s 
  
Abstt rr actt   
 
Cardiac disease is a significant cause of morbidity and mortality in dogs and humans. In 
this chapter we are going to discuss cardiac specific ASCs including how they are 
defined and differentiated in the literature, and then describe our work isolating and 
characterising canine adult cardiac stem cells (CSCs) followed by our results and 
discussion. Specifically atrial cardiac explants were taken from dogs post-mortem and 
cultured to isolate CSCs. These cells were able to survive successive passages in serum 
free media, forming cardiospheres and were capable of clonal expansion under 
controlled culture conditions, demonstrating their ability for self-renewal. 
Characterisation of the CSCs demonstrated expression of c-Kit, GATA 4 and Flk-1 with 
no expression of cardiac lineage markers. Cardiac dire ted differentiation was performed 
based on the published literature and subsequent analysis demonstrated that partial 
cardiac directed differentiation was achieved with an increase in the expression of 
Nkx2.5 and cardiac troponin T. A second differentiation experiment was performed 
using indirect co-culture of CSCs with mesenchymal stem cells which appeared to drive 
the CSCs toward an endothelial lineage. The data in this study suggests that canine adult 
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CSCs are directly comparable to human stem cells and are multipotent, and therefore 




4.1.1 Isolation and Characterisation of Cardiac Ste m Cells 
 
The heart was long thought to be a terminally differentiated organ, with no capacity for 
repair. However, in the last 15 years this has been disproven, and the heart found not 
only capable of limited repair, but also to contain  resident stem cell population which 
may contribute to this repair (Beltrami et al., 2003, Messina et al., 2004).  
 
4.1.1.1 Cardiospheres and Cardiac Stem Cells 
 
Cardiospheres were first described by Messina et al in 2004. A phase-bright cell 
population grew out of cardiac explants in tissue clture, which could be harvested and 
grown in serum-free stem cell culture conditions. Under these conditions the cells 
formed spheres and were capable of clonal expansion. Furthermore it was found that the 
spheres contained a mixed population of cells, ranging from true stem cells through 
partially differentiated cells, fully differentiated cardiomyocytes and cells of vascular 
lineages (Messina et al., 2004). Murine cardiospheres were capable of spontaneous 
differentiation and this initial work was rapidly followed by more work utilising this 
stem cell isolation technique and the investigation of differentiation techniques for other 
species. It was shown that cardiosphere derived cells  from the human and pig displayed 
properties suggestive of differentiation when co-cultured with rat neonatal 
cardiomyocytes (RNCM), including displaying calcium transients (Smith et al., 2007). 
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More recently an investigation into refining the technique to isolate CSCs from humans, 
pigs, mice and rats found that the original explant technique with only minor alterations 
consistently and reproducibly produced CSCs from all species investigated (Davis et al., 
2009). CSCs from different species have been found capable of multipotent 
differentiation along three key routes; cardiac, vascular smooth muscle and endothelial 
lineages using several differentiation techniques (see Table 4.1 below) (Messina et al., 
2004, Bearzi et al., 2007, Smith et al., 2007).  
 
4.1.1.2 Origin of Cardiac Stem Cells  
 
It was classically believed that the heart developed as a tube which folded to form the 
four main chambers of the heart. However, more recently it has been discovered that 
cardiac development is more complex, with variation seen in several key cardiac 
markers determining developmental fate. Wu et al proposed that a common precursor 
was present in the embryonic heart which later developed into the three main lineages 
based upon varied marker expression (Wu et al., 2006). Furthermore it was suggested 
that cells destined for the endothelial lineage broke away relatively early in 
development, whereas smooth muscle and cardiac cells remained closely related until 
later stages. Based upon genetic fate mapping it has now been shown that the heart 
develops in two stages, primary and secondary heart fields. During development the 
primary heart field forms the major area of the cardiac crescent, with secondary heart 
field cells present at extra-crescent edges. During development bi-lateral cardiac 
crescents fuse, at which point secondary heart field c ls migrate into primary heart field 
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regions. The secondary heart field later divides into two regions, anterior and posterior. 
The anterior region becomes the right ventricle andoutflow tract, whilst the posterior 
region becomes the atria and becomes continuous with the pro-epicardium. It has been 
found that CSCs are located throughout the heart, with primary heart field progenitors 
predominantly in the left ventricle and secondary heart field progenitors in the outflow 
tracts. This correlates with heterogeneity in marker xpression based upon 





Figure 4.1. Developmental origin and marker expression of progenitor cells from 
different heart fields during cardiac growth. The heart develops from a single primordial 
cell from the mesoderm, and develops through two heart fields, primary and secondary. 
Marker expression alters during development through these fields with progenitor 
populations residing in tissues developed from both heart fields. Isl1, Islet 1; LV, left 
ventricle; OFT, outflow tract; RV, right ventricle, SA node and SAN, sinoatrial node; 
AV node, atrioventricular node. Taken from Nakano et al (Nakano et al., 2008). 
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4.1.1.3 Cardiac Stem Cell Niche 
 
CSCs are found in discrete clusters within the interstitium of the heart, alongside 
differentiated somatic cells with cell to cell contac  between the CSCs and the myocytes 
and fibroblasts. This niche is similar to that found i  bone marrow; for example, in bone 
marrow the osteoblasts and stromal cells function as supporting cells, much like the 
myocytes and fibroblasts. Urbanek et al found that stem cell niches in the adult mouse 
heart were dispersed throughout the myocardium; however there was a twofold increase 
in volume of niche in the atria when compared to the ventricle. It was also found that the 
number of niches per mm³ of atrial and apical myocardium was approximately 8-fold 
higher than at the base mid-region (Urbanek et al., 2006).  Similarly the human right 
atria has significantly more c-Kit positive and islet 1 positive cells than the other three 
chambers within the heart. Furthermore, there is no overlap between cells expressing 
c-Kit and islet 1 suggesting that the two populations are separate, with more c-Kit 
positive cells present than islet 1 positive. Interestingly, there are more c-Kit positive 
cells within the hearts of female patients compared to male and there is an increase in 
c-Kit positive cell number with decreasing health of the heart, suggestive of an innate 
repair system having been triggered (Itzhaki-Alfia et al., 2009). 
 
4.1.2 Defining Stem Cells 
 
Stem cells have been defined as cells which are capable of self-renewal, and which have 
the ability to differentiate into multiple cell lineages. Stem cell markers have been used 
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to try to define stem cells in vitro, and also to help determine what stage of 
differentiation the cell may have reached. However, this is a developing and challenging 
area; defining the marker or groups of markers which can be reliably used to define a 
cell as a stem cell is a developing field. This is made more complicated by the possibility 
of interspecies differences and differences between different stem cell populations and 
stages of differentiation. A commonly used set of stem cell markers are Nanog, Oct 4 
and STAT 3 – each playing a critical role in self-rnewal and pluripotency. 
 
4.1.2.1 Stem Cell Markers  
 
4.1.2.1.1 Oct 4 
 
Oct 4 is a POU transcription factor which is crucial for regulation of cell fate in the early 
embryo. It has a highly preserved octamer homeodomain with a sequence ATGCAAAT 
(Pesce and Scholer, 2001).  
 
Oct 4 is expressed in the inner cell mass, and down-regulated post implantation in mice 
and human embryos (Cavaleri and Scholer, 2003). However, Kirchhof et al found that in 
the bovine and porcine species, Oct 4 was not only expressed in the inner cell mass (the 
totipotent cells) but also in the trophoectoderm; therefore Oct 4 expression differs 




Oct 4 is hypothesised to have a gene dosage effect, con rolling cell renewal at lower 
levels. Over-expression has been found to trigger ES cell specification toward cardiac 
and mesodermal development whereas Oct 4 repressed cells develop into 
trophoectoderm.  Oct 4 knockout mouse embryos are able to develop to the blastocyst 
stage, however the inner cell mass cells are not pluripotent (Nichols et al., 1998, Niwa et 
al., 2000, Chambers et al., 2003, Hou et al., 2007, Stefanovic and Puceat, 2007, Wang et 
al., 2008).  
 
Oct 4 can be also be found expressed within adult stem cells, and therefore has a general 
use as a marker of stem cells (Beltrami et al., 2007). However, Oct 4 expression has also 
been demonstrated in some adult human differentiated cells such as human peripheral 
blood mononuclear cells (Zangrossi et al., 2007).  
 
Cellular distribution of Oct 4 varies between cell lines.  In general within stem cell 
cultures, Oct 4 has a nuclear location, corresponding to its function as a transcription 
factor critical for self-renewal. However, Oct 4 has lso been demonstrated within the 
cytoplasm; Zangrossi et al found Oct 4 expression in the cytoplasm of  peripheral blood 
mononuclear cells; Cheng et al, found that cancerous germ cells expressed Oct 4 in the 
cytoplasm; whereas primordial germ cells displayed a typical nuclear expression leading 
them to the hypothesis that expression pattern may reflect the transition to a tumour cell 
line  (Cheng et al., 2007, Zangrossi et al., 2007).. 
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4.1.2.1.2 STAT 3 
 
Signal transducer and activator (STAT) proteins play a key role in cytokine signal 
transmission, mediated by the interleukin family of proteins. STAT 3 is activated by the 
interleukin-6 family of cytokines, including leukaemia inhibitory factor (LIF) and 
functions through receptor complexes containing the signal transducer gp130. These in 
turn activate the JAK pathways, thereby transmitting a cell membrane signal to the 
nucleus. Recruitment and translocation of STAT 3 to the nucleus modifies gene 
expression to sustain self-renewal (Niwa et al., 1998, Matsuda et al., 1999, Burdon et al., 
2002).  
 
STAT 3 is not ES cell specific but can be found in a umber of other cell types. It can be 
associated with cell movement such as leukocyte, epidermal and keratinocyte migration. 
It is also associated with cellular differentiation, such as B cell differentiation into 
antibody forming plasma cells and may play a role in neoplasia, where persistent 




First described in 2003, Nanog (named after ‘Tir nan Og’, the Celtic land of the ever-
young) works in parallel with STAT 3 to drive ES cell self-renewal, and blocks the 
differentiation effects of Oct 4. Also, by suppression of differentiation, Oct 4 expression 
is maintained (Chambers et al., 2003). Over-expression of Nanog promotes pluripotency 
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and this function is controlled by Nanog-Nanog dimer formation (Wang et al., 2008). 
Nanog has been found to be down-regulated transiently i  mouse embryos upon 
differentiation, and is thought to predispose cells to differentiate, but does not mark 
commitment. Interestingly, it is possible to culture pluripotent cells in the self-renewing 
state without Nanog, however it is essential for the formation of germ cells (Chambers et 
al., 2007). Adult stem cells have been described as positive for Nanog, suggesting the 
importance of this marker for pluripotency in certain cell populations (Beltrami et al., 
2007). 
 
4.1.2.2 Cardiac Stem Cell Markers  
 
More specific markers for CSCs have been described. These markers have been used in 
isolation and in panels to isolate specific progenitor populations from the heart itself. 
 
4.1.2.2.1 Islet 1 
 
Islet 1 is a developmental lineage marker which labels a cell population that contributes 
to the embryonic heart secondary heart field (Figure 4.1), including most cells of the 
right ventricle, both atria, specific regions of the left ventricle and the outflow tract. In 
mice lacking islet 1 the outflow tract, right ventricle and a large proportion of the atria 
are missing, indicating the importance of this marker in cardiac development (Cai et al., 
2003). Furthermore genetic variation in islet 1 hasbeen associated with non-syndromic 
congenital heart disease (Stevens et al., 2010). Laugwitz et al identified cells expressing 
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islet 1 in rat, mouse and human myocardium, and found mouse islet 1 positive cells 
capable of differentiation into the cardiomyocyte phenotype; mES cells isolated based 
on islet 1 expression were found to co-express Nkx2.5, and were capable of 
differentiating into cardiac, smooth muscle and endothelial cell lineages (Laugwitz et al., 
2005, Moretti et al., 2006). Human islet 1 positive ES cells are also capable of 
differentiating along all three major lineages during embryoid body development (Bu et 
al., 2009).  
 
4.1.2.2.2 Stem cell antigen 1 (Sca 1) 
 
Sca 1 has been used to isolate a cell population frm the adult heart which can 
differentiate in vitro into cardiomyocytes; Oh  et al found that Sca 1 positive cells 
isolated from the mouse were negative for cardiac structural genes and c-Kit and 
Nkx2.5, but positive for GATA 4 (Oh et al., 2003); Moretti et al found that cells isolated 
from the mouse had relatively high expression of CD45 (~40%) and low expression of 
c-Kit (~10%) (Moretti et al., 2006). Sca 1 is a commonly used marker for isolation of 
haematopoietic stem cells in the mouse. It is a member of the murine Ly6 gene family 
and encodes an 18 kDa glycosyl phosphatidylinositol-anchored cell surface protein. It 
has been proposed that Sca 1 may act as a co-signallin  molecule, which modifies the 
signalling capacity of a receptor complex, making the signal more efficient. A number of 
potential human homologs for murine Ly6 have been identified, however a direct 
homolog for Sca 1 has not been found (Holmes and Stanford, 2007). However, murine 
Sca 1 antibody has successfully been used to isolate a cell population from human 
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cardiac biopsies which are capable of high levels of differentiation (80-90%) into 
spontaneously beating cardiomyocytes when exposed to the de-methylating agent 
5’Azacytidine (5’AZA) and transforming growth factor β1 (TGFβ1) in vitro (Goumans 




C-Kit was first used to isolate a population of cells from the adult heart with properties 
of CSCs (Beltrami et al., 2003). C-Kit (CD117) is a stem cell marker and cells taken 
from the heart expressing this marker are capable of differentiating into cardiomyocytes 
(Beltrami et al., 2003, Kubo et al., 2008, Tallini et al., 2009, D'Amario et al., 2011). 
C-Kit has been used in a number of different species to define a CSC, including the 
mouse (Beltrami et al., 2003, Tallini et al., 2009) and the human (Bearzi et al., 2007, 
Aghila Rani et al., 2008). Wu et al found that isolating mES cells co-expressing c-Kit 
and the cardiac lineage marker Nkx2.5 identified a cell line capable of long-term in vitro 
expansion that was capable of differentiating into cardiomyocytes and smooth muscle 
precursors (Wu et al., 2006). Kubo found that there was an increased abundance of c-Kit 
positive cells in failing hearts of humans compared to normal hearts, and there was 





Flk-1 is also known as KDR (kinase insert domain receptor) and VEGFR-2 (vascular 
endothelial growth factor receptor 2). Flk-1 in combination with c-Kit has been used to 
isolate a population of CSCs which differentiated preferentially into endothelial and 
smooth muscle cells (D'Amario et al., 2011). It hasalso been shown that Flk-1 positive, 
c-Kit negative ES cells have the capacity for differentiation into all three major cardiac 
lineages (Yang et al., 2008) and Flk-1 positive, CXCR4 positive ES cells are enriched 
for cardiac progenitor cells (Nelson et al., 2008). It has also been proposed that Flk-1 in 
combination with islet 1 may define a population of cells with a preference for 
differentiation into endothelial and smooth muscle (Moretti et al., 2006). It has been 
suggested that Flk-1 positive cells are developmental precursors of the endocardium in 
the developing heart and can also be precursors of skeletal myocytes (Motoike et al., 




Nkx2.5 is a homeobox gene expressed early as part of the cardiac lineage (Martin et al., 
2004). Homeobox genes are part of a superfamily encodi g transcription regulatory 
proteins which act at critical points in development. The distinguishing feature of this 
family of genes is a structurally conserved DNA-binding motif known as the 
homeodomain, which contains the genetic data for prteins which are sequence specific 
DNA-binding factors. Murine Nkx2.5 is a protein of 318 amino acids, and Lints et al 
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found it to be heavily distributed in foetal and adult heart tissues, and also in NIH3T3 
fibroblasts. When Nkx2.5 expression was compared to that of α-cardiac actin and 
β-myosin heavy chain (β-MHC), it was found to be expressed prior to both in vivo, and 
in vitro, and could therefore be used as an early marker of cardiac myogenesis (Lints et 
al., 1993).  
 
4.1.2.2.6 GATA 4 
 
GATA 4 is part of the GATA family of transcription factors, known to have a regulatory 
effect upon differentiation, growth and survival of a diverse range of cell types. The 
family contains 6 proteins, GATA 1-6. GATA 1, 2 and 3 are important regulators of 
haematopoietic cells and their derivatives. GATA 4, 5 and 6 have a role in mesodermal 
and endodermal derived tissues. They are a highly conserved family of proteins 
throughout evolution, with members present in fungi, worms, flies, frogs, fish, chickens, 
mice and humans (Cantor and Orkin, 2005) and share a related zinc finger DNA-binding 
domain (Svensson et al., 1999). 
 
GATA 4 is one of the earliest transcription factors expressed in developing murine heart 
cells, and is expressed abundantly in cardiac myocytes during the animal’s lifespan 
(Heikinheimo et al., 1994). It has been shown to be a major binding factor in the 
developing heart, with over-expression increasing differentiation of beating 
cardiomyocytes and inhibition preventing differentiation and triggering apoptosis.  In 
GATA 4 knockout mice embryonic development fails, thought to be due to an 
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endodermal defect. In GATA 4 deficient mice (GATA 4 null chimera with C57/Black 6 
mice) the cardiomyocytes are able to differentiate, nd late cell markers are expressed 
including atrial natriuretic peptide (ANP) and α-myosin heavy chain (α-MHC) (Kuo et 
al., 1997). GATA 6 deficient ES cells show abnormal differentiation, and an increase in 
GATA 4 levels, so it is suggested that GATA 6 may regulate GATA 4 expression and 
GATA 4 is necessary for endodermal differentiation, but may not be essential for 
cardiomyocyte differentiation, where GATA 6 may replace it (Morrisey et al., 1998). 
GATA 4 and 6 share high homology in amino acid sequence, approximately 80-90% 
which may account for this effect (Morrisey et al.,1997). Murine GATA 6 gene contains 
an Nkx2.5 binding element essential for cardiac-specific expression of the promoter 
during cardiogenesis (Molkentin et al., 2000). GATA 4 has been shown to co-operate 
with a number of other transcription factors in vitro including MEF2, Nkx2.5 and GATA 
6 (Pikkarainen et al., 2004). 
 
GATA 5 is detected during embryonic development of the heart, lungs, bladder, 
urogenital ridge and the gut, and in adult gut, bladder, lungs, endocardium, but not the 
myocardium (Morrisey et al., 1997). 
 
4.1.3 Canine Adult Cardiac Stem Cells 
 
Canine adult stem cells have been isolated from the myocardium using fluorescence 
activated cell sorting (FACS) with antibodies for c-Kit, Sca 1 and MDR 1 (an 
ABC-transporter found in side-population cells). These cells were negative for lineage 
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markers for haematopoietic, cardiac and skeletal muscle and were capable of 
self-renewal. Following culture in differentiation media clonal cells differentiated into 
cells phenotypically resembling cardiomyocytes, endothelial cells, smooth muscle cells 
and fibroblast lineages. The cardiomyocyte-like cells xpressed GATA 4, GATA 6, 
MEF2C and Ets 1 – all factors of cardiac cell lineag s (Linke et al., 2005). 
Cardiospheres were generated using canine CSCs, plated onto a growth substrate poly-l-
ornithine. These cells were isolated from ventricular tissue and cultured in a stem cell 
media, containing growth factors, but no serum. The spheres grew up to ~230 µm 
diameter after 8 days in culture. Early spheres, around day 2-3, were strongly 
immunoreactive for stem cell markers c-Kit and pax 6; later spheres, around day 6-8 
strongly expressed cardiomyocyte specific markers – cardiac myosin heavy chain, 
cardiac troponin I (CTI) and cardiac sarcomeric actinin, as well as those for vascular 
endothelial cells – von Willebrand factor (vWF), and vascular smooth muscle 
cells-smooth muscle actin (SMA). Co-culture of the spheres with RNCMs promoted 
differentiation into both cardiomyocytes and also vascular cell phenotypes (Bartosh et 
al., 2008). 
 
4.1.4 Cardiac Stem Cells in Disease Treatment 
 
Adult stem cells derived from human endomyocardial biopsies cultured to form 
cardiospheres have been used to examine the therapeutic use of stem cells in vivo. The 
cardiosphere derived cells were injected into the border zone of acute myocardial 
infarcts in immunodeficient mice and the injected cells migrated into the infarct zone, 
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and were still present after 20 days. The percentag of viable myocardium within the 
infarct zone was higher in the cardiosphere derived cell treated group and this group also 
had a higher left ventricular ejection fraction when compared to the non-treated animals 
(Smith et al., 2007). Oh et al showed that Sca 1 positive adult CSCs from the mouse 
homed to the myocardium when injected intravenously ing a cre/lox system bound to 
the α-MHC gene. This showed that the cells relocated to the myocardium, and 
differentiated to express α-MHC – however it was impossible to discern if this 
expression was caused solely by differentiation of the injected cells, or by some level of 
cell fusion (Oh et al., 2003). Laflamme et al injected human cardiomyocytes derived 
from ES cells into infarcted rat hearts and found a improvement in contractile function 
and a limitation in dilation (Laflamme et al., 2007). Smits et al injected human CSCs, 
and cardiomyocytes derived from CSCs into the border zone of infarcts in mice and 
found that both cell populations improved cardiac function equally over three months, 
indicating that pure stem cell populations may be us d therapeutically, avoiding the 
lengthy in vitro differentiation procedures which may increase cellular mutation. 
Crucially it was seen that these cells did not fuse with the murine cells, thereby 
suggesting that it was a differentiation effect rather than cell fusion causing the 
improvements seen (Smits et al., 2009a).  
 
4.1.4.1 Native Cardiac Stem Cell Activation 
 
Realistically the therapeutic use of CSCs is always going to be limited due to the 
difficulty in isolation from cardiac tissue and the limited expansion potential in vitro. 
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However, activation of the endogenous stem cell population in situ would bypass the 
need to remove the CSCs. Linke et al demonstrated in a canine model the activation of 
resident cardiac stem cells in chronically diseased hearts using the growth factors Insulin 
like Growth Factor (IGF-1) and Hepatocyte growth factor (HGF) (Linke et al., 2005). It 
has also been demonstrated that priming of the Wilms tumour gene (Wt1) by peptide 
thymosin β4 (Tβ4) appears to drive a mild repair response in damaged myocardium 
most likely from cells of epicardial origin (Smart e al., 2011). Adopting this strategy 
would circumvent the need to remove stem cells prior to re-implantation, overcoming a 
number of the issues outlined above and is an area fo  future development. 
 
4.1.5 Differentiation of Cardiac Stem Cells 
 
CSC differentiation in vitro has been described in various species using a variety of 
culture techniques and pharmacological interventions a d importantly a variety of 
defining criteria varying from the development of spontaneous beating to the expression 
of one or more structural proteins (Table 4.1).  
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Table 4.1. Differentiation of cardiac stem cells using different species and techniques. CNX 43–connexi  43; CTI–cardiac troponin I; 
CTT-cardiac troponin T; β-MHC–β myosin heavy chain; α-MHC–α myosin heavy chain; MLC-2a-myosin light chain 2a; MLC-2v-myosin 
light chain 2v; vWF–von Willebrands Factor; SMA–smooth muscle actin., α-SA–α-sarcomeric actinin 
Author Year Cell 
source 
Technique Markers before Markers after Beating 
Beltrami et al 2003 Human Differentiation media; MEM + serum 
+ dexamethasone 
GATA 4, Nkx2.5, 
MEF2C 
GATA 4, Nkx2.5,  
MEF2C  
No 
Messina et al 2004 Human Direct co-culture with RNCM Flk-1, c-Kit, CD34 CTI, CNX 43 No 
Laugwitz et al 2005 Mouse Direct co-culture with RNCM Islet 1 α-SA, CTT No 
Goumans et 





Human Differentiation media; 
IMDM:DMEM Hams F12 + ITS+ 
premix + NEA + serum + 5’AZA + 
ascorbic acid + TGFβ1 
Sca 1, c-Kit, islet 1, 
GATA 4, Nkx2.5, 
MEF2C 
CTT, β-MHC, 
cardiac actin, α-SA, 
CTI,  
Yes 
Oh et al 2003 Mouse Differentiation media; M-199 + 
serum + 5’AZA 
Sca-1 α-SA, CTI, Nkx2.5, 
α-MHC, β-MHC 
No 
Gaetani et al 2009 Human Exposed to low frequency electro-
magnetic fields calcium ion cyclotron 
energy resonance 
CTI, Nkx2.5, MHC, 







2004 Mouse Differentitaion media; IMDM + 
serum + 5’AZA or Oxytocin 
Sca 1, Nkx2.5, 
GATA 4 














(Beltrami et al., 2003, Oh et al., 2003, Matsuura et al., 2004, Messina et al., 2004, 
Laugwitz et al., 2005, Goumans et al., 2007, Bartosh et al., 2008, Gaetani et al., 2009, 
Smits et al., 2009b).  
 
4.1.5.1 Cardiomyocyte Differentiation Mechanisms and Pathways  
 
The Wnt pathway is believed to be significant in the developing heart (Figure 4.2). It has 
been suggested that Wnt has a variable effect depennt upon both stage of 
differentiation, subset of progenitor cell, and dosage (Nakano et al., 2008). Notch is 
required to negatively regulate β-catenin of the Wnt pathway and allow cardiac 
progenitor cells to move from expansion toward differentiation (Kwon et al., 2009). 
DKK1, a Wnt inhibitor and Wnt11 and Wnt5A of the Wnt pathway were upregulated 
during cardiac differentiation on human ES cells using END-2 co-culture suggesting the 
importance of these factors during differentiation (Beqqali et al., 2006). Islet 1 
precursors are predominantly found in the secondary heart field and β-catenin is a key 
upstream regulator required to drive islet 1 expression in cardiac precursors (Cai et al., 
2003, Lin et al., 2007). Islet 1 triggers differentiation into cardiac cells by limiting 
self-renewal and interacts with STAT 3, and may control its activity in gene expression 





Figure 4.2. Cardiac differentiation controlled by the Wnt pathway. Canonical Wnt 
involving β-catenin, and non-canonical Wnt closely regulate developmental stages of 
cardiac differentiation via controlling terminal differentiation where activation and 
inhibition determine proliferation or terminal differentiation (Gessert and Kuhl, 2010).  
 
4.1.6 Clinical Trials 
 
Very few clinical trials exist using CSCs as the thrapeutic agent. This may be due to the 
difficulty in isolating the cells and difficulty in in vitro expansion thereby limiting 
available cell numbers for treatment. To date four trials are underway (Table 4.2). 
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Table 4.2. Clinical trials currently using cardiac stem cells (www. Clinicaltrials. Gov). 
Trial Name Trial Location Start and End 
SCIPIO Cardiac Stem Cell Infusion in 



















ALCADIA Autologous Human Cardiac-







TICAP Transcoronary Infusion of 
Cardiac Progenitor Cells in 









Results of these trials are awaited with great anticipation. Stem cell therapy in heart 
disease is hoped to be a successful future treatment, and has already been performed  
with alternative cell sources such as mesenchymal stem cells (discussed in Chapter 5; 
Mesenchymal Stem Cells). There is optimism regarding the use of ASCs for therapeutics 
with short term improvements seen as previously discus ed. However it will be 
interesting to compare the results using CSCs to those obtained with MSCs to see if 




This chapter investigates the isolation and culture of canine primary CSCs grown from 
harvested cardiac tissue. The CSCs will be characterised in terms of morphology, culture 
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behaviour and marker expression. Furthermore the CSCs will be differentiated toward 
cardiac lineages using two separate published techniques and a modified protocol of 
each to act as a control, and the resultant cell populations analysed for evidence of 
differentiation. 
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4.2 Materials and Methods  
 
4.2.1 Cardiac Stem Cell Isolation 
 
4.2.1.1 Tissue Samples 
 
Full thickness canine cardiac tissue was harvested from the right and left atria (including 
auricles) and ventricles immediately post mortem from dogs euthanized for clinical 
reasons, and with owners’ consent. Tissue was placed immediately into chilled cardiac 
explant media (CEM); Iscove’s Modified Dulbecco’s Medium (IMDM; Invitrogen, UK. 
Catalogue number 21056) supplemented with 10% fetalcalf serum (Invitrogen, UK), 
100 U/mL Penicillin G  and 100 µg/mL Streptomycin (both Invitrogen, UK); 2 mmol/L 
L-glutamine (Gibco, UK); 0.1 mmol/L 2-Mercaptoethanol (2-ME; Sigma, UK) and 
transported directly to the laboratory for processing. In addition, sections of myocardium 
were taken and stored immediately in RNAlater (Qiagen, UK) at -20 °C to use for whole 
heart RNA extraction. 
 
4.2.1.2 Tissue Preparation 
 
Cardiac tissue was dissected into 1-2 mm³ pieces, wa hed with Ca ++ and Mg ++ free 
PBS and digested with 0.2% trypsin (Invitrogen, UK) and 0.1% collagenase IV 
(Invitrogen, UK) for 5 minutes at 37 °C; this was repeated 3 times. The tissue explants 
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were rinsed with CEM media. The tissue was then placed into Fibronectin (Costar, 
Cambridge) coated T25 flasks with CEM media and cultured at 37 °C in 5% CO2. 
 
4.2.1.3 Isolation of Cardiac Stem Cells 
 
Explants generally became adherent to the flasks over a period of 3-4 weeks and 
generated an adherent fibroblast layer. In addition, small phase bright non-adherent cells 
appeared over the fibroblasts. These cells either appe red singly or arranged themselves 
into free-floating grape-like clusters or were loosely attached to the fibroblast layer. The 
phase bright cells were harvested by pooling the CEM media containing the phase bright 
cells with two PBS washes. The cells obtained usually r nged in number from 2 x 104 to 
3 x 105 and were considered to be CSCs. 
 
4.2.2 Cardiac Stem Cell Culture 
 
Harvested CSCs from explant culture were counted and seeded onto 24 well plates at a 
total cell count of approximately 5 x 104 in 600 µL basic cardiosphere growing serum-
free media which comprised: 35% IMDM; 65% Dulbecco’s Modified Eagle’s Medium 
(DMEM) – Ham F-12 mix (Invitrogen, UK. Catalogue number; 21331) supplemented 
with 2% 50X B27 (Invitrogen, UK); 0.1 mmol/L 2-ME; 10 ng/mL epidermal growth 
factor (EGF, Peprotech, UK); 20 ng/mL basic fibroblast growth factor (bFGF, 
Peprotech, UK); 40 nmol/L Cardiotrophin-1 (Invitrogen, UK); 40 nmol/L bovine 
thrombin (Sigma, UK); 100 U/mL Penicillin G; 100 µg/mL Streptomycin; 2 mmol/L 
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L-Glutamine. The cells were fed every 2-3 days by the addition of 2.5 ng/mL 
cardiotrophin; 1.5 ng/mL EGF and 1.5 ng/mL bFGF.  Under these conditions cells either 
remained singly or formed large spherical clusters which are referred to as cardiospheres 
from approximately 7 days. CSCs were taken for analysis at days 0, 5, 10 and 15 from 
serum free culture from multiple dogs. Repeated harvests of viable CSCs were collected 
from the original T25 flasks, approximately every 1-2 weeks over a period of up to 
4 months. 
 
4.2.3 Cardiac Stem Cell Clonal Expansion 
 
CSCs were harvested from explant flasks as described in ‘Isolation of Putative Cardiac 
Progenitor Cells’ (Chapter 2; Materials and Methods) and re-suspended in 1 mL of 
cardiosphere growing media. Cells were counted using a haemocytometer and trypan 
blue, and adjusted to a total cell count of 5 cells/mL. 96 well plates (TPP Tissue Culture 
Plates, USA) were coated with 0.1% gelatin and 100 µL of cell suspension was added to 
each well. Plates were incubated at 37 °C in 5% CO2. ells were passaged every 3-4 
days by removing the media, and washing the attached ells once with PBS, and adding 
100 µL of fresh cardiosphere media. Cell cultures were examined twice weekly, and 
wells with clonal expansion were monitored. At 80-90% confluence, media was 
removed from the cells and the cells washed once with PBS. Cells were removed from 
the gelatin with 0.05% Trypsin/EDTA (Invitrogen, UK), and re-suspended in 
cardiosphere growth media. Cells were initially spilt 1:2, and increased to a 1:5 split as 
cells numbers increased. 
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4.2.4 Magnetic Activated Cell Sorting (MACS ®) 
 
CSCs grown in either 24 well plate culture or T25 flasks in cardiosphere media were 
sorted using c-Kit (CD117) MACS® Microbeads (MiltenyBiotec, Germany). Separation 
buffer was prepared; PBS, pH 7.2 plus 0.5% FBS (Invitrogen, UK) and 2 mmol/L 
EDTA and filter sterilised. CSCs were harvested and counted and subsequently re-
suspended in 300 µL of separation buffer. 50 µL of FcR blocking reagent and 50 µL 
c-Kit beads (both Miltenyi Biotec, Germany) were adde  to the cell suspension. The 
suspension was incubated for 30 minutes at 4 °C with ro ation. The cells were then 
washed in 5 mL of cold separation buffer and centrifuged at 300g for 10 minutes, after 
which the supernatant was discarded. Cells were re-suspended in 1 mL of separation 
buffer and applied to a LS MACS column attached to a MACS Separator (both Miltenyi 
Biotec, Germany). The c-Kit negative fraction was removed from the column and placed 
into cardiosphere growing media. Following this thec-Kit positive fraction was obtained 
and placed into cardiosphere growing media. Both positive and negative fractions were 
then placed at 37°C in 5% CO2 for continuous culture, or harvested for either RNA 
extraction or immunofluorescence. 
 
4.2.5 D17 Canine Osteosarcoma Cell Culture as a Con trol Line 
 
D17 (canine osteosarcoma) adherent cells and spheres were used as a positive control 
cell line. Adherent monolayer cells were cultured in RPMI 1640 (Invitrogen, UK) with 
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10% FBS (Invitrogen, UK) on standard tissue culture plastic. D17 spheres were cultured 
using ultra-low attachment six well plates (Corning, UK) containing 2 mL N2 medium 
with 1% methylcellulose. The N2 media consisted of 2 x Dulbecco’s modified Eagle 
medium (DMEM)/F12 with progesterone (20 nmol/L), putrescine (100 mol/L), sodium 
selenite (30 nmol/L), transferrin (25 g/mL), insulin (20 g/mL) (Sigma Biochemicals) and 
two growth factors, human EGF (10 ng/mL) and human bFGF (10 ng/mL) (Peprotech). 
These cells were cultured as described previously by Wilson et al (Wilson et al., 2008). 
 
4.2.6 Transcriptional Analysis of Cardiac Stem Cell s 
 
RNA was extracted and cleaned up from cell pellets of cultured CSCs from multiple 
dogs over 15 days. 50 ng of total RNA was reverse tanscribed and PCR studies 
performed on two dogs as described in Chapter 2; Materials and Methods. Cells were 
analysed for the expression of; STAT 3, Nanog, c-Kit, islet 1 Flk-1, Nkx2.5, GATA 4 
and cardiac troponin T. GAPDH was multiplexed in each reaction. Cardiac markers 
were optimized using whole heart tissue RNA, STAT 3 using D17 RNA and Nanog 
using canine ovarian tissue RNA. Primers were design d and prepared as described in 
Chapter 2; Materials and Methods (Table 4.3). 
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Table 4.3. Oligonucleotides for canine sequences. CTT- ardiac Troponin T; Beta 1 Ad- 
β1-adrenergic Receptor; Cardiac RyR-Cardiac Ryanodine Receptor; CTI-Cardiac 
Troponin I; VEGF-Vascular Endothelial Growth Factor; vWF-Von Willebrands Factor; 
SMA-Smooth Muscle Actin. F–Forward primer; R –Reverse primer. 
 
Marker Sequence 5'-3' Size (BP) Tm (°C) 
STAT 3 F: GTG GAG AAG GAC ATC AGC AAT AA 250 56 
 R: AAC TTG GTC TTC AGG TAT GGG GC   
Nanog F: CAG AAG ATG AGG ACG GTG TTC TC 189 58 
 R: CCA GTT GCT TTT CTG CCA CCT C   
C-Kit F: ATA TCC CAA ACC GGA GCA C 193 58 
 R: TCA CCG AAG AAT TGA CAT CG   
Islet 1 F: GGT TTC TCC GGA TTT GGA AT 183 57 
 R: CAC GAA GTC GTT CTT GCT GA   
Nkx2.5 F: CCA AGG ACC CTC GAG CTG A 185 62 
 R: CGA CAG ATA CCG CTG CTG CT   
GATA 4 F: CAA GAT GAA TGG CAT CAA CC 216 57 
 R: GGT TTG AAT CCC CTC TTT CC   
Flk-1 F: CCA CCC AGA CTC AGC ATA CA 188 58 
 R: CAC TTT TGG AAT CGT GAG CA   
CTT F: GAA GGA CCT GAA CGA ACT 210 60 
 R: CCT CCT GTT CTC CTC CTC CT   
Beta 1 Ad F: GAG TAC GGC TCC TTC CTG TG 274 61 




Marker Sequence 5'-3' Size (BP) Tm (°C) 
Cardiac RyR F: AAG CGA AGC AGC CCA AGG GT 888 62 
 R: TCA GCA AAG TGT GCC GCG CT   
CTI F: TCT GCG CAT GGC GGA TGA GA 624 62 
 R: TTG CGG CCC TCC ATT CCA CT   
VEGF F: TTC CTG CAG CAT AGC  AAA TG 293 
(239,311) 
57 
 R: AGG GAG GCT CCT TCT TCC AG   
vWF F: CTG GGA GAA GAG AGT CAC GG 235 61 
 R: GTG GAT GGA GTA CAC GGC TT   
SMA F: GGG GAT GGG ACA AAA GGA CA 525 61 
 R: GCC ACG TAG CAG AGC TTC TCC TTG A   
Glomulin F: TTG AAG AGC CCT CTG GAA AA 131 57 
 R: ACT CCA AAG GGT GGA CAA TG   
Connexin 43 F: ATG AGC AGT CTG CCT TTC GT 
 
249 58 
 R: TCT GCT TCA AGT GCA TGT CC   
GAPDH F: CAT CAA CGG GAA GTC CAT CT 428 Various 








CSCs were cultured on 4 well chambered slides as describ d in Chapter 2; Materials and 
Methods. Cells were fixed and primary antibodies to c-Kit (Dako, UK. Cat no. A4502; 
previously validated in the canine (Morini et al., 2004)) and Flk-1 (Abcam, UK. Cat no. 
Ab2349; cross-reactive with canine) were diluted at a 1:100 in PBST (0.1% normal goat 
serum; 0.1% Tween 20 in PBS) and placed on the cells overnight in a humidified 
chamber at 4 °C. The following day the cells were washed, and labelled with secondary 
antibody Alexafluor 488 conjugated goat polyclonal anti-rabbit IgG (Invitrogen, UK), at 
1:500, for 1 hour at room temperature. Nuclei were subsequently labeled using a DAPI 
mount (Vectastain, Vector Labs, UK) and slides stored at -20 °C. 
 
4.2.7.2 Western Blot 
 
CSCs were isolated and harvested as previously describ d. Following 12 days in serum 
free stem cell culture the cells were harvested andprotein extracted as previously 
described. Protein was quantified using Bradford analysis, and loaded into an SDS page 
gel and transferred to a nitrocellulose membrane.  
 
The blot was then probed using three rabbit polyclonal primary antibodies; anti-Oct 4, 
anti-STAT 3 and anti-Nanog (Abcam, UK. Catalogue numbers: ab19857, ab30646, 
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ab21603 respectively) diluted at 1:500, 1:250 and 1:250 respectively and left overnight 
at 4 °C. Mouse monoclonal primary antibody to beta-actin (Abcam, UK. Catalogue 
number: ab6276) was used as a loading control, dilute  at 1:2000. Swine polyclonal to 
rabbit IgG horseradish peroxidase conjugated secondary (Dako, UK. Catalogue number 
PO217) and Goat whole molecule IgG antibody to mouse secondary antibodies (Sigma-
Aldrich, UK. Catalogue number A-3562) were used at 1:1000 dilution and left at room 
temperature for 1 hour. Biorad ECL chemiluminescent detection system (Biorad, UK) 
was used to detect protein bands, and results visualised by exposure to radiographic film. 
 
4.2.8 Cardiac Directed Differentiation of Cardiac S tem Cells 
 
CSCs were harvested from explant flasks as previously described. A 48 well plate was 
coated with 0.1% gelatin, and 2 x 104 cells were placed into each well. Two dogs were 
used for the studies, and two published differentiation protocols were followed for each 
dog – that described by Smits et al (Smits et al., 2009b) and that described by Oh et al 
(Oh et al., 2003). Triplicate wells for each dog following each protocol were plated, plus 
triplicates of a modified standard protocol as a differentiation control, and a triplicate of 
cells maintained in cardiosphere media for each dog was run as a negative control. 
Initially all wells were placed into cardiosphere media for 5 days, with half media 
changes every 2 days,  to establish stem cell colonies. At that point the individual 
protocols were initiated.  
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4.2.8.1 Differentiation based upon Smits et al 
 
Following 5 days in stem cell culture, cardiosphere media was removed and cells gently 
washed twice with PBS. Fresh cardiosphere media was added to control stem cell wells. 
Basic differentiation media was added to all differentiating cell wells; 235 mL of IMDM 
and 235 mL of Ham’s F12 nutrient mixture with GlutaMAX-I , 10 mL FBS, 1 x (5 mL) 
MEM nonessential amino acids, 1 x (5 mL) insulin-transferrin-selenium (all Invitrogen, 
UK),  and the cells were cultured in this media for 24 hours. At this point the media was 
removed, and fresh differentiation media was added including 5 µmol/L 5’ AZA (Sigma, 
UK). For a further 2 days 5 µmol/L 5’AZA was added, at which point media was 
removed and the cells were washed in PBS, followed by 2 days of standard 
differentiation media.  Following this, media was refreshed every 2 days, with 
17.5 µg/mL of ascorbic acid (Sigma, UK) added. For standard differentiation 1 ng/mL of 
TGFβ1 (Peprotech, USA. Catalogue number 100-21C) was added every 4 days; a 
modified protocol without adding TGFβ1 was performed alongside. This was continued 
for 17 days, (Figure 4.3) at which point cells were harvested and pelleted, with the 
triplicates pooled to increase cell numbers, generating an average. Throughout the 
experiment CSC control wells were cultured alongside, and had cardiosphere media 





Figure 4.3. Differentiation protocol based upon Smits et al. Cardiac stem cells (CSCs) 
were differentiated using 5’AZA and ascorbic acid (AA) with and without transforming 
growth factor-β (TGFβ1) over 22 days.  
 
4.2.8.2 Differentiation based upon Oh et al 
 
Following 5 days in stem cell culture, cardiosphere media was removed and cells gently 
washed twice with PBS. Fresh cardiosphere media was added to control wells and 
M-199 media (Cambridge Bioscience, UK) with 10% FBS was added to the 
differentiating wells and all wells left for 3 days with daily media changes. After 3 days 
the media was removed and replaced with M-199 media containing 2 % FBS with 
3 µmol/L 5’AZA. Fresh 2% serum M-199 media was added after 3 days of 5’AZA 
treatment and media refreshed every 3 days for a total of 17 days (Figure 4.4), at which 
point cells were harvested and pelleted as above. A modified protocol was run alongside 
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which did not have 5’AZA added to the M-199 media. Furthermore control cardiac stem 




Figure 4.4. Differentiation protocol based upon Oh et al. CSCs were differentiated in 
M-199 media with and without 5’AZA over 22 days. 
 
Pooled cell pellets were snap frozen and stored at - 80°C. RNA was extracted and 
reverse transcribed as described in Chapter 2; Materials and Methods and used 
downstream for semi-quantitative and quantitative PCR using primers described in 
Table 4.3. 
 
4.2.8.3 Quantitative RT-PCR Analysis of Cardiac Directed Differentiation 
 
Primers and probes for GATA 4, Flk-1 and CTT were designed and prepared as 
described in Chapter 2; Materials and Methods and primers ordered from MWG 
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Eurofins and probes from Roche. Nkx2.5 primers and probe were designed using the 
Applied Biosystems software, and ordered pre-bound to probe at a 20 x concentration 
from Applied Biosystems. Primer and probes sequences ar  described in Table 4.4. 
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Table 4.4. Primer sequences and probe product information for quantitative RT-PCR for CTT, GATA 4, Flk-1 and Nkx2.5. 
 






Probe Number (Roche, UK) or 
sequence 
CTT AGG AGG AGG AGC 
TGA TTT CAC 
 
59 CTC CTT CTC CCG 
CTC GTT 
 
60 95 132 
GATA 4 ACG GAA GCC CAA 
GAA CCT TA 
 
60 CAG GAG GAA GGC 
TCT CAC C 
 
59 71 62 
Flk-1 CAC CAC ATC CGC 
TGG TAC T 
59 GGT TTG TCA TTA 
AGA CAG CTT GG 
 
59 73 25 
Nkx2.5 CAA GGA CCC TCG 
AGC TGA T 
53 AGC TCC ACC GCC 
TTC TG 
 








4.2.8.3.1 cDNA Synthesis 
 
Extracted RNA from cardiac differentiation pellets was reverse transcribed as described 
in Chapter 2; Materials and Methods. 
 
4.2.8.3.2 PCR Master Mix 
 
A master mix was prepared for CTT, Flk-1, GATA 4, Nkx2.5 and 18s rRNA controls as 
described in Tables 4.5, 4.6 and 4.7. 
 
Table 4.5. Target gene master mix for CTT, Flk-1 and GATA 4 
 
Master mix 1 x (µL) (n x =number  of wells) 
Realtime Master mix 5 
10 x Primer/Probe (FAM) 0.3 
 
Table 4.6. Target gene master mix for Nkx2.5 
 
Master mix 1 x (µL) (n x =number  of wells) 
Realtime Master mix 5 




 Table 4.7. Target gene master mix for 18s rRNA control gene  
Master mix 1 x (µL) (n x =number of wells) 
Realtime Master mix 5 
20 x 18s VIC Control 0.15 
Water 0.15 
 
4.2.8.3.3 Primer Efficiency and Optimisation 
 
Real time plates and cover foils were ordered from Roche, UK. RNA was extracted from 
canine whole heart tissue for use as a positive control and 100 ng of total RNA was used 
for reverse transcription to cDNA. Neat cDNA was serially diluted 1:2.5, 1:5, 1:10 and 




Figure 4.5. 96-well plate plan for CTT, GATA 4, Flk-1 and Nkx2.5 primer optimization. 
Wells were designed to allow for triplicates of whole heart tissue (WHT) cDNA 
dilutions (1:2.5, 1:5, 1:10, 1:50). Triplicate wells of water negative controls were run, 
and –RT wells of sample RNA were run with each prime . Primers for CTT, GATA 4, 
Flk-1 and Nkx2.5 were bound to a FAM probe, and prime s for 18s rRNA in-house gene 
positive control bound to a VIC probe.  
 
5.3 µL of appropriate master mix (FAM; CTT, Flk-1, GATA 4 or Nkx2.5. VIC; 18s 
rRNA) and 4.7 µL of appropriate cDNA dilution was added to each well.  4.7 µL of 
diluted sample RNA (-RT) or 4.7 µL of DEPC treated water was added to each control 
well. Wells were sealed shut using a foil and centrifuged at 1500g for 2 minutes to pool 
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samples into base of wells. Plates were placed into the Roche Lightcycler 480 and run 
on a relative analysis programme as described in Table 4.8: 
 
Table 4.8. Programme data for Roche Lightcycler 480 
 
Programme Cycle Acquisition 
Pre-incubation 1 N 
Amplification 50 Quantify 
Cooling 1 N 
 
 With individual cycles as described in Table 4.9: 
 
Table 4.9. Temperature settings per cycle for Roche Lightcycler 480 
Programme Temperature (°C) Acquisition Hold  Ramp 
Pre-Incubation 95 N 10 minutes 4.4 
95 N 10 seconds 4.4 
54 N 30 seconds 2.2 
Amplification (50 x) 
72 Single 1 second 4.4 




Data was exported to Microsoft® Excel and a primer efficiency curve was generated 
including an R2 value, which gave an indication of reaction efficiency (a value closer to 
1 is more efficient).  
 
4.2.8.3.4 Relative Gene Expression Analysis 
 
Following primer optimization samples could be compared for relative expression of 
specific gene targets. 100 ng of total RNA of each sample from dog A and B Oh 
protocols were reverse transcribed and the subsequent cDNA analysed at a 1:5 dilution. 




Figure 4.6. 96-well plate plan for gene expression analysis. Wells were designed to 
allow for triplicates of sample cDNA from both dogs A and B with (+ AZA) and without 
(-AZA) 5’AZA. Triplicate wells of WHT cDNA were run alongside in multiple 
dilutions. Diluted RNA and water controls were run concurrently. Primers for CTT, Flk-
1, GATA 4 and Nkx2.5 were bound to a FAM probe, and primers for 18s rRNA in 
house gene positive control bound to a VIC probe.  
 
The plate design allowed for comparison between differentiated (+AZA) and 
undifferentiated (-AZA) samples in two dogs, A and B following the Oh protocol. 
Whole heart tissue cDNA was added to allow for a reference control sample. All 
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negatives were run on the same plate using the samemaster mix that was used for the 
samples. 
 
4.2.9 Cardiac Stem Cell Co-Culture with Mesenchymal  Stem Cells 
 
Canine CSCs were grown in indirect co-culture with autologous MSCs using a transwell 
system.  
 
4.2.9.1 Harvest of Cardiac Stem Cells and Mesenchymal Stem Cells 
 
CSCs and MSCs were harvested as described in Chapter 2; Materials and Methods and 
placed in DEM media and counted.  
 
Following the plate plan in Chapter 2; Materials and Methods, 2 x 104 CSCs were 
seeded into base wells of the 24 well plate (growth area 1.9cm2) in 600 µL of DEM 
media, with 1 x 104 MSCs seeded onto transwell inserts (growth area 0.33 cm2) in 
100 µL DEM media.  Control wells of CSCs alone were cultured alongside. Plates were 
then placed at 37 °C in 5% CO2. Day 0 CSCs were pelleted at this point, and snap frozen 
and stored at -80 °C. Images and harvests from both co-cultured and control wells were 
taken at days 6 and 10 post-plating and cells pelleted and snap frozen and stored at 
-80 °C. RNA was subsequently extracted from pellets and used for semi-quantitative 
RT-PCR analysis as described in Chapter 2; Materials and Methods for all markers in 




4.3.1 In Vitro Cardiac Explant Culture   
 
Cardiac tissue explants were taken post-mortem and cultured to enable outgrowth of 
putative stem cells. Explants become anchored to the base of the flasks within 3-4 weeks 
and an adherent fibroblast layer grew out from the explant. Varying numbers of 
spherical phase bright cells were also apparent in the culture media and appeared either 
singly or in grape like clusters; either free floating or loosely adherent to the underlying 
fibroblast layer (Figure 4.7). We defined these cells as CSCs based upon their 
characterization and published literature (Messina et al., 2004).  Subjectively, cell 
numbers peaked between 2nd and 3rd harvest  and atrial explants consistently produced 
more phase bright cells compared to the ventricles, and were therefore used for all the 





Figure 4.7. Cardiac explant culture. Large round phase bright cells migrated from cardiac explants over a layer of fibroblast like 
cells, and were often found in clusters free floating n the media or lightly attached to the fibroblast layer (magnification A, x 






4.3.2 In Vitro Culture of Cardiac Stem Cells 
 
Following harvest from explant culture CSCs were placed into serum free stem cell 
media. Over a 2-3 week culture period cells maintained their large circular size, typically 
forming cardiospheres (Figure 4.8). Over time these cardiospheres continued to increase 
in size and number, and could be harvested, and passaged. CSCs could be maintained in 





Figure 4.8. Cardiospheres in culture. CSCs formed large clusters in serum free culture 
conditions appearing morphologically like cardiospheres (magnification x 100). 
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4.3.3 Clonal Expansion of Cardiac Stem Cells 
 
To demonstrate clonal expansion, a characteristic of stem cell populations (Messina et 
al., 2004), the CSCs were plated at low density. Single cells adhered to gelatin within 12 
hours following low density cell plating. Over 5-7 days these individual cells produced 
large spherical colonies indicative of clonal expansio . These spheres could be passaged, 
creating more spheres. At passage, a large central cell could be seen, surrounded by cells 




Figure 4.9. Clonal expansion of CSCs. The cells were capable of clonal expansion in 
serum free culture conditions; CSC plated at low cell number could be seen as individual 
stem cells in adherent culture (A and B) which formed spheres over 7 days (C and D) 
(A-D, magnification x 200). Passage of cardiospheres following clonal expansion (E) 
demonstrated cells of varying sizes surrounding a large central cell resembling a CSC 
(magnification x 400).  
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4.3.4 Characterisation of Cardiac Stem Cells   
 
4.3.4.1 Oct 4, Nanog and STAT 3 Stem Cell Markers 
 
4.3.4.1.1 Western Blot 
 
CSCs were analysed for their expression of the pluripotency stem cells markers Oct 4, 
Nanog and STAT 3 using western blotting of protein xtracted from cardiosphere 
cultures and both adherent and sphere forming D17 cells as a control. Following 
extraction, total protein was quantified using Bradfor  analysis. Low levels of total 
protein were extracted (0.09 µg/mL) from cardiosphere pellets, and therefore a limited 
amount of protein was loaded into the blot (approx 0.6 µg total). Blots were probed for 
approximately 45 hours using primary antibody for Oct 4, Nanog and STAT 3, with 
secondary antibody exposure lasting 90 minutes at room temperature. All three 
antibodies identified protein bands in the two canine protein samples and both the 
adherent and sphere D17s. STAT 3 appeared at the predicted size of 88 kDa in all cell 
lines (Figure 4.10). However, both Nanog and Oct 4 appeared at a larger size than that 
predicted (100 kDa versus 39 kDa and 75 kDa versus 43 kDa respectively) and was 
therefore considered to be non-specific binding (data not shown). Beta-actin controls 





Figure 4.10. Western blot analysis of STAT 3 expression in cardiospheres (CSC) and 
D17 cell lines; adherent (D17Ad) and sphere (D17Sp). TAT 3 at expected product size 
88kDa. Beta-actin loading control at expected size 42kDa. 
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4.3.4.1.2 Immunofluorescence for Oct 4, Nanog and STAT 3 
 
Cardiosphere cultures were examined for Oct 4, Nanog and STAT 3 expression using 
immunofluorescence. A strong fluorescent signal for Oct 4 could be detected in both 
cardiosphere cells and adherent D17s (control cells). Staining appeared to be both 
nuclear and cytoplasmic and the majority of cells were Oct 4 positive in both CSCs and 
control cells (Figure 4.11. Images donated by Dr Sally-Anne Argyle). Nanog 
fluorescence was also present in CSCs, however in contrast to Oct 4, the staining was 




Figure 4.11. Immunofluorescence analysis of CSC cultures for Oct 4 following growth in cardiosphere media with adherent D17 
cells for positive control. Oct 4 (FITC) is seen distributed heavily within both (A) Cardiospheres (B) D17 cells. Oct 4 labelled 









Figure 4.12. Immunofluorescence (IFA) analysis of CSC cultures following growth in cardiosphere media. CSC cultures were 
positive for Nanog within cytoplasm (FITC, A), nuclei counterstained for DAPI. Negative control of secondary antibody alone 






4.3.4.2 Cardiac Stem Cell Markers  
 
4.3.4.2.1 Expression at Transcriptional Level 
 
Cellular harvests from multiple dog explant cultures were placed into cardiosphere 
culture media and subsequently harvested at different time points, over a 15 day period. 
Cellular marker expression levels were examined compared to whole heart tissue using 
an internal GAPDH positive control as a multiplex raction. Over the time course there 
was very little change in expression patterns across all markers, indicating that the cells 
were maintaining their expression profiles over time within the cardiosphere media 
when examined with two dogs (Figure 4.13). Furthermore, comparing expression of the 
same markers using multiple dogs demonstrated little variation between CSCs harvested 
from different dogs (Figure 4.14). Due to experimental limitation, some dog CSCs were 
analysed at multiple time points, whereas others were analysed at only one harvest. 
STAT 3 levels remained high throughout the time course, and had similar levels to the 
whole heart. C-Kit levels appeared high throughout the time course, and higher for the 
stem cells than for whole heart tissue with some variation between dogs and time points. 
Islet 1 was not expressed in CSC populations with the exception of dog 10 at day 6, and 
dog 8 at day 15 and in these isolated cases the cultures appeared to have a reduced 
expression of c-Kit and Flk-1. We were unable to analyse these populations further. 
Flk-1 appeared to have high expression across all time points, with a suggestion of lesser 
expression in whole heart. Both Nkx2.5 and CTT were only expressed in the whole heart 
cultures, whereas GATA 4 was expressed at relatively constant levels across all the time 
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points, and with a similar level in the whole heart. It was seen that for the time 0 analysis 
there appeared to be a reduced level of expression for all markers, including the 
standardised control GAPDH; GAPDH levels returned to a constant high level from day 





Figure 4.13. Semi-quantitative RT-PCR of extended culture CSCs from two dogs. Cells 
were cultured in serum free media and examined for marker expression at a 
transcriptional level. No difference was seen with eit er dog in marker expression over 
15 days when compared to whole heart tissue (WHT). 
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Figure 4.14. Semi-quantitative RT-PCR of extended culture CSCs from multiple dogs. Little difference in seen in marker 
expression when comparing between CSCs from different dogs over all time points examined (days in serum free media). Dog 






4.3.4.2.2 Immunofluorescence Imaging for C-Kit and Flk-1 of Cardiac Stem Cells 
 
CSCs were grown on chambered slides on gelatin to allow cells to adhere. 24 hours 
following plating individual cells were fixed and labelled for c-Kit and Flk-1 expression 
using immunofluorescence (IFA) (Figure 4.15 and 4.16). C-Kit clearly had a cell surface 
and cytoplasmic distribution (Figure 4.15), whereas Flk-1 had a nuclear location, both as 
expected (Figure 4.16 A). DAPI was used to counterstain nuclei, and negative controls 





Figure 4.15. CSCs express c-Kit using IFA. C-Kit expression was located within 
cytoplasm and upon cell surface within adherent cells. Representative light microscope 
images are seen paired with IFA images. Negative controls were performed using 






Figure 4.16. . CSCs express Flk-1 using IFA. Flk-1 expression was located within the 
nucleus of adherent cells (A). Representative light microscope images are seen paired 
with IFA images. Negative controls were performed using secondary antibody only (B), 
showing DAPI only staining. Magnification x 400. 
 
Following this stem cells were again grown on gelatin coated chambered slides for 
5 days to allow the growth of cardiospheres. These were labelled for c-Kit. Again 
negatives controls were run in conjunction as before (Figure 4.17).Cardiospheres were 
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found to be strongly positive for c-Kit expression, which was not seen in negative 
controls. DAPI labelling of nuclei clearly showed living cells within the spheres.  
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Figure 4.17. Cardiospheres were found to strongly express c-Kit. (A) Multiple cardiospheres can be seen at low magnification 





magnification (B) the sphere cells can be seen brightly labeled for c-Kit (magnification 
x 400). Negative control spheres were labelled with secondary antibody only and clearly 
show no c-Kit labeling within spheres.   
 
4.3.5 Magnetic Cell Sorting of Cardiac Stem Cells 
 
Putative CSCs were partially selected for stem cell phenotype by transfer into 
cardiosphere media for a minimum of 7 days. Following this CSCs were sorted for c-Kit 
using MACS. The c-Kit magnetic beads pulled out an approximately 2-4% positive 
fraction from the cell suspension, clearing debris and fibroblast cells from the initial cell 
suspension. These cells appeared morphologically similar to the putative cardiac stem 




Figure 4.18. Culture morphology of c-Kit sorted cells at 7 and 14 days post sorting. 
Spheres and adherent cells formed in both c-Kit positive and negative populations at 
both time points. Magnification x 100 
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4.3.5.1 Transcriptional Analysis of MACS Sorted Cells 
 
RT-PCR analysis was used to examine the expression of c-Kit, Flk-1 and islet 1 in cells 
immediately post-sorting. Three dogs were used, creating triplicate results. No 
difference was seen in the expression of c-Kit across the positive and negative fractions 
suggesting poor selection efficiency. Furthermore no difference was seen in the 
expression of islet 1 and Flk-1. D17 adherent cell RNA and whole heart tissue RNA 
were run as positive controls, and GAPDH was multiplexed as an internal positive 
control (Figure 4.19). 
 
C-Kit sorted cells were then placed into CSC culture conditions in cardiosphere media 
for 14 days to examine any expression changes over tim . Two dogs were used for this 
study. No difference in c-Kit expression was seen btween positive and negative sorted 
fractions at time 0, 7 or 14 days using semi-quantit tive RT-PCR (Figure 4.20). GAPDH 




Figure 4.19. Semi-quantitative RT-PCR analysis of c-Kit sorted cells. Expression of c-Kit, Flk-1 and Islet 1 was compared in 
positive and negative fractions in triplicate, using D17 and whole heart tissue (WHT) RNA as positive controls, and GAPDH run 








Figure 4.20. Semi-quantitative RT-PCR analysis of c-Kit sorted cells over time in culture. Once sorted cells were cultured for 
14 days, and RNA extracted as days 0, 7 and 14. Samples were run with duplicate dogs (A and B). GAPDH was run as a 





4.3.5.2 Immunofluorescence following MACS of Cardiosphere Cultures 
 
Protein expression of Oct 4, Nanog, STAT 3 and c-Kit protein expression was 
investigated following MACS sorting for c-Kit of CSCs which had been in cardiosphere 
media for 16 days.This was examined in both positive and negative fractions. There was 
an approximately 2-4% pull down of c-Kit positive clls from the whole cardiosphere 
preparation, comparable with previous sorting. Labelling for Oct 4, Nanog, STAT 3 and 
c-Kit was poor, with low fluorescent signal seen in cytoplasmic locations in all cells 
examined (data not shown).  
 
4.3.6 Differentiation of Cardiac Stem Cells using Publish ed Protocols 
 
4.3.6.1 Cell Morphology during Differentiation 
 
CSCs were plated onto adherent gelatin cultures and exposed to four alternative 
differentiation protocols; two standard and two modifie  (see Materials and Methods 
above) in triplicate wells. A negative control culture of CSCs maintained in stem cell 
media was run concurrently, and formed cardiospheres as previously described and 
maintained these over three weeks. In all the wells fo owing the four protocols (Figure 
4.21) the CSCs initially formed a flattened extending morphology, with evidence of cell 
replication with increasing confluence. Over the period of the experiment the cells 
continued to form confluent flattened layers, but in the protocols aimed specifically 
toward differentiation (Smits protocol with TGFβ and Oh protocol with 5’AZA) there 
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appeared to be lining up and organisation of the cells, when compared to the modified 
protocols aimed at limited or no differentiation (Smits protocol excluding TGFβ and Oh 




Figure 4.21. Morphology of CSCs during cardiac directed differentiation. CSCs kept in 
serum free cardiosphere media showed round phase bright morphology after 12 hours, 
which then developed into cardiosphere formation seen at 8 days and maintained for 3 
weeks. CSCs cultured using the Oh and Smits protocol both showed flattened elongated 
morphology after 3 days in culture. Morphology of CS s after 3 weeks in each protocol 
and modified protocols show some morphological alter tion. Magnification x 200.  
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4.3.6.2 Marker Expression Patterns of Differentiated Cardiac Stem Cells 
 
Following the differentiation experiment, triplicate wells were pooled and RNA 
extracted. Using semi-quantitative RT-PCR, gene expression profiles for each protocol 
were analysed and compared to a standard CSC and whole heart expression pattern 
(Figure 4.22). CSCs following the differentiating and modified Smits protocols appeared 
to have similar expression patterns; c-Kit, Nkx2.5, vWF and CTT had low expression 
compared to WHT whereas GATA 4, Flk-1, VEGF had high expression. SMA and 
glomulin showed similar expression levels to WHT, and there was no expression of CTI, 
the ryanodine receptor and the β1-adrenergic receptor. Those following the Oh 
differentiating and modified protocols suggested more striking differences in expression 
levels. Specifically for the Oh protocols; c-Kit appeared to have lower levels of 
expression in the differentiated cells compared to the modified protocol; Nkx2.5 
appeared upregulated in the differentiated cells; GATA 4 expression remained high 
following both protocols; no islet 1 expression was seen; Flk-1 expression seemed to 
decrease in differentiated wells compared to undifferentiated; SMA and  glomulin 
expression seemed to remain at high levels across bth Oh protocols; CTT appeared 
upregulated in differentiated wells, particularly for dog B compared to the modified 
protocol. VEGF displayed multiple bands corresponding to splice variants. In all four 
protocols no expression of the cardiac functional protein genes CTI, cardiac ryanodine 




Figure 4.22. Semi-quantitative RT-PCR analysis of marker expression following 
differentiation using Oh standard and modified protoc ls (O + and -) and Smits standard 
and modified protocols (S + and -) for two dogs, A and B. Control samples of cardiac 
stem cells (CSCs) and whole heart tissue (WHT) were run as controls representing pre-
differentiation and complete differentiation respectively. VEGF–vascular endothelial 
growth factor; VWF–von Willebrands Factor; SMA–smooth muscle actin; CTT-cardiac 
troponin T; CTI–cardiac troponin I; RyR–cardiac ryanodine receptor; 
B1 Ad-β1-adrenergic receptor. GAPDH was run as a multiplexed in house control gene.  
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4.3.6.3 Quantitative RT-PCR Analysis of Oh Protocols 
 
Following the semi-quantitative RT-PCR analyses of the CSC differentiation experiment 
it was indicated that the Oh differentiation protocol generated a stronger cardiac 
differentiation effect than the Smits protocol. Therefore four key markers of interest 
were selected to be analysed quantitatively, to ensur  that suggested differences seen on 
gel analysis corresponded to real differences in expression levels. Nkx2.5, Flk-1, GATA 
4 and CTT expression were examined using quantitative RT-PCR. All experiments were 
standardised using 18s ribosomal RNA, and compared di ctly to whole heart expression 
levels. Initial primer optimization was performed and generated R2 values which were 








Figure 4.23. R2 values for GATA 4, Nkx2.5, Flk-1 and CTT and their corresponding 18s 
rRNA VIC values following quantitative RT-PCR primer optimization.   
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Following primer optimization, gene expression analysis was performed for each marker 
for both Oh differentiated and modified protocol samples from both dogs relative to day 
0 CSC expression. A  3.4 fold, and 5.1 fold (dog A and B respectively) up-regulation in 
expression of Nkx2.5 was seen in the cells under the differentiated protocol compared to 
that using the modified protocol, however GATA 4 appeared unchanged between the 
two protocols for both dogs, with fold changes of 1.1 and 1.3 for dogs A and B 
respectively. CTT had an approximately 1.5 fold up-regulation in differentiated cells in 
dog A, and a 3.3 fold up-regulation in dog B. Flk-1 was seen to be at lower expression in 
differentiated cells, with a 6.4 fold down-regulation for dog A, and 3.2 fold 
down-regulation for dog B between differentiated an u differentiated protocols (Figure 
4.24).   
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Figure 4.24. Quantitative RT-PCR analysis of marker expression from two dogs, A (red) and B 
(blue) following Oh protocol cardiac directed differentiation. Fold change was recorded relative 
to day 0 expression. Differentiation with and without 5’AZA is compared for four markers of 
interest, GATA 4, Nkx2.5, CTT and Flk-1. 
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4.3.7 Co-Culture of Cardiac Stem Cells with Mesench ymal Stem Cells 
 
4.3.7.1 Cellular Morphology during Differentiation 
 
Following plating of CSCs onto gelatin in transwell co-culture plates, the cells became 
adherent and assumed a more flattened morphology. Cells increased in number over 
time in culture, and morphologically there was a suggestion of a more organised pattern 
of cells in the control wells compared to the co-cultured wells in both dogs A and B,  
which became particularly evident at day 10. In co-cultured wells by day 10 there 
appeared to be a cellular morphological change withcells starting to assume a more 









Figure 4.25. Cellular morphology during co-culture of canine CSCs with autologous 
MSCs. Canine CSCs demonstrated morphological changes during co-culture compared 
to control wells at both time points for dogs A and B (Magnification A, C, E, G  x 100; 
B, D, F, H  x 200). 
 
4.3.7.2 Transcriptional Analysis of Cardiac Stem Cells during Indirect Co-Culture 
 
Gene expression analysis was performed on pooled triplicate RNA from co-culture and 
control wells using semi-quantitative RT-PCR (Figure 4.26). CD44 and CD34 (MSC 
markers) expression was seen in both dogs at high levels from day 0 through to day 10. 
Furthermore, there was a suggestion of increased expression of CD34 in co-cultured 
wells compared to control wells at both time points. Dog A had high levels of CD45 
expression at day 0 which decreased to lower levels at day 6, and even less by day 10. 
Dog B also had high CD45 expression at day 0, which remained high at day 6 for both 
control and co-cultured wells, but then decreased in co-cultured wells at day 10, whereas 
control wells remained high. Dog A had low levels of c-Kit expression at day 0, which 
disappeared completely at day 6, and returned with faint expression at 10, with a slightly 
higher level in control wells compared to co-cultured. Dog B had a higher level of c-Kit 
expression at day 0 than dog A, but again all expression disappeared by day 6 in all 
wells, and only day 10 co-cultured wells showed very low level expression. Both dog A 
and B demonstrated expression of GATA 4 at day 0, which appeared to increase in all 
wells at day 6, and then increase again in all wells by day 10. Both dog A and B showed 
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no expression of Nkx2.5 at day 0, which is then faitly expressed in all wells at day 6 
and then expressed at higher levels by day 10 with slig tly higher expression in control 
wells compared to co-cultured. Flk-1 expression was relatively low at day 0, with 
slightly higher expression seen for dog B than dog A. Expression appeared to increase 
dramatically in co-cultured wells at day 6 compared to controls in both dogs, and then 
by day 10 expression was higher in all wells, but again appeared slightly higher in co-
cultured wells than control wells. VEGF expression demonstrated multiple banding 
representative of splice variation in both dogs. Expression appeared to be relatively 
steady throughout the experiment. Both dogs expressed vWF at day 0, which was then 
switched off at day 6 in control wells, whereas in co-culture wells expression remained 
high. In dog A expression was present in controls wells at day 10, with higher 
expression in co-culture wells. In dog B expression is ot seen in control wells at day 20, 
with higher expression seen in co-culture wells. SMA was expressed in both dogs at a 
steady level throughout the experiment. Glomulin expr ssion levels appeared to be 
highest at day 10 in all samples in both dogs, compared to day 0 and 6. Connexin 43 
(CNXN 43) was expressed at steady levels at all time points in dog A, whereas in dog B 
there appeared to be slightly lower expression at day 0, but then high expression is 
maintained in all samples at all time points thereafter. Islet 1, β1-adrenergic receptor, 





Figure 4.26. Semi-quantitative RT-PCR analysis of CSC co-culture expression changes. 
CSCs from two dogs, A and B, were co-cultured in a transwell system with autologous 
MSCs and were subsequently analysed at three time points, day 0, 6 and 10. Control 
wells (Co) were run concurrently with co-culture wells (Cc) at each time point. 
VEGF-vascular endothelial growth factor; vWF–von Willebrands Factor; SMA–smooth 
muscle actin; Glom–Glomulin; CNXN43–Connexin 43. GAPDH was run as a 




4.4.1 Can Adult Cardiac Stem Cells be Isolated and Cultur ed from the Dog?  
 
In this study we have isolated cells from the canine heart, which demonstrate phenotypic 
and genotypic characteristics consistent with an adult stem cell. The culture technique 
that this study employed proved reliable in reproducing directly comparative 
cardiosphere populations from multiple dogs of different breeds, ages and sex. In 
addition, our cell populations behaved in a similar w y to that described in the literature 
for a number of other species including humans (Messina et al., 2004, Smith et al., 
2007).  
 
An interesting observation made at the start of the s udy was that sections of atrial tissue 
explants produced greater populations of stem cellsompared to sections of similar size 
harvested from ventricular tissue. This finding was so consistent that we subsequently 
confined our harvests to atrial tissue. This observation is supported by the literature with 
descriptions of stem cell niche locations in other species, demonstrating that although 
stem cell niches in the adult heart are dispersed throughout the myocardium, the number 
of niches are typically higher in the atrial and apic l myocardium compared to the base 
mid-region of the heart (Urbanek et al., 2006).  
 
The canine CSC population was phenotypically similar to other stem cell populations, 
capable of being maintained over extended periods of time in serum free conditions. In 
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addition cells were capable of clonal expansion, a critical characteristic of stem cells. 
Following low-density plating, large dense clusters of cells grew out from single cells. 
On subsequent passage it was observed that there was a large central cell, surrounded by 
cells of varying size. This could reflect both asymmetric division, another key 
characteristic of stem cells, and also that the cells were of different ages, suggesting the 
original stem cell was generating daughter cells over time, and not in a single division. 
 
4.4.2 Do Canine Cardiac Stem Cells Express Stem Cell Mark ers? 
 
From an expression profile perspective, canine CSCs expressed certain markers that 
would be consistent with other stem cell types and in addition did not express lineage 
markers such as cardiac structural proteins or contractile proteins. We firstly 
investigated the expression of stem cell pluripotency markers. 
 
4.4.2.1 Oct 4, Nanog, STAT 3 
 
Expression of three classical stem cell markers, Oct 4, Nanog and STAT 3 was 
examined using a combination of RT-PCR, IFA and western blotting. Oct 4 expression 
was demonstrated in cardiosphere culture using IFA, and showed expression in 
cytoplasmic locations. Given the non-specific banding results from the western blot, the 
positive IFA result must be interpreted with caution. Oct 4 expression has been 
described in adult stem cells (Beltrami et al., 2007), however Oct 4 is known to have 
multiple splice variants, including Oct 4A, Oct 4B, and Oct 4B1 (Takeda et al., 1992, 
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Atlasi et al., 2008). The location of each of these variants is different, with Oct 4A 
predominantly nuclear and Oct 4B cytoplasmic, and Oct 4B1 found in both locations  
(Wang and Dai, 2010). Expression of the different variants alters with cell source; Oct 
4A and Oct 4 B1 are expressed primarily in ES cells and are therefore reliable markers 
for stemness. However, Oct 4B is expressed in somatic cells, and therefore cannot be 
used as a stem cell marker (Atlasi et al., 2008). To complicate the field further, Oct 4B1 
is capable of alternative splicing and re-forming Oct 4B, generating three alternative 
protein isoforms (Gao et al., 2010). Therefore, the positive result using cardiospheres 
may represent a non-stem cell variant of Oct 4 expression.  
 
Nanog expression was seen using IFA in CSCs, but was found to have non-specific 
banding using western blot, and no transcript identifi d using RT-PCR. The discrepancy 
in expression is difficult to explain. An alternative splice variant of Nanog has been 
described, which showed increased expression within adult stem cells compared to ES 
cells, however both forms of Nanog were found to act in a similar fashion and therefore 
the relevance of the new variant is questionable (Kim et al., 2005b). Nanog location is 
generally considered to be nuclear, and functions as a nuclear transcription factor driving 
self-renewal (Chambers et al., 2003). The cytoplasmic staining seen in our cells using 
IFA, in combination with the negative RT-PCR result may imply non-specific binding 
of the Nanog antibody in canine adult stem cells.  
 
STAT 3 was expressed using RT-PCR and western blot in CSCs at high levels. STAT 3 
functions in conjunction with Nanog to maintain self-r newal, however given the 
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spurious Nanog results it would be difficult to make the assumption of this factor acting 
in that way in canine CSCs (Chambers et al., 2003). STAT 3 is not stem cell specific, 
and has been described in somatic cells. Furthermor STAT 3 is now found to be highly 
associated with oncogenic transformation; persistent activation of STAT 3 leads to a 
more aggressive cancer cell type, and poorer prognosis (Hirano et al., 2000, Yu et al., 
2009a). Expression of STAT 3 in the heart is thought to have a cardioprotective 
property, and is upregulated in response to stress signals (Boengler et al., 2008) and 
STAT 3 expression is upregulated via the CXCR4 pathw y in response to ischemia 
(Huang et al.). STAT 3 translocates to the mitochondria and protects against ischemia 
via induction of oxidative phosphorylation (Wegrzyn et al., 2009, Qiu et al., 2011). 
STAT 3 is therefore a critical factor expressed within cardiomyocytes and it could be 
assumed therefore that expression would be expected within the CSC population, 
reflected by our results.  
 
Oct 4, Nanog and STAT 3 were initially chosen due to their common use as 
pluripotency markers in stem cells. However, based upon the results obtained the 
breadth of markers was widened to include stem cell markers more specific to adult stem 
cells, and in particular those from the heart. As can be seen from this data, there are 
significant limitations in using antibodies for gene marker expression analysis, given the 
shortage of canine specific antibodies. This highlights the need for several modes of 
analysis when comparing gene expression.  
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4.4.2.2 Cardiac Stem Cell Markers 
 
The CSCs were subsequently analysed for their expression of published CSC markers. 
Canine CSCs were c-Kit positive. As previously discussed c-Kit has been used to define 
and isolate CSCs from a number of species especially humans and c-Kit positive stem 
cells are capable of differentiating into cardiomyoc tes (Beltrami et al., 2003, Goumans 
et al., 2007, Kubo et al., 2008, Tallini et al., 2009).  
 
The canine CSCs also expressed Flk-1 at both RNA and protein level. Flk-1 analysis of 
early harvest stem cells using immunofluorescence confirmed the presence of the protein 
at a nuclear location, indicating an active form.  Flk-1 has been shown to be expressed in 
some, but not all CSC populations. Bearzi et al described a human cardiac stem cell 
population positive for c-Kit, and negative for Flk-1 (Bearzi et al., 2007). In a 
subsequent study, the same author also described a c-Kit positive, Flk-1 positive 
population which behaved as a coronary vascular progenitor cell (Bearzi et al., 2009). 
Yang et al isolated a Flk-1 positive, c-Kit negative stem cell population from the human 
heart which gave rise to colonies which contained all three cardiac lineages (Yang et al., 
2008). This interesting variation in c-Kit and Flk-1 expression may represent a 
heterogeneous stem cell population or may represent cells at different stages of stemness 
or differentiation.  
 
In this study CSCs and whole heart demonstrated high levels of GATA 4 expression. 
This correlates with results seen by Goumans et al where whole human heart tissue had 
 148 
similar expression profiles to their stem cell populations (Goumans et al., 2007). GATA 
4 has been shown to be repressed by the expression of Nanog; during our experiments 
we found no reliable expression of Nanog and a high level of GATA 4 expression, 
which correlates with this data (Kim et al., 2005b). GATA 4 is one of the earliest 
transcription factors expressed in the developing heart, and is expressed abundantly in 
CSCs and cardiac myocytes during their lifespan. GATA 4 is thought to have 
cardioprotective properties, preventing post-infarction remodelling (Heikinheimo et al., 
1994, Matsuura et al., 2004, Laugwitz et al., 2005, Beltrami et al., 2007, Goumans et al., 
2007, Rysa et al., 2010); it is therefore unsurprising that it was expressed in both the 
whole heart controls, the stem cells and subsequently differentiated cell populations.  
 
Nkx2.5 was expressed in whole heart tissue but surpri ingly not in the canine CSCs. 
Nkx2.5 is a homeobox gene, is expressed early as part of the cardiac lineage (Martin et 
al., 2004) and has commonly but not exclusively been found to be expressed in CSCs 
(Beltrami et al., 2003, Laugwitz et al., 2005, Goumans et al., 2007). Oh et al isolated a 
population of murine cardiac stem cells using the mouse specific marker Sca 1 which 
were c-Kit and Nkx2.5 negative, and performed directed differentiation upon these cells 
which was then associated with an upregulation in Nkx2.5 and cardiac structural gene 
expression (Oh et al., 2003). Therefore the absence of Nkx2.5 expression may reinforce 
the primordial stem cell nature of our CSCs. 
 
Canine CSCs were positive for the endothelial marker vWF. Interestingly, this has been 
proposed as an important finding in cardiac progenitor cells, which is not seen in other 
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stem cell populations such as mesenchymal stem cells and this result may reinforce the 
multipotent potential of our isolated cells, and in particular their potential for endothelial 
differentiation (Hu et al., 2003, Kattman et al., 2006, Welikson et al., 2007).  
 
Islet 1 was not expressed consistently within the CSCs isolated. Interestingly, islet 1 
positive cells were isolated twice, as could be seen in the CSCs culture expression 
analysis (Figure 4.14). Two separate dogs were positive for islet 1, dog 8 and dog 10 and 
these cells appeared to demonstrate a reduced expression of c-Kit and Flk-1. No other 
canine CSCs isolated were positive for islet 1. Interestingly, dog 10 was analysed at two 
time points, day 0 and day 6, and was only found to be positive only at day 6. This may 
mean that islet 1 is switched on in serum free culture, but given that no other CSCs 
demonstrated this then the cell may have a predetermin d ability for islet 1 expression. 
Dog 8 was also found to express islet 1 at day 15, but due to the limitations of the 
experiment, no other time points were examined. We were unable to isolate CSCs 
specifically using islet 1 given its nuclear location therefore this interesting finding was 
unable to be analysed further. Islet 1 has been describ d as a cardiac stem cell marker, 
and labels cardiac progenitors from the secondary heart field (Cai et al., 2003). 
Traditionally these cells co-express Flk-1, and the reduced expression of Flk-1 seen in 
our stem cell population is therefore interesting. As previously described, c-Kit/Flk-1 
variation in expression labels different subsets of cardiac stem cells, and our results may 
be a reflection of this heterogeneity. It may also be possible that the islet 1 cell 
populations are an earlier precursor to the c-Kit/ Flk-1 positive stem cells, and are found 
in lesser numbers, hence explaining our only occasion l isolation.  
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Connexin 43 is used for cell-cell signalling and contact and is generally highly expressed 
within cardiac tissues (Dhein et al., 2002). Connexi  43 has been shown to increase 
following CSC differentiation (Messina et al., 2004). We found connexin 43 to be 
expressed in both CSCs and cells which had undergon differentiation. This limits the 
use of connexin 43 as a marker, and does concur with Gaetani et al who also found 
connexin 43 expression in CSCs before and after differentiation (Gaetani et al., 2009). 
However, the expression of connexin 43 in CSCs does imply a pre-determined 
functional ability for cell-cell signaling. Connexin 43 is commonly cited in the literature 
as a standard marker for cardiomyocyte differentiation. We investigated the expression 
of this marker not only in our cell populations and control tissues, but also found 
expression in several non-cardiac tissues. This is likely due to its nature as a gap 
junction protein and the fact that it can be found in several organ types, including uterus, 
ovaries and kidneys (Beyer et al., 1987).  
 
In concurrence with CSC populations isolated from other species including humans, our 
cell population appeared to be CD45 negative (thereby not haematopoietic in origin) and 
lineage negative (Beltrami et al., 2003, Oh et al., 2003, Bearzi et al., 2007, Goumans et 
al., 2007), in that there was no evidence of expression of the cardiac functional genes 
CTT, CTI, RyR and the β1-adrenergic receptor. This implies the primordial nture of 
these cells, given their direct isolation from cardi c tissue, and may support the 
suggestion that they are precursors of several cardiac cell types. 
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4.4.3 VEGF Splice Variation and Significance to Cardiac S tem Cells?  
 
A further interesting finding was VEGF splice variation. A different variant pattern was 
seen between whole heart tissue and CSCs. VEGF is a major inducer of angiogenesis 
and may mediate the migration of CSCs via PI3K/Akt pa hway (Tang et al., 2009). 
VEGF is known to have several isoforms, all described in humans; VEGF121, VEGF145, 
VEGF165 and VEGF189, VEGF206. Furthermore, each VEGF splice variant binds to a 
specific receptor; VEGF121 and VEGF165 bind to Flt-1 whereas VEGF121, VEGF145 and 
VEGF165 bind to Flk-1 (Neufeld et al., 1999). Each variant is hought to play a different 
role; VEGF145 has been found to be the major isoform expressed in human reproductive 
carcinomas, VEGF121 and VEGF165 are thought to be involved in angiogenesis, and 
induce proliferation and VEGF189 is thought to be involved in endothelial cell 
proliferation (Poltorak et al., 1997). VEGF121, VEGF145 and VEGF165 are believed to be 
secreted forms, whereas VEGF189 and VEGF206 are cell surface bound and it has been 
found that human blastocysts differentially express variants during implantation (Krussel 
et al., 2001) 
 
 In animals VEGF variants are known as VEGF120, VEGF164, VEGF182 and VEGF188; 
however VEGF182 and VEGF188 are usually impossible to separate due to only an 18bp 
difference in size.  Multiple splice variants have b en previously described in the dog 
and VEGF164 has been found to be the dominant isoform in the canine heart, with 
VEGF120 seen at low levels, and VEGF182 and VEGF188 seen as one band using RT-PCR 
(Jingjing et al., 2000, Bartosh et al., 2008, Uchida et al., 2008). No canine equivalent of 
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human VEGF145 and VEGF206 has been found even though canine and human VEGF 
share high amino acid homology (95%). Furthermore a significant increase in all VEGF 
isoforms in proportion to original levels was noted in canine hearts following ischemia 
(Jingjing et al., 2000). Based upon this information and our results it is most likely that 
VEGF164 and the combined VEGF182/188 are the dominant isoforms seen in whole heart 
tissue. Interestingly, in the CSC population these variants are also expressed, but a 
strong third band is seen which would correspond to the expression of VEGF120 with a 
combined lower strength band corresponding to VEGF182/188. This finding may be of 
great importance when isolating CSCs and could be used to determine stem cell type 
over differentiated cell types. The significance of the increased expression of VEGF120 is 
yet to be discovered, but is an area of future research.  
 
4.4.4 Can Canine Cardiac Stem Cells be Sorted using C-Kit ? 
 
C-Kit has commonly been used as a marker to sort putative CSCs from a mixed cardiac 
cell population (Beltrami et al., 2003, Kubo et al., 2008, Tallini et al., 2009). A magnetic 
cell sorting technique was utilised to sort a c-Kit positive and negative fraction from 
general explant cultures. This produced an approximate 2-4% positive cell fraction; this 
compares to Beltrami et al, which investigated lineage negative, c-Kit positive cells 
from whole  rat heart, and found low numbers of positive cells at 1 cell in approximately 
1 x 104 myocytes (Beltrami et al., 2003). The positive cell fraction displayed sphere 
forming properties, and was maintained in serum free culture in cardiosphere media for 
a further 13 days, before harvesting for RNA isolati n. Semi-quantitative RT-PCR 
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analysis of c-Kit sorted cells at day of sorting demonstrated no obvious difference in 
c-Kit, Flk-1 and islet 1 expression between the positive and negative sorted fractions. 
Furthermore, sorted cells grown in stem cell culture showed no alteration in the 
expression of c-Kit over 14 days. This may suggest an inefficiency using the MACS 
technique, or may reflect the exponential nature of PCR amplification or a combination 
of the two. The sorted c-Kit populations were furthe  analysed for the expression of Oct 
4, Nanog, STAT 3 and c-Kit using IFA. Very poor labeling of the cells was seen with 
weak fluorescent signal in cytoplasmic locations for all four markers (data not shown). 
As previously discussed, Oct 4 and Nanog should be located in the nucleus, and c-Kit 
and STAT 3 can be cytoplasmic. The poor quality fluorescence meant that no result 
could be determined from this particular experiment. Again the technique was limiting, 
with very few cells available following sorting, whic  may have been due to cell death 
following sorting, therefore limiting the number ofviable cells to grow on chambered 
slides. Furthermore as discussed previously there is a difficulty in obtaining canine 
specific antibodies making likelihood of poor specificity higher.  
 
 154 
4.4.5 Are Canine Cardiac Stem Cells Capable of Card iac Directed 
Differentiation? 
 
4.4.5.1 Cardiac Differentiation using Published Techniques 
 
CSC differentiation has been described using a variety of culture techniques and 
pharmacological interventions. Tallini et al differentiated murine cardiac c-Kit positive 
cells using bFGF (Tallini et al., 2009). Messina found that murine cardiospheres began 
spontaneous contractions, however human cardiospheres required co-culture with 
RNCM (Messina et al., 2004). Laugwitz also co-cultured murine islet 1 cells with 
RNCM to drive the differentiation process (Laugwitz et al., 2005, Moretti et al., 2006). 
Goumans et al differentiated human progenitor cells using 5’AZA followed by the 
addition of TGFβ1 and ascorbic acid (Goumans et al., 2007, Smits et al., 2009b) based 
on a technique described for murine ES cells (Behfar et l., 2002). Oh et al used 5’AZA 
and a serum concentration drop to trigger differentiation in murine adult stem cells (Oh 
et al., 2003). We selected two published techniques – Smits et al and Oh et al, and used 
standard differentiation protocols and modified protoc ls to assess differentiation. Under 
both standard differentiation protocols there were obvious phenotypic changes, with 
suggestion of cellular alignment, when cell populations were compared to the modified 
versions of each protocol and to control untreated c ll populations.  The alignment of 
cells observed in the standard protocols may represnt development of an organised 
cell-cell contact, suggesting a more defined phenotype.  
 
 155 
 However, despite phenotypic changes in the standard Smits protocol versus the 
modified protocol excluding TGFβ1, there was very little difference between these cell 
populations at the level of transcriptional analysis over the range of markers analysed, 
suggesting that changes in gene expression observed were not associated with the 
exclusion of TGFβ1.  Interestingly, both cell populations lost evidenc  of c-Kit and vWF 
expression, present in the untreated CSCs which may be a result of time and method of 
culture. There was also evidence of low levels of expr ssion of CTT and Nkx2.5, which 
were not expressed in the untreated CSCs, which may have been an effect of TGFβ1. 
There was no evidence of expression of other structu al proteins such as CTI, RyR and 
β1-adrenergic receptor. This technique appeared to generate inefficient cardiac directed 
differentiation. 
 
 More striking changes were observed at the transcriptional level when comparing the 
standard Oh protocol versus the protocol excluding 5’AZA. This may suggest that 
5’AZA and serum concentration are critical factors in altering expression profiles in 
canine stem cells. Following the standard Oh protocol, there was a loss of expression of 
c-Kit and vWF as for the Smits protocols. There was also expression of Nkx2.5 and CTT 
and unlike the Smits protocols expression levels were high. Cells treated following the 
modified Oh protocol also expressed CTT, but at a lower level than those under the 
standard protocol and did not lose c-Kit and vWF expr ssion or exhibit Nkx2.5 
expression. The smooth muscle markers SMA and glomulin were highly expressed in all 
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the cell populations. Again there was no evidence of expression of other structural 
proteins such as CTI, RyR and β1-adrenergic receptor.  
 
We therefore analysed the relative expression of the cardiac lineage markers Nkx2.5, 
GATA 4, Flk-1 and the cardiac differentiated marker CTT using quantitative RT-PCR 
following cells undergoing the standard and modifie Oh protocols. There was 
upregulation in the expression of Nkx2.5 and CTT, and down regulation of Flk-1 in the 
cells following the standard protocol compared to th se following the modified protocol 
which confirmed the findings seen in standard RT-PCR and reinforced the suggestion of 
cardiac directed differentiation, and potentially a move away from endothelial lineages. 
There was little difference seen in the expression levels of GATA 4 between the 
modified and differentiated protocols; GATA 4 expression is seen in both the cardiac 
stem cells and whole heart controls, which may suggest that maintenance of its 
expression is a requirement of these cells during the differentiation process.  
 
Previous studies have used a variety of criteria to define cardiac differentiation. 
Spontaneous beating, not observed in our cells, is often used as a determinant of stem 
cell differentiation, and has been described in several papers; interestingly it is suggested 
that human cardiospheres require co-culture with RNCM to enable the initiation of 
beating and it may be that this technique is requird for beating in canine cells (Matsuura 
et al., 2004, Messina et al., 2004, Beltrami et al., 2007, Goumans et al., 2007, Smith et 
al., 2007, Tallini et al., 2009).  
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In our study we utilised a comprehensive range of differentiation markers. Specifically 
in cells exposed to the standard Oh protocol, there was evidence of incomplete 
differentiation. This is based on phenotypic changes in the cells, the loss of the stem cell 
marker c-Kit, the loss of expression of vWF and the appearance of expression of both 
Nkx2.5 and the structural protein CTT. However other proteins involved in the 
contractile machinery of a differentiated cardiomyoc te were not expressed including 
CTI, RyR and the β1-adrenergic receptor (Figure 4.27). We have therefore made the 
assumption that cardiac directed differentiation was achieved in part only, and that 
further investigation would be required to find the factor or factors required to trigger 






Figure 4.27. Cardiomyocyte functional proteins associated with cardiac contraction. 
Following stimulation of the β1-adrenergic receptor with catecholamines such as 
noradrenaline, cyclic AMP (cAMP) is generated from ATP by the catalytic action of 
adenyl cyclase. cAMP activates the intracellular enzyme Protein Kinase A (PKA), which 
has several effects; a) PKA phosphorylates the calcium channels (ica) in the cell 
membrane increasing their open state, allowing more calcium influx into the cell and 
ultimately for stronger contractile force, b) PKA phosphorylates phospholamban, a 
regulatory protein for the inward calcium pump into the sarcoplasmic reticulum (SR), 
thus reducing phospholamban inhibition and removing free calcium into the SR, c)PKA 
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phosphorylates the ryanodine receptor, which acts in response to increased calcium by 
releasing further calcium into the cytosol of the cell. This released calcium from the SR 
binds to cardiac troponin C which is part of the troponin complex including C, T and I, 
which alters the position of the inhibiting tropomyosin molecule, exposing the actin sites 
and allowing for myosin to bind, and contraction to occur. Thus the β1-adrenergic 
receptor, the ryanodine receptor, and cardiac troponin T and I are all critical elements in 
a functional cardiomyocyte (labeled with blue arrow) and were chosen as cardiac 
specific analysis genes.  
 
4.4.5.2 Cardiac Differentiation using Indirect Co-Culture 
 
Co-culture of different cell populations has previously been shown to drive 
differentiation. Co-culture of CSCs with RNCM has been shown to be an effective 
method to provide beating differentiated cardiac cells in humans, dogs and mice 
(Messina et al., 2004, Laugwitz et al., 2005, Bartosh et al., 2008). Furthermore, ES cells 
and CSCs have been found to move toward cardiac lineages when co-cultured with 
MSCs (Hatzistergos et al., 2010, Yue et al., 2010). In all of these systems there is direct 
contact between the cell populations. However, this technique would have been 
technically difficult in downstream analysis and furthermore in primary dog cells direct 
co-culture may allow for the development of cell fusion which may be a significant 
limitation of previous studies using this technique. We therefore decided to co-culture 




Morphologically CSCs showed little difference after 6 days co-culture, compared to 
controls. However by day 10, there was a more heterogeneous morphology seen in 
co-cultured wells, with irregular growth patterns with cobblestone appearance when 
compared to control wells, which showed cells starting o align. This was seen in all 
wells. In terms of marker expression, there was some variation in specific markers. 
CD45, a haematopoietic marker appeared to decrease with time in culture, decreasing in 
the population of cells derived from one dog more quickly than the other. Given this is 
seen in both co-culture and control wells, this may be either related to time in culture or 
adherent culture. C-Kit expression was at low levels in day 0 CSCs and disappeared 
completely by day 6. By day 10 faint expression had returned, and showed variable 
expression as seen in our previous experiments. The cardiac development markers 
GATA 4, Nkx2.5 and Flk-1, and the smooth muscle marker glomulin all appeared to 
increase expression over time in culture, which may suggest movement toward cardiac 
differentiated lineages. There was however a stronger expression of Nkx2.5 in control 
wells, and an increased expression of Flk-1 in co-culture wells suggesting that co-culture 
may delay or decrease cardiomyocyte directed differentiation. Interestingly, vWF 
showed increased expression in co-culture wells, and when combined with the Flk-1 
result may suggest that co-culture with MSCs are driving the CSCs toward a more 
endothelial cell type, which may also be reflected in the cellular morphology. 
Furthermore, VEGF splice variant banding appeared similar to CSCs throughout the 
experiment, however some variation in band strength is seen which may be related 
toward cell differentiation as previously discussed, and the relevance of which is to be 
 161 
investigated in future work. No expression of cardic functional genes was seen. In 
summary, there is some suggestion of differentiation being triggered using indirect 
co-culture with MSCs, however this differentiation may in fact be toward cardiac 




We have shown that cells which form cardiospheres can be grown from canine cardiac 
tissue in culture. Our results indicate that these cells have key characteristics of stem 
cells both in terms of cell behaviour and marker expr ssion. These cells are capable of 
maintaining these characteristics in extended culture in serum free media, and of clonal 
expansion and asymmetric division.  Using two alternative differentiation protocols, it 
has been seen that the CSCs can be driven toward a cardiomyocyte lineage, with 
downregulation of cardiac stem cell markers, and an increase in cardiac lineage markers 
using 5’AZA, and may be driven toward endothelial lneages using indirect co-culture 
with MSCs. However, in both systems the differentiation process did not produce viable 
terminally differentiated cell lineages, and therefo  the technique required to drive these 
processes will need to be investigated further.  
 
These experiments strongly support the use of canine cardiac stem cells in further 
studies. The changes exhibited by the cells following the differentiation protocols are 
very encouraging and we will be undertaking further r search to fully elucidate the 
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conditions required for true differentiation of the stem cells into functioning 
cardiomyocytes. 
 
In conclusion we have provided compelling evidence that the canine heart has a resident 
population of adult stem cells, which can be reliably and reproducibly isolated and 
cultured from atrial explants. This cell population in terms of marker expression has 
many similarities with other described stem cell populations including the human and 
thereby may well provide a realistic cell population f r in vitro veterinary studies and act 
as a large animal model for cardiac stem cell research.  
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CHAPTER 5  
Canii ne Mesenchymall  Stem Cell ll s and 
the Cardii ovascull ar System 
 
Abstt rr actt   
 
Mesenchymal stem cells (MSCs) have a capacity for multi-lineage differentiation thus 
providing a promising source of stem cells for regeneration.  This chapter initially 
discusses the isolation of MSCs from different species and sources, and the use of MSCs 
as alternative to CSCs for cardiac disease investigation and therapeutics given the 
limitations in cell number and difficulty in obtaining these cardiac cells (discussed in 
Chapter 4). This chapter then describes the isolation and detailed characterisation of 
primary canine MSCs. Secondly this chapter investigates the ability of canine MSCs to 
differentiate toward cardiac lineages. Canine MSCs were isolated from bone marrow 
aspirates and cultured using traditional techniques. Canine MSCs behaved in culture and 
appeared morphologically similar to previously described MSCs from other species. 
Furthermore, canine MSCs demonstrated a marker panel similar to other MSC 
populations including expression of CD44 and STRO-1, and negative for CD34 and 
CD45. Canine MSCs were subsequently exposed to a standard cardiac differentiation 
protocol with no significant alteration in marker pofile seen indicating that cardiac 
 164 
differentiation was not achieved. Furthermore canine MSCs were grown in co-culture 
with canine CSCs, and again, no evidence of cardiac ifferentiation was seen using the 
criteria set out in this study.  
This study highlights the ease of obtaining an alternative adult stem cell source from the 
dog which may be easily isolated and cultured, and closely resembles MSCs described 





Mesenchymal stem cells (MSCs) are derived from the mesodermal lineage, and offer an 
opportunity to study adult stem cells in vitro. MSCs have a capacity for multi-lineage 
differentiation and therefore provide a promising source of stem cells for regenerative 
medicine. Furthermore MSCs have been shown to have a paracrine effect upon damaged 
tissues which may be of great therapeutic potential.  
 
5.1.1 Mesenchymal Stem Cells 
 
It was recognized in the 1960’s that the bone marrow c mpartment held cells which 
were capable of regeneration. Irradiated mice were injected with bone marrow cells and 
the subsequent colonies that formed in the spleen cou ted. This work suggested that the 
cell colonies formed were in proportion to the number of cells injected, and that each 
colony was derived from a single cell with a multiple differentiation potential (Becker et 
al., 1963). This work led onto the development of bne marrow transplants for treatment 
of haematopoietic disease, which was a major breakthrough in the treatment of 
leukaemia (Mathe et al., 1963). Adult stem cells (ASCs) were subsequently described 
formally in the 1970s, where multiple cells from within the haematopoietic compartment 
were found to have been derived from a common precursor – a stem cell (Fialkow, 
1973).  Bone marrow derived stem cells capable of mesodermal differentiation were 
classified by Caplan et al in 1991 as MSCs, and were capable of differentiation along 
three main routes; osteoblast, chondrocyte and adipocyte (Caplan, 1991).  
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5.1.1.1 Mesenchymal Stem Cell Source 
 
Since the original isolation of MSCs from the bone marrow compartment, they have 
been isolated from other sites within the body. Two major locations are used commonly 
as an alternative to the bone marrow: Adipose derived MSCs can be obtained in greater 
number, require less invasive collection techniques (Pittenger et al., 1999, Strem et al., 
2005) and are capable of extended time in culture with low levels of senescence 
allowing maximization of cell numbers from original sampling and extended time 
experiments (Zuk et al., 2002); Umbilical cord blood MSCs require no invasive surgical 
procedure but can only be harvested during birth.  MSCs collected from both these 
locations are genotypically and phenotypically similar to bone marrow derived MSCs, 
and are capable of multipotent differentiation (Kestendjieva et al., 2008, Seo et al., 
2009). Other locations have also been described, including circulating MSCs and those 
isolated from mesodermal compartments such as muscle although less information is 
available concerning these cell populations (Bosch et al., 2000, Kuznetsov et al., 2001).  
 
5.1.1.2 Defining Mesenchymal Stem Cells 
 
MSCs have traditionally been described using marker expression panels. However the 
range of markers utilized by different investigators makes the distinction challenging 
when isolating a single common stem cell population. Furthermore, isolation is 
traditionally based upon adherence to tissue culture plastic, but in the case of murine 
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MSCs, these are usually pre-selected against CD11b, therefore making inter-species 
comparisons difficult (Kopen et al., 1999, Baddoo et al., 2003, Tropel et al., 2004). Due 
to the increased variation in MSC populations described, the International Society for 
Cellular Therapy released a document stating the minimum criteria required to define 
human MSCs, the key features of which were; cells must express a  defined marker 
panel (Table 5.1); cells must be isolated using tissue culture plastic adherence; finally, 
cells must be capable of differentiation into osteoblasts, chondrocytes and adipocytes 
(Dominici et al., 2006).  
 
Table 5.1. Minimal marker expression profile for human MSCs (Taken from (Dominici 







CD14 or CD11b 




Two further markers commonly used to describe MSCs are CD44 and STRO-1. CD44 is 
a glycoprotein surface marker, and has been shown t be expressed by MSCs isolated 
from all three common compartments and from different species (Pittenger et al., 1999, 
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Meirelles Lda and Nardi, 2003, Kern et al., 2006). STRO-1 has been described as a 
positive marker used to isolate a cell subset from human bone marrow with MSC 
properties, allowing for a purer starting cell population (Simmons and Torok-Storb, 
1991, Gronthos et al., 1994, Dennis et al., 2002) 
 




MSCs are capable of differentiation into several mesod rmal lineages in vitro. In 
particular connective tissue cell types are readily produced using well described 
techniques; osteoblast, adipocyte, chondrocyte and myocytes have all been produced 
from MSCs (Johnstone et al., 1998, Pittenger et al., 1999, Gang et al., 2004). 
Mesodermal differentiation of MSCs is discussed in more detail in Chapter 7; MSC to 
Cartilage Differentiation 
 
5.1.2.2 Non-connective Tissue  
 
It has also been suggested that MSCs are capable of differentiation into non-connective 
tissue cell types. Astrocyte and neuronal differentiation in vivo supports the potential of 
using MSC sources for a multitude of neuronal disorders (Kopen et al., 1999, Jiang et 
al., 2002, Zeng et al., 2011). Furthermore, MSCs may be capable of differentiation into 
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hepatocytes representing a future source of cells for treatment of hepatic disorders (Sato 
et al., 2005).  
 
5.1.2.3 Cardiac Differentiation of Mesenchymal Stem Cells In Vitro 
 
Cardiac disease is one of the biggest causes of morbidity and mortality in dogs and 
humans. As already discussed in Chapter 4, adult stem cells may offer an opportunity to 
study disease processes in vitro and ultimately be used in therapeutics. CSCs are cpable 
of cardiac directed differentiation, however are limited by the difficulty in isolation and 
the low cell numbers achieved in culture.  MSCs may offer a realistic alternative to 
CSCs for both in vitro studies and therapeutics given their ease of isolaton and ability 
for multipotent differentiation.  
 
Using rodent models it has been suggested that MSCs are capable of cardiac 
differentiation in vitro using the de-methylating agent 5’AZA, demonstrating a  increase 
in cardiac specific genes and rhythmical beating (Makino et al., 1999, Fukuda, 2001, 
Kruglyakov et al., 2006). Furthermore, the addition of cardiotrophin 1 has been found to 
have an additive effect upon 5’AZA, improving efficiency of cardiac differentiation 
(Xinyun et al., 2010). This work has been repeated using human MSCs demonstrating 
successful cardiac directed differentiation with increased expression of cardiac specific 
genes such as β-MHC and α-cardiac actin and although no spontaneous beating was seen 




Co-culture with RNCM is a common alternative differentiation technique to using 
5’AZA.  Co-culture of human MSCs with RNCMs triggered an upregulation of cardiac 
troponin T and GATA 4, but not cardiac troponin I and myosin heavy chain, which may 
reflect only partial differentiation (Koninckx et al., 2009). Direct co-culture of rat MSCs 
with both cardiomyocytes and smooth muscle cells triggered differentiation toward the 
tissue the cells were co-cultured with. This could not be recapitulated during indirect 
co-culture, suggesting a requirement for cell-cell ontact (Wang et al., 2006). However, 
in the reverse experiment, MSCs have been found to trigger cardiac differentiation of ES 
cells, using both direct co-culture and MSC conditioned medium, which suggests that 
soluble released factors from MSCs do have an influe ce over differentiation (Yue et al., 
2010).  
 
Alternative differentiation methods have been described including nitric oxide agents, 
hypoxia and conditioned media all with differing degr es of success (Shim et al., 2004, 
Xie et al., 2006, Rebelatto et al., 2009).  
 
5.1.2.3.1 Defining Differentiation 
 
The criteria used to define differentiation varies through the literature, but is generally 
based upon an increase in cardiac lineage marker exp ession, and behaviour and 
morphology in culture. MSCs have been isolated from different locations, and taken 
from different species. Therefore making comparisons between cell populations is 
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reliant upon consistency in marker expression. However, markers used to define 
differentiation vary and also criteria such as evidnce of beating are not always used 
when stating successful differentiation. The lack of fixed criteria used to define 
differentiation does make it more challenging to interpret these studies. It must also be 
borne in mind that in both direct co-culture in vitro and direct implantation of MSCs into 
the heart in vivo (particularly in species whereby colour labeling of cell populations in 
impossible) there is a possibility of cell fusion, thus skewing any marker expression 
results and beating analysis (Oh et al., 2003, Rose et al., 2008).  
 
5.1.2.3.2 Pathways of Differentiation 
 
Cardiac differentiation of MSCs is a complex process with a multiplicity of pathways 
playing critical roles. Although cardiac directed differentiation of MSCs has been 
described using several techniques, little is known regarding the specific pathways 
involved.  
 
Some information is available from the limited studies performed and can be 
summarised thus:  
• Stromal cell derived factor 1 (SDF-1) is a member of the chemokine CXC 
subfamily and was found to promote cardiac differentiation of human and mouse 
bone marrow derived MSCs in vitro, suggesting that the CXCR4/PI3K/AKT 
pathways are significant in cardiac differentiation (Chen et al., 2008).  
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• MSCs increase the expression of c-Kit in neonatal cardiomyocytes via the 
secretion of insulin like growth factor 1 (IGF-1) and the PI3K/AKT pathways 
(Yu et al., 2009b).  
• The glycogen-synthase-kinase family has individual and specific effects on 
cardiac differentiation. GSK3-β has been found to play a critical role in cardiac 
differentiation of mouse MSCs when found in the cytoplasm through 
down-regulation of β-catenin of the Wnt pathway, whereas GSK3-α was found to 
inhibit cardiac differentiation when found in the nucleus by down regulating 
c-Jun of the JNK pathway (Cho et al., 2009).  
• Furthermore, injection of GSK3-β overexpressing MSCs into damaged 
myocardium improves the efficiency of MSC mediated r pair, by increasing 
survival of MSCs and angiogenesis (Cho et al., 2011).  
 
From this summary it can be seen that there are many different pathways involved in 
cardiac directed differentiation of MSCs, and that e ch pathway is crucial but further 
work is required to examine the interplay between each specific factor involved. 
 
5.1.3 The Use of Mesenchymal Stem Cells in Cardiac Disease 
 
Due to their ease of isolation, the variable locations they can be cultured from and the 
proposed ability for cardiac differentiation there has been extensive investigation of this 
ASC source as a therapeutic agent and as a source of cellular precursors. Human bone 
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marrow stem cells were found to differentiate into cardiomyocytes when transplanted 
into the adult mouse heart (Toma et al., 2002) and green fluorescent protein (GFP) 
labeled mouse bone marrow cells injected intravenously into mice with an induced 
myocardial infarction were found to assist in restora i n of cardiac function parameters 
and cardiac remodelling (Orlic et al., 2001a).  
 
Animal models and clinical trials in humans using MSCs in cardiac disease have 
suggested a short term improvement in some cases. Injection of MSCs into porcine 
infarcted hearts differentiated into cardiomyocytes and vascular structures, and also 
upregulated the presence of c-Kit positive CSCs (Hatzistergos et al., 2010).  The current 
rodent models are poor substitutes for direct comparisons to humans in terms of both 
size and cardiac physiology and as previously discus ed larger animal models are being 
utilized including the pig and the dog, and data generated from these studies has the 
potential to be used in veterinary medicine.  
 
5.1.3.1 Canine Mesenchymal Stem Cells and Cardiac Disease 
 
Canine MSC isolation was first described by Kadiyala et al in the mid 1990’s. These 
cells were isolated using standard human techniques of ti sue culture plastic adherence 
and were capable of osteochondrogenic differentiation (Kadiyala et al., 1997). Following 
their isolation, a large amount of work was performed investigating their use for joint 
and cartilage diseases; but more recently the use of canine MSCs for cardiac diseases 
has been investigated. Currently, dogs are being used as models for human disease 
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research, and the results from these studies can be directly translated into veterinary 
medicine. Bone marrow derived MSCs need to be investigated for their safety when 
used for cardiac therapy in dogs, and route of delivery, cell type and cell number are all 
critical factors. Currently conflicting literature surrounds the use of MSCs in canine 
heart disease, with one study seeing minimal fibrotc change when autologous MSCs 
were injected directly into myocardium (Li et al., 2003) whereas  acute myocardial 
ischaemia and subacute myocardial microinfarction were seen in an alternative study 
when autologous MSCs were injected into the heart vi  the coronary artery (Vulliet et 
al., 2004).  
 
In a chronic ischemia study using dogs as a model, allogeneic bone marrow derived 
MSCs were injected into chronically infarcted myocardium and were found to improve 
vascularisation and cardiac function over 60 days (Silva et al., 2005). Human MSCs 
transfected with pacemaker genes were transplanted i to the heart of dogs with induced 
heart block (whereby the electrical signal cannot pass through the heart tissue). In these 
dogs pacemaking function was seen for up to 6 weeks of study, providing a possible 
alternative to the use of electrical pacemakers (Plotnikov et al., 2007). These results may 
suggest a positive effect of MSCs in longer term repair of the heart, counteracting the 
acute damage previously described. 
 
In two further studies utilizing human MSCs injected into the canine heart, it was found 
that MSCs home to the site of ablation following radio-ablation therapy and differentiate 
into cardiomyocyte-like cells (Kim et al., 2011) and that MSCs laced onto an 
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extra-cellular matrix scaffold can be used to repair full-thickness right ventricular 
defects (Potapova et al., 2008). No data is available on the clinical benefits of MSCs 
injected into canine hearts for the treatment of naturally occurring congenital or acquired 
canine cardiac diseases but based on the preliminary data from experimental studies and 
findings from human clinical trials this is an area worthy of further study.  
 
5.1.3.2 Mobilisation of Native Mesenchymal Stem Cells in Heart Disease 
 
Cells expressing cardiac lineage markers Nkx2.5, GATA 4 and MEF2C reside in the 
bone marrow of young mice and humans, and decrease in number with age. These cells 
come from the non-adherent CXCR4 positive, CD45 negative non-haematopoietic 
mononuclear cells and it is proposed that these cells have the propensity for cardiac 
regeneration following mobilization after cardiac injury (Kucia et al., 2004). It has been 
observed that in humans following acute myocardial infarction, an increase in 
circulating MSCs occurs. This mobilization is heavily influenced by the expression of 
SDF-1 signaling to the bone marrow to release CXCR4 positive muscle progenitor cells 
which home to the heart (Wojakowski et al., 2004). Also the KitL ligand (stem cell 
factor, SCF) is released in response to cardiac injury, which stimulates the activation of 
c-Kit positive MSCs to be released from the bone marrow and these cells home to the 
damaged myocardium and release pro-angiogenic factors (Fazel et al., 2008). This data 
suggests that there is potential for MSCs present in the bone marrow to generate repair 
in the heart following injury, and optimising this cell population may allow for 
autologous cardiac therapies without the need for surgical intervention.  
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5.1.4 The Paracrine Effects of Mesenchymal Stem Cel ls in the Heart 
 
It is believed that MSCs exert a paracrine effect upon cardiac tissue which modulates 
and controls inflammation and fibrosis following dam ge, and as previously mentioned 
MSCs are thought to translocate from the bone marrow to the heart following damage 
signals. Furthermore, it is believed MSCs secrete sveral factors important for cell 










Figure 5.1. Paracrine effects of MSCs in cardiac disease. A host of factors are released 
from tissue and from the MSCs themselves in response to damage, triggering several 
events which limit scar formation and promote healing (see abbreviations list for 
specific factors). Immunomodulation occurs via the inhibition of T lymphocytes, natural 
killer (NK) cells and dendritic cells (iDC and mDC) and the suppression of 
immunoglobulin release. Apoptosis is limited and angiogenesis stimulated to maintain 
and provide blood flow to the damaged areas. Tissue pecific stem cells are activated by 
MSCs and scarring limited by anti-fibrotic mediators. The release of a host of 
chemokines attracts leukocytes to the damaged tissue to maintain normal tissue viability 
(Meirelles Lda et al., 2009). 
 
Specifically certain key factors have been shown to be critical for cardiac protection. 
Matrix metalloproteinases (MMPs) are released during cardiac damage and these were 
found to activate c-Kit in bone marrow derived MSCs (Fazel et al., 2008). MSCs were 
also found to stimulate the activity of MMPs and decrease the viability of cardiac 
fibroblasts, thereby decreasing collagen secretion. MSCs also decreased the expression 
of MMP inhibitors released from cardiac fibroblasts, reducing the fibrotic damage seen 
in cardiac disease (Mias et al., 2009). MSCs modifie  to over-express Akt have been 
found to reduce infarct size in rodent models following cardiac injury, and it is believed 
that the Secreted frizzled protein (Sfrp 2) is a key factor in this effect (Gnecchi et al., 
2005). Sfrp 2 is an upstream regulator in the canonical Wnt pathway, and 
cardiomyocytes treated with this protein increase cellular β-catenin and the expression of 
anti-apoptotic genes (Mirotsou et al., 2007). MSC conditioned media has beneficial 
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effects on the proliferation and survival of cardiac stem cells located within the heart 
itself, and it is proposed that secreted factors such as HGF, IGF-1 and VEGF may be 
responsible for these effects (Nakanishi et al., 2008). Notch pathways are crucial in 
embryonic development in the heart, and it has been proposed that Notch 1 from bone 
marrow derived MSCs is important in cardiac repair following ischemic damage by the 
mediation of neovascularisation (Li et al., 2011). It can be seen from this data that the 
paracrine effects of MSCs are diverse and involve a large number of different factors 
and pathways, and much cross-talk between pathways appears to occur. This is a 
developing field and the future may include the development of released factors as 
specific targeted therapies, as has been proposed by He et al. This group showed that 
exogenously administered Sfrp 2 significantly reduced fibrosis following cardiac 
damage in rodent models; the idea for which was based upon previous studies of MSC 
over expression of this protein (He et al., 2011). 
 
5.1.5 Mesenchymal Stem Cell Clinical Trials for Car diac Disease 
 
Clinical trials using MSCs for cardiac disease are lready underway and overall 
demonstrate a trend for generalized short term improvement. However these trials have 
been undertaken following limited basic stem cell science research making it difficult to 
ascertain at this stage whether the improvements seen are caused by a paracrine effect 
promoting scar remodeling versus a replacement/renewal effect, or perhaps a 
combination of both. Trials include the REGENERATE, TOPCARE, ASTAMI and 
BOOST trials (Schachinger et al., 2004, Meyer et al., 2006, Assmus et al., 2007, Lunde 
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et al., 2007, Yeo and Mathur, 2009). These trials all uggest a generalised improvement 
in measurable outcomes in patients with cardiac disease, such as increased ejection 
fraction and decreased end-systolic volume.  
 
A separate trial has found that injection of bone marrow derived stem cells into the 
coronary artery following an acute myocardial infarction does not improve measurable 
outcomes as before, however they do promote infarct remodeling and the significance of 
which will need to be investigated in follow up of this patient group (Janssens et al., 
2006).  
 
Long term follow up of these MSC treated patients is t ll ongoing, and results of these 
studies will be critical in deciding the future of MSC therapy in cardiac disease. Further 





This chapter describes the isolation and culture of canine primary MSCs from the bone 
marrow. Detailed characterisation of the isolated population will be performed and the 
differentiation potential toward cardiac lineages investigated. 
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5.2 Materials and Methods 
 
5.2.1 Isolation and Culture of Canine Mesenchymal S tem Cells 
 
5.2.1.1 Tissue Samples 
 
Femurs from recently euthanized dogs were dissected and exposed from the lateral 
thigh, and the shaft split using a small hacksaw distal to the femoral head and proximal 
to the femoro-patellar joint, releasing a mid-diaphyseal section. The medullary cavity of 
these sections were washed with standard mesenchymal stem cell media; DMEM low 
glucose containing Glutamax-I (Invitrogen, UK), with 10% FBS (Invitrogen, UK) and 
100 U/mL penicillin G and 100 µg/mL streptomycin (both Invitrogen, UK), and 
17 U/mL of Heparin (Wockhardt Ltd, UK), and chilled on ice. If possible cells from 
femoral sections from both hind legs were pooled to maximize cell number.  
 
5.2.1.2 Sample Preparation 
 
Heparinised media containing bone marrow cells was m de up to 10 mL total volume 
using pre-warmed PBS, and layered onto 16 mL of Ficoll Paque Premium (GE Life 
Sciences) in a 50 mL Falcon tube. The samples were centrifuged without brake setting 
for 30 minutes at 450g. The interface layer was colle ted using Pasteur pipettes and 
transferred to a 15 mL Falcon tube and made up to 8 mL using PBS. This was then 
centrifuged for 5 minutes at 150g to pellet the cells. The PBS was removed and 
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discarded and the cell pellet re-suspended in 1 mL of warmed MSC media, and the cells 
counted as previously described using white cell counting mount solution (1% w/v 
crystal violet and 2% v/v glacial acetic acid in distilled water).  
 
5.2.1.3 Isolation of Stem Cells 
 
Cells were plated at approximately 1 x 104 cells/T25 and placed at 37 °C, 5 % CO2. 
Cells were left for 2-4 days to allow the adherent cell layer to attach, and then media 
containing dead cells and debris was removed and discarded and the adherent cells 
washed using PBS. Fresh MSC media was replaced, and the cells washed every 2-3 days 
until cells were 80-90% confluent (usually 1-2 weeks). Cells were then passaged using 
0.05% trypsin-EDTA (Gibco, UK) to loosen cells, and counted with a haemocytometer 
and trypan blue live cell stain (Sigma, UK). Approximately 1 x 103 cells/cm2 was 
replaced at each passage in tissue culture flasks. An increase of approximately 1 log 
scale of cells was achieved between passage, and 4-5 passages were possible before 
senescence.  
 
5.2.1.4 Mesenchymal Stem Cell -80 °C Storage 
 
Early passage (<3) canine MSCs were trypsinised from tissue culture flasks as 
previously described, and counted. Cells were centrifuged for 5 minutes at 1500 rpm to 
pellet and re-suspended in freezing media; 60% FBS, 30% standard MSC media, 10% 
dimethyl sulfoxide (DMSO) (Invitrogen, UK). 1 x 106 minimum total cells were placed 
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into 1 mL of freezing media in a cryovial (BioSigma, Italy) and the cells placed at -80 
°C in an isopropanol chamber for 24 hours before being transferred into longer term 
liquid nitrogen storage.  
 
Cells were revived by removing cryovials from liquid nitrogen storage and swirling the 
vial in a water bath at 37 °C for a maximum of 2 minutes to defrost the freezing media. 
Pre-warmed standard MSC medium was then added to the vial in a dropwise fashion in a 
1:1 ratio and the cell suspension then transferred to a 15 mL Falcon tube. A further 3 mL 
of MSC medium was added, and the cells centrifuged at 1500 rpm for 5 minutes. The 
cell pellet was re-suspended in 1 mL of MSC media and the cells counted. Cells were 
re-plated at approximately 3-5 x 106 total cells in a T75 flask. Cells were placed at 37 
°C, 5% CO2, with media refreshes every 3 days until cells were 80-90% confluent and 
ready for passage.  
 
5.2.2 Mesenchymal Stem Cell Characterisation 
 
5.2.2.1 Transcriptional Analysis of Mesenchymal Stem Cells 
 
MSC RNA was extracted and reverse transcribed, and PCR reactions performed as 
previously described in Chapter 2; Materials and Methods. MSCs were analysed for 
expression of several key markers; CD44, CD34, CD45 and c-Kit, and compared to 
RNA from splenic tissue known to express haematopoietic markers, and therefore acting 
as a negative control for MSCs. 
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Furthermore analysis of day 0 MSCs was performed during cardiac differentiation 
analysis, and included cardiac markers from cardiomyocyte, endothelial and smooth 
muscle lineages (Table 5.2). 
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Table 5.2. Canine oligonucleotides used for MSC analysis. CTT-Cardiac Troponin T; 
Beta 1 Ad-β1-adrenergic Receptor; Cardiac RyR-Cardiac Ryanodine R ceptor; 
CTI-Cardiac Troponin I; VEGF-Vascular Endothelial Growth Factor; vWF-von 
Willebrands Factor; SMA-Smooth Muscle Actin. F: Forwa d Primer. R: Reverse Primer 
 
Marker Sequence 5'-3' Size (BP) Tm (°C) 
CD44 F: TAC GCA GGT GTG TGT TCC CAT GT 214 58 
 R: GGT TTG CAG CAC AAA TAG CA   
CD34 F: TGA CAC CCC AAG TAC CAT CA 162 60 
 R: GGC TCC TTC TCA CAC AGC AC   
CD45 F: AGC TAA GGC GAC AGA GAT GC 157 60 
 R: ACT GGG CGG GTC TCT TTT CT   
C-Kit F: ATA TCC CAA ACC GGA GCA C 193 58 
 R: TCA CCG AAG AAT TGA CAT CG   
Islet 1 F: GGT TTC TCC GGA TTT GGA AT 183 57 
 R: CAC GAA GTC GTT CTT GCT GA   
Nkx2.5 F: CCA AGG ACC CTC GAG CTG A 185 62 
 R: CGA CAG ATA CCG CTG CTG CT   
GATA 4 F: CAA GAT GAA TGG CAT CAA CC 216 57 






Marker  Sequence 5'-3' Size (BP) Tm (°C) 
Flk-1 F: CCA CCC AGA CTC AGC ATA CA 188 58 
 R: CAC TTT TGG AAT CGT GAG CA   
CTT F: GAA GGA CCT GAA CGA ACT 210 60 
 R: CCT CCT GTT CTC CTC CTC CT   
Beta 1 Ad F: GAG TAC GGC TCC TTC CTG TG 274 61 
 R: AGC ACT TGG GGT CGT TGT AG   
Cardiac RyR F: AAG CGA AGC AGC CCA AGG GT 888 62 
 R: TCA GCA AAG TGT GCC GCG CT   
CTI F: TCT GCG CAT GGC GGA TGA GA 624 62 
 R: TTG CGG CCC TCC ATT CCA CT   
VEGF F: TTC CTG CAG CAT AGC  AAA TG 293 
(239,311) 
57 
 R: AGG GAG GCT CCT TCT TCC AG   
vWF F: CTG GGA GAA GAG AGT CAC GG 235 61 
 R: GTG GAT GGA GTA CAC GGC TT   
SMA F: GGG GAT GGG ACA AAA GGA CA 525 61 
 R: GCC ACG TAG CAG AGC TTC TCC TTG A   
Glomulin F: TTG AAG AGC CCT CTG GAA AA 131 57 
 R: ACT CCA AAG GGT GGA CAA TG   
Connexin 43 F: ATG AGC AGT CTG CCT TTC GT 249 58 
 R: TCT GCT TCA AGT GCA TGT CC   
GAPDH F: CAT CAA CGG GAA GTC CAT CT 428 Various 




5.2.2.2 Translational Analysis of Mesenchymal Stem Cells 
 
Canine MSCs (passage 2) were seeded onto 4 well chambered slides (Corning, UK) at a 
density of 2 x 104 cells/well. Cells were cultured for 48 hours at which point cells were 
approximately 60% confluent. The media was removed an  slides were air dried and 
then fixed directly in 4% paraformaldehyde for 20 minutes, followed by two PBS 
washes and subsequently placed in 100% ethanol for 5 minutes, followed by 2 x PBS 
washes to permeabilise the cells. Blocking buffer (10% normal goat serum (Invitrogen, 
UK); 0.1% Tween 20 (Sigma, UK)) in 1x PBS was applied for 1 hour at room 
temperature. Primary antibodies; rat anti-dog CD44 (AbD Serotec MCA1042G), and 
mouse anti-human STRO-1 (R&D Systems MAB1038) diluted at 1:100 and 1:50 
respectively in PBST (0.1 % normal goat serum, 0.1% Tween 20 in PBS) were added 
directly to the slides and incubated at 4 °C overnight in a humidified chamber. 
Following this slides were washed in PBS twice before secondary antibody was added. 
Alexafluor 488 goat anti-rat IgG and 568 goat anti-mouse IgM (Invitrogen A11006 and 
A21043 respectively) were diluted 1:500 in PBS and i cubated for 1 hour at room 
temperature. Nuclear counterstaining was performed using DAPI mount (Vectastain, 
USA) and slides covered with coverslips (VWR International, USA), and sealed using 
clear nail varnish. Negative controls were performed using secondary antibody only, 
with all other procedures performed as for positive samples. Images were taken using 
the Zeiss Axiovert 40CPL microscope and processed uing the Axiovision programme.   
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5.2.3 Cardiac Directed Differentiation of Mesenchym al Stem Cells using 
Published Techniques 
 
5.2.3.1 Culture and Harvest for Transcriptional Analysis 
 
Canine MSCs (passage 3) were trypsinised from standard culture and counted as 
previously described. 5 x 104 cells in 0.5 mL of MSC media was added to 1 well of a 
24-well plate. Plates were labelled for three time points, 7, 14 and 21 days. Each 
experiment was run in triplicate. A triplicate set of wells was plated to allow for time 0 
control (Figure 5.2).  
 
 
Figure 5.2. Plate plan design for MSC differentiation toward cardiac lineages. Triplicate 
wells were prepared for day 0, and three further time points, day 7, 14 and 21.  
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The cells were left overnight in MSC media to allow them to adhere at 37 °C, 5% CO2. 
The following day media was aspirated and 2 x PBS washes performed to all wells. 
Time 0 triplicate wells were trypsinised off, and centrifuged at 1500 rpm, for 5 minutes 
to pellet cells. Supernatant was removed and discarded, and the cells washed in PBS. 
The cells were then re-centrifuged to pellet and PBS removed and discarded and the 
cells snap frozen in dry ice, and stored at -80 °C. 500 µL of MSC media was added to 
the remaining control wells. 500 µL of MSC media with 3 µmol/L 5’AZA (Sigma, UK) 
was added to the differentiated wells. Half media ch nges were performed to all wells, 
with either standard MSC media or media containing 3 µmol/L 5’AZA every 3 days for 
3 weeks (Figure 5.3). Harvests of triplicate wells were taken at days 7, 14 and 21 and 
pelleted as described for day 0. RNA was subsequently x racted, and triplicate RNA 
samples pooled for semi-quantitative RT-PCR, performed as described in Chapter 2; 
Materials and Methods with primers described in Table 5.2. Quantitative RT-PCR was 
also performed and is described below. Both semi-quantitative and quantitative RT-PCR 




Figure 5.3. Experimental design for MSC differentiation toward cardiac lineage. 
Following initial set up 3µmol/L 5’AZA was added to differentiating wells every 3 days 
for 21 days. Harvests were collected weekly, and negative controls were run alongside 
with no addition of 5’AZA.  
 
5.2.3.2 Quantitative RT-PCR Analysis of Mesenchymal Stem Cell Differentiation 
 
Primers and probes were designed and prepared for Flk-1 and CTT as described in 
Chapter 2; Materials and Methods, and primers ordered from MWG Eurofins and probes 
from Roche. Nkx2.5 primer and probe was designed using the Applied Biosystems 
software, and ordered pre-bound to probe at a 20 X concentration from Applied 
Biosystems. Sequence details can be found in Chapter 4; Cardiac Stem Cells.  
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5.2.3.2.1 cDNA Synthesis 
 
Extracted RNA from cardiac differentiation pellets from each time point in triplicate 
were reverse transcribed as described in Chapter 2; Materials and Methods. 
 
5.2.3.2.2 PCR Master mix 
 
A master mix was prepared for CTT, Flk-1, Nkx2.5 and 18s rRNA controls as described 
in Tables 5.3, 5.4 and 5.5: 
 
Table 5.3. Target gene master mix for CTT and Flk-1 
 
Master mix 1x (µL) (n x =number  of wells) 
Realtime Master mix 5 
10x Primer/Probe (FAM) 0.3 
 
Table 5.4. Target gene master mix for Nkx 2.5 
 
Master mix 1x (µL) (n x =number  of wells) 
Realtime Master mix 5 
20x Primer/Probe (FAM) 0.15 
Water 0.15 
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Table 5.5. Target gene master mix for 18s rRNA control gene  
 
Master mix 1x (µL) (n x =number of wells) 
Realtime Master mix 5 




5.2.3.2.3 Primer Efficiency and Optimisation 
 
Primer pairs were optimized as described in Chapter 4; Cardiac Stem Cells.  
 
5.2.3.2.4 Relative Gene Expression Analysis 
 
Following primer optimization samples could be compared for relative expression of 
specific gene targets. 100 ng of total RNA of each sample from dog A and B were 
reverse transcribed and the subsequent triplicate cDNA analysed. A plate plan for 
relative expression is shown in Figure 5.4. 
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Figure 5.4. 96-well plate plan for gene expression analysis. Wells were designed to 
allow for triplicates of sample cDNA, differentiated (Diff) and undifferentiated (Undiff) 
run again in triplicate for technical replicates. Triplicate wells of day 0 cDNA were run 
alongside as a reference gene. Primers for CTT, Flk-1 and Nkx2.5 were bound to a FAM 
probe, and primers for 18s rRNA in-house gene positive control bound to a VIC probe. 
Negative control of water and RNA (-RT) were run on the same plate. One plate was run 
per dog per time point (day 7, 14 and 21).  
 
This plate design allows for comparison between differentiated (Diff) and 
undifferentiated (Undiff) samples in two dogs, A and B, over three time points. Day 0 
cDNA has been added to allow for a reference control sample. All negatives were run on 
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the same plate using the same master mix that was used for the samples. All plates used 
the same cDNA to allow for control across individual pl te runs.  
 
Samples were run using programme and cycles describd in Tables 5.6 and 5.7; 
 
Table 5.6. Programme data for Roche Lightcycler 480 
 
Programme Cycle Acquisition 
Pre-incubation 1 N 
Amplification 50 Quantify 
Cooling 1 N 
 
 With individual cycles as follows: 
 
Table 5.7. Temperature settings per cycle for Roche Lightcycler 480 
 
 Temperature °C Acquisition Hold (Time) Ramp 
Pre-Incubation 95 N 10 minutes 4.4 
Amplification (50x) 95 N 10 seconds 4.4 
 54 N 30 seconds 2.2 
 72 Single 1 second 4.4 
Cooling 40 N 10 seconds 1.5 
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5.2.4 Mesenchymal Stem Cell Co-Culture with Cardiac  Stem Cells 
 
Canine MSCs were grown in indirect co-culture with autologous CSCs using a transwell 
system.  
 
5.2.4.1 Harvest and Transcriptional Analysis of Mesenchymal Stem Cells 
Following Co-Culture 
 
MSCs and CSCs were harvested as described in Chapter 2; Materials and Methods and 
placed in DEM media and counted.  
 
Following the plate plan as described in Chapter 2; Materials and Methods, 2 x 104 
MSCs were seeded into base wells of the 24 well plate (growth area 1.9cm2) in 600 µL 
of DEM media, with 1 x 104 CSCs seeded onto transwell inserts (growth area 0.33 cm2) 
in 100 µL DEM media.  Control wells of MSCs alone were cultured alongside. Plates 
were then placed at 37 °C, 5% CO2. Day 0 MSCs were pelleted at this point, and snap 
frozen and stored at -80 °C. Images and harvests from both co-cultured and control wells 
were taken at days 6 and 10 post plating and cells p eted and snap frozen and stored at 
- 80°C. RNA was subsequently extracted from pellets and 150 ng total RNA used for 
semi-quantitative RT-PCR analysis as described in Chapter 2; Materials and Methods 




5.3.1 In Vitro Culture of Primary Canine Mesenchymal Stem Cells 
 
5.3.1.1 Morphology and Culture Characteristics 
 
Canine MSCs were isolated from 23 dogs of variable ag , breed and sex. Dogs were 
euthanized for clinical reasons and tissue donated with owners’ consent. Following bone 
marrow harvest into heparinised media, cells were isolated using standardised Ficoll 
technique and tissue culture plastic plating. MSCs adhered naturally to tissue culture 
plastic over 2-4 days. Non-adherent (non-mesenchymal) cells floated free and were 
readily discarded. Morphologically the cells appeared flattened and adherent, with 
multiple jagged projections (Figure 5.5). These cells were capable of rapid expansion, 
with log increases in cell number at passage once fully established. Canine MSCs 
typically senesced between passage 4 and 6, at which point the cells increased in size 







Figure 5.5. Morphology of primary canine MSCs. Canine MSCs resembled previously 
described MSCs from other species, adhering readily to tissue culture plastic, and 
forming long, flattened cells with multiple jagged projections. A and C magnification 









5.3.1.2 Canine Mesenchymal Stem Cell Characterisation using RT-PCR 
 
Canine MSCs were analysed for the expression of the MSC markers CD44, c-Kit, CD34 
and CD45 using semi-quantitative RT-PCR and haematopoietic splenic tissue RNA as a 
control. MSCs were found to be positive for CD44, and demonstrated low expression of 
c-Kit, CD34 and CD45. Splenic tissue was found to be positive for CD34, CD45, CD44 















Figure 5.6. Semi-quantitative RT-PCR analysis of MSC (M) expression compared to haematopoietic splenic tissue (S) 
expression of CD34, CD45, c-Kit and CD44. Each PCR was multiplexed with GAPDH (labelled at 428 base pairs), and bands of 









5.3.1.3 Mesenchymal Stem Cell Characterisation using Immunofluorescence 
 
Canine MSCs were grown on 4 well chambered slides and analysed for expression of 
CD44 and STRO-1 at translational level using IFA. Both markers were found to be 
expressed in the adherent cell population with exprssion seen at cytoplasmic/cell 






















Figure 5.7. Canine MSCs labeled for CD44 and STRO-1. Strong positive staining was 
seen for both markers. CD44 (A) was seen throughout the surface of the cell. STRO-1 
(C) appeared to be found within the cytoplasm of the cells, and particularly dense around 
nuclei. Negative controls (B and D) for each were performed with secondary antibody 








5.3.2 Cardiac Differentiation of Canine Mesenchymal  Stem Cells using 
Published Protocols 
 
Cardiac differentiation was attempted using the de-methylating agent 5’AZA over a 
three week time course, based upon published literature. 
 
5.3.2.1 Morphology during Differentiation 
 
Morphologically at early time points (day 7) the cells closely resembled day 0 MSCs in 
both the test and control populations. By day 14 there appeared to be some suggestion of 
alignment of the cells in test wells compared to control. By day 21 the lining up 
appeared more pronounced, with cells swirling in test wells, whereas in control wells 









Figure 5.8. Cellular morphology during cardiomyocyte differentiation of canine MSCs. 
Canine MSCs showed minor morphological changes during the differentiation protocol. 
Some suggestion of cellular alignment was seen by day 14 in the cells undergoing 
differentiation (Test) (C-H) which was not seen in day 0 (A and B) and control cells (I-
O). (Magnification A, C, E, G, I, L and N is x 100; B, D, F, H, J, M, and O is x 200). 
 
5.3.2.2 RT-PCR Analysis of Cardiac Directed Differentiation 
 
Using semi-quantitative RT-PCR, marker expression was examined in two dogs, A and 
B, following cardiac directed differentiation (Figure 5.9 and Figure 5.10 respectively). In 
dog A, Nkx2.5 was expressed in day 0 MSCs, which appe red increased in test cells of 
all time points, with decreased expression in control cells compared to day 0. In dog B 
there appeared to be lower expression of Nkx2.5 at day 0, which then increased in all 
cells at all time points. Flk-1 expression appeared low at day 0 in both dogs, and then 
increased in dog A test cells at days 7 and 21 compared to control. In dog B levels 
appeared to remain low, with a slight increase suggested in control cells at day 7, and 14. 
VEGF expression remained constant throughout the diff rentiation in all cells compared 
to day 0, and demonstrated multiple banding corresponding to the splice variants of 
VEGF. SMA, Glomulin, CD44 and Connexin 43 expression levels remained unchanged 
in test and control samples in both dogs over time compared to day 0 MSCs. In both 
dogs no expression of GATA 4, islet 1, c-Kit, CD34, CD45, vWF, CTI, CTT, RyR and 





Figure 5.9. Marker expression changes over time during cardiac directed differentiation 
for dog A. Day 0 (0) baseline MSCs were compared to MSCs undergoing differentiation 
(D) and those under control conditions (U) at three time points, days 7, 14 and 21. 





Figure 5.10. Marker expression changes over time during cardiac directed differentiation 
for dog B. Day 0 (0) baseline MSCs were compared to MSCs undergoing differentiation 
(D) and those under control conditions (U) at three time points, days 7, 14 and 21. 
GAPDH was run as an internal multiplexed control.  
 
5.3.2.3 Quantitative RT-PCR Analysis of Cardiac Directed Differentiation 
 
Nkx2.5, Flk-1 and CTT were further examined using quantitative RT-PCR for both dogs 
A and B (Figure 5.11 and 5.12 respectively). Nkx2.5 generally increased relative to day 
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0 in cells undergoing differentiation of both dogs compared to controls. Specifically, in 
dog A at day 14 and 21, there was an approximately 2.5-3 fold increase in test cells 
compared to day 0, however at day 7 both test and control cells demonstrated this 
increase. In dog B there was a larger relative increase in both test and control samples, 
with a fold increase of approximately 6-8 times in test and 5-6 times in control samples 
at all time points compared to day 0.  
 
Flk-1 expression showed more variability than Nkx2.5, but again showed a general trend 
for higher expression in test samples than control. D g A had a 2-3 fold increase in 
expression in test cells relative to day 0 at days 14 and 21, however at day 7 increase 
was only 1.5 fold, and was comparable to that of control samples. At days 14 and 21 
control samples showed a relative expression of 1 t 1.5 fold, indicating levels similar to 
that of day 0. In dog B there was a 4 fold increase in t st cell expression of Flk-1 by day 
7, which dropped to 1.5-2 fold for days 14 and 21. In control cells there was an initial 
increase to 2-2.5 fold by day 7, which returned to levels comparable with day 0 MSCs at 
days 14 and 21. There was more fluctuation seen in Flk-1 expression of dog B, with a 
less pronounced increased expression in test cells compared to controls.  
 
No expression was seen for CTT using quantitative RT-PCR (data not shown) in any of 





Figure 5.11. Quantitative RT-PCR analysis of dog A expression of Nkx2.5 and Flk-1 
during cardiac directed differentiation relative to day 0. Test (+) and control (-) results 





Figure 5.12. Quantitative RT-PCR analysis of dog B expression of Nkx2.5 and Flk-1 
during cardiac directed differentiation relative to day 0. Test (+) and control (-) results 
are shown for days 7, 14 and 21. 
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5.3.3 Co-Culture of Mesenchymal Stem Cells with Car diac Stem Cells 
 
5.3.3.1 Cellular Morphology during Differentiation 
 
Canine MSCs were co-cultured in a transwell system with autologous CSCs. The 
transwell inserts ensured that there was no direct c ll to cell contact or cell fusion 
possible, thereby ensuring that only media and expressed factors were shared between 
the cell populations. Two separate dogs were run concurrently, A and B (these were not 
the same dogs used for the previous differentiation technique using 5’AZA). 
Morphologically the cells appeared to increase significantly in number over the time 
course of the experiment (Figure 5.13), and in particular dog B, which by day 6 showed 
a dense monolayer of cells in the control wells (Figure 5.13 Dog B day 6). Dog A 
co-culture wells appeared to have a very dense layer of cells by day 10, which formed 
cross-striation patterns in co-culture not seen in co trol wells (Figure 5.13, Dog A, G 
and H). During culture it was noted that dog B MSCs in a co-culture well peeled away 
from the gelatin coated well base by day 6 and formed a pellet of cells, which did not 







Figure 5.13. Cellular morphology during co-culture of Canine MSCs with autologous 
CSCs. Canine MSCs showed minor morphological changes during co-culture compared 
to control wells at both time points for dog A , and cells peeling away into a pellet in co-
culture wells of dog B (Magnification A, C, E, G x 100; B, D, F, H x 200). 
 
5.3.3.2 Transcriptional Analysis of Mesenchymal Stem Cells during Indirect Co-
Culture with Cardiac Stem Cells 
 
Using semi-quantitative RT-PCR (Figure 5.14) cells from both dog A and B expressed 
CD44 at baseline and continued to express it at stedy levels in both cell populations 
throughout the experiment. Dog A did not express CD34 throughout the experiment, 
however Dog B expressed CD34 at baseline, and clearly maintained expression in 
control wells at days 6 and 10, whereas in co-cultured wells expression was significantly 
lower at both time points. Islet 1 expression was seen at very low levels with dog A at all 
time points. Dog B also demonstrated low levels of islet 1 expression at baseline, day 6 
control wells and day 10 co-culture wells, whereas d y 6 co-culture did not express and 
day 10 control wells had much reduced expression. Nkx2.5 expression remained at 
similar high levels compared to baseline in dog A throughout the experiment. In dog B 
Nkx2.5 levels appeared to reduce in both control and co-culture wells at day 6, 
compared to day 0, and increase in control wells at day 10. Flk-1 expression remained 
relatively steady throughout the experiment for dog A, whereas for dog B there was a 
suggestion of reduced Flk-1 in both control and co-culture samples at day 6, and 
co-culture samples at day 10. VEGF expression remained steady throughout the 
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experiment for dog A, with multiple banding representative of splice variants. In dog B, 
there appeared to be a more pronounced upper band in co-culture wells at both time 
points when compared to baseline controls. vWF was not expressed by dog A, but there 
was low level expression in dog B, which appeared to be increasing with time in culture. 
SMA was steadily expressed throughout the experiment for both dogs (a dual band is 
seen representative of SMA above and GAPDH below, due to similar band sizes). 
Glomulin was steadily expressed in all wells in dog A and dog B except for a decrease in 
expression in co-culture wells at day 6 for dog B. Connexin 43 was expressed at steady 
levels for both dogs throughout the experiment. Cells from dog A and B were negative 
for CD45, β1-adrenergic receptor, c-Kit, GATA 4, CTI, cardiac ryanodine receptor and 
CTT (Data not shown).  
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Figure 5.14. Semi-quantitative RT-PCR analysis of MSC expression during co-culture 
with autologous CSCs. Expression of each marker in control (Co) and co-cultured (Cc) 
wells at days 6 and 10 are compared to day 0 MSC baseline controls, and GAPDH. 
VEGF-vascular endothelial growth factor, vWF–von Willebrands factor, SMA–smooth 
muscle actin, Glom–glomulin, CNXN 43–connexin 43. GAPDH was run as a 




MSCs offer great potential in the field of regenerative medicine due to their relative ease 
of handling in terms of isolation and culture, their apparent ability for multi-lineage 
differentiation and their potential in providing an autologous source of cells for 
regenerative therapies. Furthermore canine MSCs may offer a cell source to use for 
studying a number of diseases of great significance i  the canine population. Cardiac 
disease, as previously discussed is the third biggest cause of mortality in pet pedigree 
dogs and development of an in vitro system for growing cardiomyocytes would greatly 
improve the opportunities for study. The behaviour f dog cells may also inform studies 
on other mammalian species most notably humans since they share living environments 
and develop similar acquired diseases resulting from a combination of genetic and 
environmental influences. In this study we aimed to is late and characterise canine 
MSCs, and to evaluate their in vitro differentiation potential toward cardiac lineages 
using two techniques; addition of the de-methylating agent 5’AZA and indirect 
co-culture with autologous cardiac stem cells.   
 
5.4.1 Can Canine Mesenchymal Stem Cells be Isolated  and Cultured from 
the Bone Marrow? 
 
This study demonstrates successful culture of primary bone marrow derived MSCs from 
the dog using a standardized technique (Dominici et al., 2006). This was reproducible in 
dogs of various ages, sex and breed. Cells were isolated using tissue culture plastic 
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adherence, a key determinant of MSC behaviour, and cell populations demonstrated log 
increases in cell number at passage once fully established.  
 
Morphologically the cells resembled previously described MSC populations having a 
flattened, elongated appearance with multiple jagged projections (Pittenger and Martin, 
2004, Shim et al., 2004).  Canine MSCs would typically senesce between passage 4 and 
6, at which point the cells would increase in size and the spindle projections would 
fatten. The canine MSCs closely resembled human MSC populations described in the 
literature which typically senesce relatively early under standard culture conditions 
(Banfi et al., 2000, Sekiya et al., 2002).  
 
5.4.1.1 Characterisation of Canine Mesenchymal Stem Cells 
 
No single marker is available to define a MSC and therefore panels of markers are 
generally employed, but panels used vary between publications (Dominici et al., 2006). 
This of course has lead to some variability in terms of characterisation based on marker 
expression and may allow for variability within cell populations isolated. A key marker 
expressed by MSCs is CD44, and our canine MSCs werepositive for CD44 using both 
RT-PCR and IFA.  
 
Despite the lack of a single marker to define MSC populations, STRO-1, a classic 
human MSC marker, has been used to enrich MSC populations from bone marrow 
isolates (Simmons and Torok-Storb, 1991, Gronthos et al., 1994, Dennis et al., 2002). 
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Canine MSCs were found to be STRO-1 positive using IFA, alluding further to 
similarities between canine and human MSC populations.  STRO-1 is not available for 
use in rodent cells, a limitation in terms of cell comparisons.  
 
Canine MSCs were CD45 and c-Kit low in early passage nalysis and negative in later 
passage analysis using RT-PCR. This difference may reflect haematopoietic 
contamination in early analysed MSCs and is an unavoid ble problem when isolating 
primary MSCs from bone marrow in the manner described; whereby any contaminating 
cellular expression is exponentially amplified in PCR to give low background result. 
Furthermore, the majority of canine MSCs isolated were CD34 negative, although one 
population was CD34 positive (seen analysed in co-culture experiments discussed 
below).  
 
5.4.2 Can Canine Mesenchymal Stem Cells be Differen tiated Toward 
Cardiac Lineages?  
 
5.4.2.1 Cardiac Differentiation using Published Techniques 
 
 In this study we exposed primary canine MSCs to the 5’AZA differentiation technique 
described in the literature (Kruglyakov et al., 2006). We set criteria for cardiac 
differentiation based on behaviour in culture, including evidence of independent 
rhythmical beating and the expression of cardiac structural and functional genes.  
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We initially examined the morphology of the cells during the differentiation over a three 
week period. Morphologically there were some minor changes in appearance of the 
canine MSCs during cardiac directed differentiation. In differentiated wells, in particular 
at later time points there appeared to be some sugge tion of lining up of the MSCs, 
which was not seen in the undifferentiated wells. This may represent a more organized 
cellular pattern, or may be a direct consequence of 5’AZA addition. In a functional 
cardiomyocyte the alignment of cells allows for themost efficient contraction, and is a 
critical factor in cardiac development. The lining up seen in the differentiated MSCs 
may have been the beginning of cardiomyocyte spatial patterning. 
 
We then examined the differentiated and undifferentiated cells at all time points for 
marker expression. We developed a bespoke panel of markers representing those 
expressed by MSCs, cardiac cell lineages, and those expressed by known stem cell 
populations. Specifically this panel of markers included markers which have been used 
to define successful cardiac differentiation in previous work (Table 5.8). 
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Table 5.8. Markers expressed in MSC populations following cardiac differentiation 
Author Species Markers expressed in differentiated MSCs 
Krugalykov et al Rat GATA 4, Nkx2.5, CXN43, CTT, CTI, Cardiotrophin 1 
 
Xu et al  Human β-MHC, desmin, α-cardiac actin, CTT 
 
Shim et al Human CTI, desmin, GATA 4, Nkx2.5, CTT 
 
Antonitisis et al Human vimentin, α-cardiac actin, β-MHC, CTT 
 
Makino et al Mouse GATA 4, Nkx2.5 
 
Fukuda et al Mouse MEF2A, MEF2D 
  
(Makino et al., 1999, Shim et al., 2004, Xu et al., 2004, Kruglyakov et al., 2006, 
Antonitsis et al., 2007).  
 
All of the markers examined during cardiac directed differentiation generally maintained 
expression levels with two exceptions; Nkx2.5, a cardiac homeobox gene, and Flk-1, an 
endothelial marker. This suggests that there was minimal effect of 5’AZA upon the 
MSCs in driving the cells towards a cardiac lineage, particularly given the lack of 
expression of cardiac structural protein genes. Nkx2.5 and Flk-1 have both been used to 
define cardiac stem cells (Beltrami et al., 2003, Goumans et al., 2007, Yang et al., 2008) 
and were included in the panel to allow for comparisons to that cell source. Some 
variability was seen in expression of Nkx2.5 and Flk-1 between the two dogs examined, 
however this is to be expected given the primary source of the cells and individual dog 
variation. The general trend in both markers was increased expression in differentiated 
cells, however there was not a striking difference, and both markers were expressed in 
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day 0 baseline MSCs. Nkx2.5 is an primitive cardiac marker (Lints et al., 1993) and 
Flk-1 a primitive endothelial marker (Yamaguchi et al., 1993) and the expression of both 
of these in MSCs may be due to the combined mesodermal lineage of the cell types. The 
variation in Nkx2.5 and Flk-1 expression is likely to have been driven by the addition of 
the demethylating agent 5’AZA, increasing transcription of these markers and this 
increase has been described in previous studies using 5’AZA for cardiac differentiation 
(Makino et al., 1999, Kruglyakov et al., 2006).  In comparison to our isolated canine 
CSCs, Nkx2.5 was seen to increase similarly, however CSCs decreased Flk-1 expression 
following cardiac differentiation. This interesting difference may be representative of 
movement of the CSCs towards cardiomyocytes and MSCs towards a more endothelial 
cell type. 
 
Based on the marker expression and morphology following cardiac differentiation of 
canine MSCs no conclusive evidence of cardiac differentiation following 5’AZA 
differentiation protocols was seen. Interestingly there is some evidence to suggest that 
differentiation ability of MSCs varies amongst MSC populations and those isolated from 
different regions of the body (Kern et al., 2006, Liu et al., 2007, Vidal et al., 2008). 
There is no evidence to discuss this for cardiac differentiation, but it has been noted for 
connective tissue differentiation (discussed in Chapter 7) and this may be relevant to this 
experiment, and should be investigated further by performing cardiac differentiation 
using MSCs from different sources. 
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5.4.2.2 Differentiation of Canine Mesenchymal Stem Cells using Indirect 
Co-Culture 
 
Stem cell co-culture has commonly been used as a method for triggering differentiation 
of cell populations, in particular MSCs co-cultured with cardiomyocytes either 
indirectly, or directly can drive MSC differentiation toward the cardiac lineage (Wang et 
al., 2006, Koninckx et al., 2009). Furthermore, it has been shown that MSCs can move 
toward cardiac lineages when cultured in cardiomyocyte onditioned media in hypoxic 
conditions (Xie et al., 2006). MSCs have also been found able to drive cardiac 
differentiation themselves both in embryonic stem cells and cardiac stem cells 
(Hatzistergos et al., 2010, Yue et al., 2010). With these findings in mind, a novel indirect 
co-culture experiment using autologous canine MSCs and CSCs was established.  
 
Initial examination of morphology indicated some changes both between control and 
co-culture wells, but also between dogs. Dog A varied l ttle in culture morphologically, 
but subjectively there was suggestion of cross-striation of cells in co-culture wells by 
day 10 not seen in control wells. Dog B MSCs in co-cultured wells peeled away from 
the base of the well by day 6 and grew in a 3D pellet, which was not seen in the control 
wells. This peeling away is curious, as it did not occur in the control wells, and both 
wells received the same number of initial cells. The peeling away may be a reflection of 
increased cell replication with confluence being reached rapidly, or perhaps of strong 
cell-cell bonds forming and subsequent cellular contraction. It would be safe to conclude 
that either way there was an influence from the co-cultured CSCs given the peeling did 
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not occur in control wells, and this may be due to released soluble factors from the CSCs 
which the MSCs responded to.    
 
Using transcript analysis it became apparent that there was little difference in transcript 
expression during co-culture in both dogs. No cardiac lineage markers were expressed, 
and there was no beating or obvious morphological changes to suggest successful 
cardiac differentiation.  
 
Of note in this experiment was the difference in starting population of cells from dogs A 
and B at baseline. Dog B was CD34 positive, which was not seen in dog A cells and 
critically does imply that comparisons between A and B are difficult given they are 
potentially separate populations of cells. CD34 is generally believed to be negative in 
MSC populations (Dominici et al., 2006) and had not been found expressed in previous 
canine MSCs that we isolated. CD34 appears to function as a cell surface adhesion 
molecule (Nielsen and McNagny, 2008) but may also play a role in angiogenesis 
(Copland et al., 2008).  Human MSCs have been describ d as both positive (Shim et al., 
2004) and negative for CD34 (Pittenger et al., 1999, Xu et al., 2004, Antonitsis et al., 
2007). Kim et al found that human MSCs were negative for CD34 antibody using FACS 
analysis, but found the cells expressed CD34 using RT-PCR (Kim et al., 2005a). This 
variation in CD34 expression seen in both human MSCs and the dog MSCs in this study 
may simply be technique dependent but may reflect cll heterogeneity, or importantly 
indicate a subpopulation of MSCs, which express both mesenchymal, and 
haematopoietic markers. The decrease in CD34 expression een in the co-cultured cells 
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may be due to spatial differences in culture, given that the cells formed a pellet which 
may decrease CD34 expression, but may also be due to fac ors expressed by CSCs 
which influenced CD34 expression in these cells. This effect will need to be examined 
further to elucidate the precise mechanism behind CD34 downregulation. 
 
5.4.2.3 Differentiation of Mesenchymal Stem Cells and their Role in Cardiac 
Disease 
 
It can be seen from our experiments that cardiac directed differentiation of primary 
canine MSCs was unsuccessful. Differentiation of MSCs in vitro is a contentious issue; 
alternative literature describing co-culture experiments and 5’AZA differentiation have 
shown that differentiated cells demonstrated no electrophysiological properties of 
cardiomyocytes. Furthermore the efficiency of differentiation was seen to be very low at 
approximately 0.07% (Martin-Rendon et al., 2008, Rose et al., 2008). This demonstrates 
the conflicting evidence within this field, and tha ccurately defining differentiation 
using cellular morphology and marker expression is controversial. 
 
Even though cardiac differentiation was unsuccessful and therefore limits the use of 
MSCs to study cardiac diseases in vitro, it does not preclude the use of MSCs for cardiac 
disease. As we have shown, the CD34 positive MSCs down-regulated CD34 in response 
to co-culture with CSCs, and also altered their VEGF banding expression which may 
represent cytokine release and cellular proliferation associated with the paracrine effects 
of MSCs. It has been shown that MSCs can survive in the damaged heart for extended 
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periods of time (Stuckey et al., 2006) yet it is unknown if MSCs transform into 
cardiomyocytes in vivo, undergo cell fusion giving rise to cells phenotypically similar to 
cardiomyocytes (Nygren et al., 2004), or act in a paracrine fashion modulating immune 
responses (Meirelles Lda et al., 2009).  MSCs may exert a paracrine influence in 
multiple ways, including trophic, immunomodulatory, anti-fibrotic and chemotactic 
effects and large numbers of secreted molecules are thought to be involved in these 
pathways. In vitro MSC conditioned media protects against apoptosis induced by 
hypoxia increasing both proliferation of cardiac stem cells and expression of cardiac 
specific markers such as β-MHC, c-Kit and atrial natriuretic peptide in rat CS s 
(Nakanishi et al., 2008, Yu et al., 2009b). Furthermore MSCs exert an influence upon 
the Wnt pathway by secreting antagonists of canonical Wnt ligands following 
myocardial damage leading to up-regulation of anti-poptotic genes (Mirotsou et al., 
2007, He et al., 2011). Therefore the paracrine effcts of canine MSCs and their role in 
cardiac disease is an exciting area of future reseach.  
 
5.4.3 VEGF Splice Variation and Significance to Mes enchymal Stem Cells? 
 
VEGF was seen in multiple bands representative of its several splice variants throughout 
all experiments, and there was no significant altertion in banding expression between 
differentiated cells and those of day 0 MSCs in 5’AZA differentiation. The lack of 
general banding change in the majority of the MSCs reinforces the conclusion that 
cardiac directed differentiation was unsuccessful, given the alternative banding pattern 
seen in differentiated whole heart tissue which wasnever seen in any MSC population 
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(see Chapter 4; Cardiac Stem Cells). However, there was an increase in the expression 
of the upper band of VEGF corresponding to VEGF182/188 in co-cultured wells of dog B 
during in-direct co-culture which was intriguing. VEGF isoforms VEGF120, VEGF164 
and VEGF188 each have similar yet individual effects. All three promote MSC 
proliferation with VEGF120 and VGEF188 associated with increased expression of growth 
factors and cytokines and VEGF164 promoting genes associated with remodeling and 
endothelial differentiation (Lin et al., 2008).  It is likely that the increase in the upper 
band in dog B MSCs in co-cultured wells is representative of an upregulation of 
VEGF182/188 and thus growth factor and cytokine expression release in response to being 
in the co-culture environment which may have played a part in the down-regulation seen 




This study demonstrates a number of interesting findings. Firstly, canine MSCs can be 
isolated from the bone marrow using traditional techniques and compare favourably with 
human MSCs. Secondly, dog MSCs are not capable of differentiation into functional 
cardiomyocytes, demonstrated using two separate techniques and the differentiation 
criteria set out in this study.  This study indicates he need for further work in identifying 
factors which affect efficiency of cardiac differentiation, and may warrant more global 
marker characterisation of individual MSC populations given the variety seen in baseline 
marker expression. Furthermore, this study has highlighted the need for further analysis 
of the paracrine effects of MSCs and the role these may have in cardiac disease therapy.  
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CHAPTER 6  
Mouse Mesenchymall  Stem Cell ll s and 
the Cardii ovascull ar System 
 
Abstt rr actt   
 
Based upon the results obtained in Chapter 5 it was deemed relevant to obtain an MSC 
source from an alternative species which had successful cardiac directed differentiation 
described in the literature. Murine MSCs are a readily available source of adult stem 
cells enabling extensive in vitro study of this cell population. Furthermore, due to the
availability of mouse models, in vivo studies utilizing MSCs are widely used. MSCs 
have been described as multipotent, and have been proven capable of differentiation into 
several connective tissue types. Furthermore some studie  have suggested an ability to 
differentiate into non-connective tissue cell types such as cardiomyocytes. The aim of 
this study was to differentiate murine MSCs towards cardiac lineage to allow for 
comparison with canine MSCs using culture with 5’ Azacytidine. Critically, baseline 
analysis of gene expression of passage four MSCs demonstrated expression of key 
cardiac markers including cardiac troponin T and I, and the ryanodine receptor.  
Furthermore, expression analysis of these genes changed with time in culture and 
passage number with no significant alteration when subjected to a cardiac differentiation 
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protocol. This study therefore highlights the importance of characterizing the 
undifferentiated cell population extensively, and indicates the limitations in 




Mesenchymal stem cells (MSCs) are defined using three key parameters as discussed in 
Chapter 5; Mesenchymal Stem Cells and the Cardiovascul r System. In brief they must  
adhere to tissue culture plastic, express specific surface antigens and be capable of  
multipotent differentiation in vitro (Dominici et al., 2006). In recent years, aided by ease 
of isolation and culture, this cell population from the mouse has been extensively studied 
in relation to use of these cells as a model for in vitro and in vivo MSC research 
including differentiation potential and their use as  therapeutic agent and a source of 
cellular precursors for tissue regeneration. 
 
6.1.1 Differentiation Potential of Mouse Mesenchyma l Stem Cells 
 
Murine MSCs are capable of differentiation along three standard routes namely 
osteoblast, adipocyte, and chondrocyte cell types (Phinney et al., 1999, Meirelles Lda 
and Nardi, 2003, Tropel et al., 2004). Furthermore th re is a suggestion that these 
mesodermal lineage cells have the ability to differentiate into non-connective tissue cell 
types such as neuronal, endodermal and cardiomyocyte (Kopen et al., 1999, Orlic et al., 
2001a, Jiang et al., 2002). 
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6.1.1.1 Differentiation of Murine Mesenchymal Stem Cells toward Cardiac 
Lineages 
 
6.1.1.1.1 In Vivo Differentiation 
 
It has been suggested that murine MSCs are capable of differentiating into 
cardiomyocytes in vivo when injected into the border zone of artificially created infarcts 
in mice and may contribute to improved repair of the infarcted area (Orlic et al., 2001a). 
Furthermore, murine MSCs have been found to translocate to damaged myocardium 
from the bone marrow in response to injury. Orlic et al described the relocation of 
murine c-Kit positive MSCs from the bone marrow to the damaged myocardium 
following induced myocardial infarction and it was proposed that this cell movement 
was in response to cytokines, including granulocyte olony stimulating factor (G-CSF) 
and stem cell factor (KitL) (Orlic et al., 2001b). More recently it has been found that 
mobilized c-Kit/Flk-1 positive cells from the bone marrow relocate to damaged 
myocardium and improve myocardial repair by promoting angiogenesis by increasing 
VEGF expression (Fazel et al., 2006). Therefore it is likely that MSCs play multiple 
roles in the damaged heart; there is a suggestion that MSCs differentiate to functional 
cardiomyocytes, which may incorporate into damaged tissue to replace lost cells, but 
there is also evidence that MSCs affect repair by paracrine means, improving 
vascularisation of damaged areas. These systems need further investigation to determine 
the pathways involved, and the development of in vitro MSC cardiac differentiation has 
been the first step towards allowing further research in this area. 
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6.1.1.1.2 In Vitro Differentiation 
 
 Murine MSCs have been described as being able to differentiate into cardiac tissue in
vitro using the de-methylating agent 5’AZA. Bone marrow derived MSCs positive for 
GATA 4, Nkx2.5 and MEF2C prior to differentiation were exposed to 3 µmol/L 5’AZA 
for 24 hours which after 4 weeks induced spontaneously beating cells positive for 
sarcomeric myosin, actinin and desmin (Makino et al., 1999, Fukuda, 2001). A variation 
in the 5’AZA technique was used by Kruglyakov et al whereby bone marrow derived 
GATA 4 and Nkx2.5 positive MSCs from the rat were exposed to 3 µmol/L 5’AZA 
every 3 days for 21 days to initiate cardiac directed differentiation. This resulted in an 
increase in cardiac troponin I and T and connexin 43 suggestive of successful cardiac 
differentiation (Kruglyakov et al., 2006). These in vitro derived cardiomyocytes may be 
used for the investigation of the role of MSCs within the damaged heart; for instance 
investigating the mechanisms of cardiac differentiation and the growth factors and 
cytokines which may be released in response to damage. However, the ability of MSCs 
to differentiate toward cardiomyocytes in vitro is controversial. Cardiac differentiation 
in vitro is defined using marker expression and evidence of beating as has been 
previously discussed (Chapter 5; Canine MSCs and the Cardiovascular System), but 
there is a significant variation in the markers used to determine successful MSC 
differentiation. Furthermore, there are questions rega ding the MSC marker profile prior 
to differentiation. Mouse MSCs have been found to expr ss cardiac markers, such as 
cardiac troponin T and I at baseline which indicates an MSC population with 
 232 
cardiogenic potential but therefore makes it more difficult to define successful 
differentiation based upon cardiac marker expression (Rose et al., 2008).  
 
6.1.2 Marker Variation Between Murine and Human Mes enchymal Stem 
Cells 
 
Rodent modeling is commonly used to investigate MSC properties and characteristics, 
however characterization of MSC populations is challenging given the wealth of 
markers available (Kolf et al., 2007). When reviewing the literature differences between 
human and murine MSC populations become readily apparent   (Table 6.1). 
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STRO-1 + - 
CD29 + + 
CD44 + + 
CD106 + + 
CD11b - - 
CD31 +/- - 
CD34 +/- +/- 
CD45 - - 
C-Kit - +/- 
Sca 1 - + 
CD90 + - 
Flk-1 +/- - 
 
Human; STRO-1 (Simmons and Torok-Storb, 1991, Dennis et al., 2002); CD29, CD44, 
CD106, CD90 (Pittenger et al., 1999); CD44, CD11b, CD31, c-Kit, CD90, Flk-1 (Colter 
et al., 2001); CD34, CD45 (Etheridge et al., 2004, Shim et al., 2004). 
Mouse; CD44, CD29, CD106, CD11b, CD31, CD45, c-Kit, Sca 1 (Baddoo et al., 2003); 
CD29, CD44, Cd11b, CD31, CD45, Sca 1 (Meirelles Lda and Nardi, 2003); CD29, 
CD44, CD11b, CD31, c-Kit, CD90 (da Silva Meirelles t al., 2006); CD11b, CD31, 
CD34, CD90, Flk-1 (Peister et al., 2004); c-Kit (Orlic et al., 2001a). 
 
 234 
Marker variation has led to difficulties in making comparisons of MSCs between 
different species, such as between mouse and human. Variation is also seen in MSC 
populations isolated from within a single species, which has led to further confusion 
within the field (Peister et al., 2004). This variation in marker expression may represent 
different MSC populations, each with their own properties and differentiation potential, 
but may also represent a single MSC population at different stages of development and 
cellular expression. Characterising MSCs extensively prior to experimentation is 





The aim of this chapter is to use mouse MSCs as a model for in vitro cardiac 
differentiation for canine MSCs based upon the literature claiming successful in vitro 
differentiation and the work performed in Chapter 5; Canine Mesenchymal Stem Cells 
and the Cardiovascular System. Cell morphology and extensive baseline marker 
characterization will be performed on the mouse MSCs, followed by cardiac directed 
differentiation. The differentiated cells will then be analysed using transcriptional 
analyses and compared to the canine results.  
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6.2 Materials and Methods 
 
6.2.1 Murine Mesenchymal Stem Cell Culture 
 
6.2.1.1 Isolation and Culture of Primary Murine Mesenchymal Stem Cells 
 
Four 34 day old male entire C57/Bl6 mice were euthanised humanely using a schedule 1 
procedure and donated to this project. The diaphyses of the femurs and tibias of each 
mouse were flushed into heparinised MSC media (as described in Chapter 5), with 
pooling of each bone source per mouse. Cell suspensions were made up to 10 mL using 
standard MSC media. 16 mL of Ficoll Paque Premium (GE Healthcare, UK) was loaded 
into the base of a 50 mL Falcon tube. Cell suspension was gently overlaid onto the 
surface of the Ficoll, and then the Falcon tubes were c ntrifuged at 450g for 30 minutes 
without a brake at room temperature. Following centrifugation, the interface layer was 
gently aspirated and transferred to a 25 mL Falcon tube and made up to 10 mL with 
PBS. The cells were then centrifuged at 150g for 5 minutes at room temperature, and the 
PBS removed and the cells washed with 7 mL of standard MSC media. The cells were 
again centrifuged for 5 minutes at 150g, and the pellet subsequently resuspended in 
1 mL of standard MSC media. Cells were counted using the haemocytometer and white 
cell counting mount fluid (1% w/v crystal violet and 2% v/v glacial acetic acid in 
distilled water). Cell count for each mouse ranged from approximately 9 x 105 to 2.5 
x 106 cells total. These cells were plated into T25s, thereby giving a final cell density of 
3.6 x 104 cells/cm2 to 1 x 105 cells/cm2. Media changes were performed on the cells 
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twice weekly. At 2 weeks post harvest the cells were passaged into new T25s. Cells 
were washed using PBS and 0.05% Trypsin-EDTA was applied to the cells and 
incubated at 37 °C, 5% CO2 for 5-10 minutes to release the cell attachments. Cell
suspension was aspirated from the flasks, and 5 mL of standard MSC media added to the 
mix. Cells were then centrifuged at 1200 rpm for 5 minutes to pellet, and cells 
resuspended in 2 mL of standard MSC media. Cell suspensions were then directly 
transferred to new T25 flasks and replaced at 37 °C, 5% CO2. At 4-5 weeks post harvest 
cells had stopped growing and evidence of cell death was seen, therefore flasks were 
discarded.  
 
6.2.1.2 Commercially Available Murine Mesenchymal Stem Cell Culture 
 
Murine MSCs were purchased from Invitrogen (Cat. No510502-01) and thawed from 
liquid nitrogen storage at 37 °C in a water bath for up to 2 minutes. 10 mL murine MSC 
media; DMEM low glucose containing Glutamax-I (Invitrogen), with 10% MSC 
qualified FBS (Invitrogen Cat. No. 12662-011) and 100 U/mL penicillin G and 
100 µg/mL streptomycin (both Invitrogen) was added in a slow drop-wise fashion. The 
cells were then centrifuged for 5 minutes at 300g at room temperature. The cell number 
was calculated and cells were plated at a cell density of 5,000 cells per cm2 in a T75 at 
37 °C, 5% CO2 in murine MSC media. Cells were passaged every 3-4 days, and no 
evidence of senescence was observed. 
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6.2.1.2.1 Culture of Murine Mesenchymal Stem Cells in Murine and Standard 
(Canine) Media 
 
Following initial culture in murine MSC media (containing MSC qualified FBS) 1.25 
x 105 murine cells were transferred into 7 mL standard MSC media (containing basic 
FBS, previously used for Canine MSC work, Chapter 5; Canine Mesenchymal Stem 
Cells and the Cardiovascular System) at second passage in a T25. A subculture of 
murine MSCs was then run in tandem in each media. Media changes were performed 
every 3/4 days, and cells were passaged at 80-90% confluency (approximately twice a 
week). 1.25 x 105 cells were replaced into a T25 at each passage. A harvest of cells were 
pelleted at passage 4 (post-revival) and at passage 18. These cells were snap frozen and 
RNA subsequently extracted and cleaned up using DNase 1. RNA was quantified using 
the Thermo Scientific Nanodrop ™ machine and 500 ng of RNA was reverse transcribed 
using Omniscript RT kit and the cDNA stored at -20 °C. cDNA was used for PCR 
reactions to compare between passage 4 and 18 for murine MSCs cultured in both 
murine MSC media and standard (canine) media using primers designed using the 
murine genome and primer 3 software (Table 6.2). PCR reactions were analysed using 




6.2.2 Characterisation of Murine Mesenchymal Stem C ells 
 
6.2.2.1 Characterisation of Murine Mesenchymal Stem Cells using RT-PCR 
 
Murine MSCs were analysed during cardiac differentiation for all markers described in 
Table 6.2 using semi-quantitative RT-PCR, as described below.  
 
6.2.2.2 Characterisation of Murine Mesenchymal Stem Cells using IFA 
 
2 x 104 murine MSCs were added to each well of a 4 well chambered slide at passage 4. 
These cells were incubated for 48 hours at 37 °C, 5% CO2 at which point the cells had 
adhered to the slides and increased to approximately 50% confluency. Slides were 
washed and were fixed as described in Chapter 2; Materials and Methods. Primary 
antibody rabbit polyclonal to CD44 – C terminal (Abcam, UK. Catalogue Number; 
Ab65829) was added to the slides at 1:200, diluted in PBST (0.1% normal goat serum; 
0.1% Tween 20 in PBS) and left overnight in a humidifie  chamber at 4 °C. The 
following day the cells were washed, and labeled with secondary antibody Alexafluor® 
488 conjugated goat polyclonal anti-rabbit IgG (Invitrogen, UK. Catalogue number 
A-11034), at 1:500, for 1 hour at room temperature. Nuclei were subsequently labeled 
using a DAPI mount (Vectastain, Vector Labs, UK) and slides stored at -20 °C. Slides 
were viewed and imaged using the Axiovision programme (Carl Zeiss International).  
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6.2.3 Mouse Mesenchymal Stem Cell Differentiation t o Cardiac Lineages 
 
6.2.3.1 Cardiac Differentiation Technique 
 
Mouse MSCs were differentiated toward a cardiac lineage using the same technique as 
described for canine MSCs (Chapter 5; Canine Mesenchymal Stem Cells and the 
Cardiovascular System). Murine MSCs were differentiated in both standard canine MSC 
media (containing basic FBS) and murine MSC media (containing MSC qualified FBS). 
At set up a pellet of day 0 cells was snap frozen as control cells. During differentiation 
harvests of cells were taken at day 7, 14 and 21 as previously described and cell pellets 
snap frozen and all cell pellets were stored at -80 °C.  
 
6.2.3.2 RNA Extraction and Reverse Transcription 
 
RNA extraction and reverse transcription for semi-quantitative RT-PCR was performed 
as described in Chapter 2; Materials and Methods. In brief, RNA was extracted using the 
RNeasy® mini kit and cleaned up with DNase 1. 100 ng of RNA was reverse transcribed 
using the Omniscript RT kit, and subsequent cDNA stored at -20 °C.  
 
6.2.3.3 Polymerase Chain Reaction  
 
cDNA from the reverse transcription step was used for PCR to analyse for marker 
expression. Primers for each marker were designed sp cifically for the mouse (Table 
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6.2), and where possible were intron spanning. All amplicons were subsequently 
sequenced to confirm primer specificity.  
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Table 6.2. Murine oligonucleotides. CTT-Cardiac Troponin T; Beta 1 Ad-β1-adrenergic 
receptor; Cardiac RyR-Cardiac Ryanodine Receptor; CTI-Cardiac Troponin I; 
VEGF-Vascular Endothelial Growth Factor; vWF-Von Willebrands Factor; 
SMA-Smooth Muscle Actin. F: Forward Primer. R: Reverse Primer 
 
Marker Sequence 5'-3' Size (BP) Tm (°C) 
C-Kit F: AGG GAT TCC CGG AGC CCA CA 252 65 
 R: GGG CCT GGA TTT GCT CTT TAA ATG C   
Islet 1 F: GGT TTC TCC GGA TTT GGA AT 183 57 
 R: CAC GAA GTC GTT CTT GCT GA   
NKx2.5 F: GTG AAA CCT GCG TCG CCA CCA T 469 59 
 R: TAG ACC TGC GCC TGC GAG AAG A   
GATA 4 F: CAA GAT GAA TGG CAT CAA CC 216 57 
 R: GGT TTG AAT CCC CTC TTT CC   
Flk-1 F: AAG GCG CTG CTA GCT GTC GC 164 65 
 R: TCC CGC TGT CCC CTG CAA GT   
CTT F: TGT CCA ACA TGA TGC ACT TTG GAG G 165 65 
 R: GCT CCT TGG CCT TCT CTC TCA GT   
Beta 1 Ad F: TCC TTC TAC GTG CCC CTG TGC A 440 59 
 R: CGC TGG AAA GCC TTG CGA AGT   
Cardiac RyR F: GTT CTG CAG TGC ACG GCG ACC 268 66 
 R: GGC CTC CAC CTT GAG CAG TCT TCA T   
CTI F: CAG CGA TGC GGC TGG GGA AC 297 66 




Marker Sequence 5'-3' Size (bp) Tm (°C) 
VEGF F: GTG CAC TGG ACC CTG GCT TT 300 62 
 R: CCG CAT GAT CTG CAT GGT GAT GT   
vWF F: GGG TCT GCA ACT GCC CAC CC 160 66 
 R: GTG GGG CCC AAT GTT GGC CT   
SMA F: GCC CAG CCA GTC GCT GTC AG 180 66 
 R: TTA CTC CCT GAT GTC TGG GAC GTC C   
CD44 F: AGC ACC TTG GCC ACC ACT CCT A 306 59 
 R: AGC TGC AGT AGG CTG AAG GGT T   
CD34 F: TGG CCC AGG GTA TCT GCC TGG 212 66 
 R: GCT GGG AAG TTC TGT GCT ATT GGC C   
CD45 F: CCT TAC CTG CTC GCA CCA CTG AA 419 59 
 R: GCT TGC AAG GCC CAG AGT GGA T   
Connexin 43 F: ATG AGC AGT CTG CCT TTC GT 249 58 
 R: TCT GCT TCA AGT GCA TGT CC   
GAPDH F: CAT CAA CGG GAA GTC CAT CT 428 Various 
 R: GTG GAA GCA GGG ATG ATG TT   
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A master mix for all primers was prepared using the Promega Go-Taq PCR kit (Table 
6.3): 
 
Table 6.3. Target gene master mix for PCR.  
 
Master Mix Component 1 x (µL) 
DEPC Treated Water 32.25 
dNTP 1 
MgCl2 4 
5 x GoTaq Buffer 10 
Target Forward Primer 0.25 
Target Reverse Primer 0.25 
GoTaq polymerase 0.25 
 
48 µL of PCR master mix was added to 2 µL of sample cDNA in a PCR reaction tube 
(Axygen, USA). Reactions were run as described in Chapter 2; Materials and Methods. 
Gene target primers were run at a final concentration of 0.5 pmol/µL with GAPDH run 
as a separate sample. Negative controls of RNA and water were run alongside to confirm 
absence of genomic DNA contamination. PCR results were analysed using agarose gel 




6.3.1 Murine Mesenchymal Stem Cell Isolation and Cu lture 
 
6.3.1.1 Primary Mesenchymal Stem Cell Isolation and Culture 
 
Murine MSCs were isolated from femurs of male C57/Bl6 mice which were 
approximately 34 days old. Cells were plated as described and maintained in standard 
MSC media. Media changes were performed twice weekly, and at first media change a 
significant number of floating cells and debris was noted. After 2 weeks of culture it 
appeared cells had senesced, and were therefore passaged to try and revive growth. Live 
cells were seen following passage, and 1 week post passage cells were starting to enlarge 
in size and spread out resembling MSCs isolated from the dog. Regular media changes 
were performed; however by 1 month post harvest cells were dying, and significant 
debris was seen in media. By 5 weeks post harvest all flasks from the 4 mice were 
discarded due to cell death and poor growth.  
 
6.3.1.2 Commercially Available Murine Mesenchymal Stem Cell Culture 
 
Purchased murine MSCs were cultured as described in Materials and Methods above. 
Morphologically murine MSCs had a flattened adherent shape, with jagged projections 
(Figure 6.1). These cells were capable of tripling cell number when passaged every 3-4 
days. This continued through to passage 18, when experiments were stopped, with no 
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evidence of senescence. No difference was seen in cell morphology in cells cultured in 




Figure 6.1. Purchased murine MSCs in culture. MSCs displayed typical morphology, 
with long flattened cells with multiple jagged projections. A-magnification x 100, 
B-magnification x 200.    
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Figure 6.2. Purchased murine MSC cultures in mouse MSC media (A and B) and 
standard (canine) MSC media (C and D). Images taken at passage 4, 3 days post 
passage. A and C magnification x 100, B and D magnification x 200.  
 
6.3.2 Characterisation of Murine Mesenchymal Stem C ells  
 
6.3.2.1 Characterisation of Murine Mesenchymal Stem Cells using RT-PCR 
 
Murine MSCs were analysed at day 0 during the cardiac fferentiation experiment (see 
Figure 6.5), giving a full profile of baseline MSC expression. Murine MSCs expressed 
CD44 and CD34, and also expressed Nkx2.5 and VEGF at high levels. Low level 
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expression of GATA 4, Flk-1, CTI, RyR and connexin 43 was also seen. Baseline MSCs 
did not express Islet 1, β1-adrenergic receptor, c-Kit, CD45 and CTT. 
  
6.3.2.2 Characterisation of Murine Mesenchymal Stem Cells using IFA 
 
Passage 4 murine MSCs were grown on 4 well chambered slides and analysed for CD44 
expression using IFA. CD44 was expressed in the adherent murine MSCs, with 
expression seen at cytoplasmic/cell membrane location. Negative controls confirmed 




Figure 6.3. CD44 expression in murine MSCs. CD44 was found to be located 
predominantly in an extra-nuclear location, with some evidence of nuclear packaging 
(A). Negative controls were run alongside, labeled with secondary antibody only (B). 
DAPI was used for nuclear counterstain. Magnification x  400. 
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 6.3.3 Cardiac Differentiation of Murine Mesenchymal Stem Cells 
 
Cardiac differentiation was performed using the de-methylating agent 5’AZA over a 
three week time course as introduced in Chapter 5.  
 
6.3.3.1 Morphology during Differentiation 
 
Morphologically murine MSCs altered little during cardiac directed differentiation 
(Figure 6.4). No difference between cell populations in differentiated and 
undifferentiated wells were noted. Cell number increased rapidly, creating highly 










Figure 6.4. Murine MSC differentiation toward cardiomyocyte lineages. Differentiated 
wells were compared to undifferentiated wells at three time points, day 8, 15 and 20 post 
initiation. Images were taken at magnification x 100 and x 200.  
 
6.3.3.2 Semi-Quantitative RT-PCR Analysis of Cardiac Differentiation 
 
Murine MSCs were analysed for marker expression usig emi-quantitative RT-PCR 
and 100 ng of total RNA (Figure 6.5). Nkx2.5 and VEGF expression appeared to remain 
high and unchanged during cardiac directed differentiation in both cells undergoing 
differentiation and controls, compared to day 0 MSCs. GATA 4 appeared to increase in 
differentiated samples over time. Flk-1 appeared to have higher levels of expression in 
differentiated samples at all time points compared to day 0. SMA showed decreased 
expression  in all samples when compared to day 0. CTI appeared to increase in all 
samples when compared to day 0. The ryanodine receptor was expressed at very low 
levels in all samples. CD44 was expressed in all samples, with higher level expression in 
differentiated cells compared to day 0. CD34 expression appeared to initially increase in 
differentiated cells at day 7, compared to undifferentiated, however this then shifted at 
day 14 and 21 with slightly higher expression seen in undifferentiated cells compared to 
differentiated. Connexin 43 appeared to be higher in all differentiated and 
undifferentiated samples when compared to day 0. The samples were negative for Islet 
1, β1-adrenergic receptor, c-Kit, vWF, CD45 and CTT at all time points. No difference 






Figure 6.5. Semi-quantitative RT-PCR for marker expr ssion of baseline MSCs (0) and 
cells undergoing differentiation (+) and controls (-) during cardiac directed 
differentiation over 7, 14 and 21 days. Vascular Endothelial Growth Factor, VEGF; 
Smooth Muscle Actin, SMA; Cardiac Troponin I, CTI; Cardiac Ryanodine Receptor, 
RyR; Connexin 43, CNX43. 
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6.3.4 Murine Marker Expression Changes with Passage   
 
Murine MSCs were passaged for approximately 8 weeks, with 2 passages a week as 
described in Materials and Methods (section 6.2). Marker expression was compared 
using semi-quantitative RT-PCR between an early passage (passage 4; p(4)) and late 
passage (passage 18; p(18)) harvest of MSCs grown in both murine MSC and standard 
MSC media with 500 ng of total RNA input. Notable differences were seen in 
expression of several markers across passage number. CTT was found to be expressed in 
both passage 4 and 18 MSCs and an upregulation of Islet 1, GATA 4, CTT, CTI, CD44 
and connexin 43 was seen, and a decrease in the expr ssion of SMA (Figure 6.6). Cell 
numbers at passage remained consistent, with no evidence of senescence or 
morphological changes. No difference was seen between c lls grown in murine MSC 




Figure 6.6. Murine MSC marker expression at early (P(4)) and late passage (P(18)). 
Differences were seen in expression of several markers (noted in red) with increasing 
passage number. Vascular Endothelial Growth Factor, VEGF; Smooth Muscle Actin, 
SMA; Cardiac Troponin T, CTT; Cardiac Troponin I, CTI; Cardiac Ryanodine 





6.4.1 Murine Mesenchymal Stem Cell Culture and Char acterisation 
 
6.4.1.1 Isolation and Growth of Murine Mesenchymal Stem Cells 
 
Initially murine MSCs were isolated in the same manner as for canine MSCs. However 
this technique failed to produce viable cells. This may be due to several factors. Firstly, 
when establishing murine MSC cultures it has been fou d that cellular plating density is 
crucial and a density which is either too high or too low prohibits the generation of long 
term cultured cells (Meirelles Lda and Nardi, 2003, Peister et al., 2004). This may have 
been influential in setting up our own primary murine MSCs, although our cell densities 
agreed most closely with those described by Meirells et al they were significantly 
higher than those described by Peister et al. Another factor which may explain the 
unsuccessful primary culture was the technical difficulty in using Ficoll separation 
where the interface layer, which is usually apparent with canine MSCs, was not obvious. 
This layer is critical for collecting the appropriate cells and this established technique 
worked well with canine cells, but proved difficult with the mouse. We found at cell 
count that numbers appeared relatively high compared to those we obtained from canine 
bone marrow, however following the initial two days in culture a significant amount of 
free floating cells and debris were removed with the first wash. It is likely therefore that 
a large proportion of the original cells counted were not MSCs but in fact 
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haematopoietic and fat cells. Following the failed attempt to culture primary MSCs we 
then used a commercially available murine MSC cell line for all further experiments.  
 
Murine MSCs obtained from a commercial source grew asily using the culture 
conditions described in the manual for the cells. These cells resembled other MSC 
populations described, and furthermore closely resembl d the primary canine MSCs 
isolated during our experiments (Pittenger and Martin, 2004, Shim et al., 2004). The 
cells replicated rapidly, requiring regular passage once established. No evidence of 
senescence was seen during the culture of these cell  and extended passage was achieved 
(passage 18) at which point experiments were ended. This may represent a more 
immortalized cell line than that found with primary canine MSCs and it is important to 
define this given the extent of comparisons made betwe n murine models and primary 
cells from other species; both human and canine MSCs tend to senesce around passage 
4-6, and this difference in culture behaviour may be relevant (Banfi et al., 2000, Sekiya 
et al., 2002).  
 
6.4.1.2 Characterisation of Murine Mesenchymal Stem Cells 
 
Characterisation of baseline MSCs found them to be CD44 positive by both IFA and 
RT-PCR, a crucial factor for defining an MSC population. Furthermore they were CD45 
negative, ruling out haematopoietic contamination. Interestingly the murine MSCs were 
CD34 positive. Generally it is accepted that MSCs should be CD34 negative as 
mentioned in Chapter 5; Canine MSCs (Dominici et al., 2006). However, differences in 
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CD34 expression have been observed in murine MSCs, with interesting variation in the 
angiogenic potential between positive and negative populations (Copland et al., 2008). 
Furthermore CD34 expression is variable between strain  of mouse used to isolate 
MSCs (Peister et al., 2004). Human MSCs have been dscribed as both positive (Shim et 
al., 2004) and negative for CD34 (Pittenger et al., 1999, Etheridge et al., 2004, Xu et al., 
2004, Antonitsis et al., 2007) and our isolated canine MSCs were predominantly CD34 
negative (discussed below in 6.4.4). There is therefore a discrepancy in CD34 expression 
which needs to be taken into account when comparing different MSC populations, and 
the presence or absence of CD34 expression may define two separate MSC populations, 
each with their own differentiation ability, paracrine effects and angiogenic potential. 
 
The purchased murine MSCs also expressed Flk-1 at a very low level which contradicts 
findings described by Peister t al and therefore reinforces variety within murine MSCs 
(Peister et al., 2004). Furthermore, our murine MSCs did not express c-Kit; c-Kit 
expression in murine MSCs is variable, but is generally shown to be negative (Baddoo et 
al., 2003). Meirelles et al described a bone marrow derived population of MSCs which 
were c-Kit low, and found that levels of c-Kit decrased with increasing passage, which 
may explain the lack of c-Kit expression in the purchased murine MSCs (da Silva 
Meirelles et al., 2006). Interestingly Orlic et al described a bone marrow derived stem 
cell population which was selected for c-Kit expression and was found capable of 
cardiac repair (Orlic et al., 2001a). More recently it has been found that a c-Kit enriched 
MSC population showed expression of cardiac markers (G ajales et al., 2010), therefore 
c-Kit expression may in fact be important for cardic applications of MSCs. C-Kit is a 
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cell surface marker and could therefore be used for cell sorting, although as discussed in 
Chapter 4; Cardiac Stem Cells, cell sorting of canine cells for this marker was unreliable 
using MACS.  
 
6.4.2 Cardiac Differentiation of Murine Mesenchymal  Stem Cells 
 
Using rodent models it has been suggested that MSCs are capable of cardiac 
differentiation in vitro using the de-methylating agent 5’AZA (Makino et al., 1999, 
Fukuda, 2001, Kruglyakov et al., 2006). We exposed early passage murine MSCs to 
cardiac differentiation based upon the technique described by Krugalykov et al and 
analysed the resultant cell populations at 3 weekly time points in differentiated and 
control cells compared back to day 0 baseline MSCs. We defined cardiac differentiation 
based upon behaviour in culture, including evidence of independent rhythmical beating 
and the expression of cardiac structural and functio al genes. Using the culture 
behaviour and comprehensive panel of markers no conclusive evidence of cardiac 
differentiation was seen in the mouse MSC population following 5’AZA differentiation. 
However murine MSCs did show altered expression of several markers examined over 
the course of the differentiation experiment. GATA 4 appeared to increase in all samples 
over the time course, with a higher expression in the differentiated samples, and Flk-1 
demonstrated higher expression in the differentiated samples at all time points when 
compared to the undifferentiated counterparts. CTI and CNXN 43 expression appeared 
higher in all samples when compared to day 0, whereas SMA appeared to decrease. No 
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beating was seen during the experiment and therefor it was deemed that cardiac 
differentiation did not occur. 
 
6.4.3 Cardiac Gene Expression in Murine Mesenchymal  Stem Cells 
 
During the cardiac differentiation experiment, it was found that the murine MSCs 
expressed several key markers at baseline day 0 which are considered to be cardiac in 
origin, which had been previously described in mouse MSCs and implies a 
predetermined cardiogenic potential (Kruglyakov et al., 2006, Rose et al., 2008, Grajales 
et al., 2010). Murine MSCs expressed VEGF and Nkx2.5 at high levels and low levels of 
GATA 4, CTT, CTI, RyR and connexin 43 were also seen. Baseline MSCs did not 
express the β1- adrenergic receptor. Taking the expression of these markers alone it 
could be argued that these cells have distinct cardiomyogenic potential, as already 
mentioned. However taking into account the apparent long term culture ability of these 
cells, it may also be that the mouse MSCs have a gre ter number of genes switched on, 
reflective of their more immortalized state.  
 
6.4.3.1 Cardiac Gene Expression Alteration Over Time in Culture 
 
Prompted by the suggestion that murine MSCs were altering gene expression pattern 
over time in culture we decided to investigate the eff cts of passage number on the 
murine MSCs by comparing early and late passage cells. No alteration in morphology 
was seen over the time period in culture but several markers demonstrated alterations in 
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expression level. Interestingly expression of two further cardiac markers; islet 1 and 
CTT was seen following an increase in total RNA input into the reverse transcription 
reaction (Figure 6.6), which suggested that RNA input is a critical factor when analyzing 
gene expression. We furthermore noted an increase in expression of islet 1, GATA 4, 
CTI, CTT, CD44 and connexin 43, and a decrease in the expression of SMA from early 
to late passage respectively. These results taken in isolation could suggest movement 
toward a cardiac lineage expression profile simply as a function of culture duration 
alone.  
 
Key differences in expression of cardiac lineage genes in murine MSCs may be 
inadvertently used as proof of differentiation. Differentiation of MSCs in vitro is a 
contentious issue. Evaluating the literature, the criteria used to define differentiation is 
variable but generally based upon increases in cardiac lineage marker expression, cell 
morphology and cell behaviour in culture.  However, when we take into consideration 
that the murine MSCs used in this study expressed genes deemed to be indicative of a 
cardiac phenotype at baseline and levels of expression altered by duration of culture it 
would be wrong to state successful differentiation driven by 5’AZA.  Alteration in gene 
expression by passage number has been reported previously in murine MSCs (Meirelles 
Lda and Nardi, 2003). More recently Grajales et al described a c-Kit enriched bone 
marrow stem cell population which appeared to increase CTT expression due to time in 
culture alone, and suggested that increasing passage number improved the differentiation 
ability of bone marrow derived stem cells (Grajales et al., 2010). These results highlight 
the importance of interpretation of differentiation data, and in defining differentiation 
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criteria prior to the experiment particularly in the context of species type and passage 
number and illustrate the importance of appropriate controls.  
.  
6.4.4 Comparisons Between Canine and Murine Mesench ymal Stem Cells 
 
Canine and murine MSCs had significant similarity in morphology in culture. 
Furthermore, both cells could be passaged frequently (once-twice a week). However, 
canine MSCs senesced relatively early when compared to the continuous replication 
capacity of the murine MSCs seen during this experim nt. Both canine and murine 
MSCs were positive for CD44. Canine MSCs were also positive for STRO-1 however 
this marker is not available for use in mouse cells. Both populations were negative for 
the haematopoietic marker CD45, reassuring that in both populations the cells had 
limited haematopoietic contamination. Both populations were also negative for c-Kit, a 
commonly used cardiac stem cell marker. Canine MSCs were predominantly negative 
for CD34, except for one population isolated (Chapter 5) whereas the mouse MSCs were 
consistently positive for CD34. Based on the literature already discussed there is 
heterogeneity in this marker expression, and this may reflect either different cell types or 
alternatively expression changes of this marker at different points in cell growth. Murine 
and canine MSCs expressed the following cardiac markers; Nkx2.5, Flk-1, islet 1, 
VEGF, SMA, and Connexin 43, but these markers in combination do not suggest a 
cardiac genotype. However murine MSCs also expressed GATA 4, CTT, CTI, and the 
ryanodine receptor which could be construed as cardiac in origin. Neither canine nor 
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murine MSCs expressed the β1-adrenergic receptor, important in receiving adrenegic 
signaling in excitation of cells (Table 6.4) 
 
Table 6.4. Marker expression of canine and murine MSCs 
Marker Dog MSC Mouse MSC 
CD44 + + 
CD34 +/- + 
CD45 - - 
c-Kit - - 
Islet 1 +/- + 
Nkx2.5 + + 
GATA 4 - + 
Flk-1 + + 
CTT - + 
CTI - + 
Β1-Adrenergic Receptor - - 
Cardiac Ryanodine Receptor - + 
VEGF + + 
vWF - - 
SMA + + 




The differences seen between canine and murine MSCs may be explained by the original 
isolation technique employed. As shown here isolating murine MSCs using the 
traditional method did not work and furthermore this method has been found to generate 
a heterogeneous population of cells from the mouse including haematopoietic and 
fibroblastoid cells (Phinney et al., 1999). Therefo we purchased murine MSCs, and 
these cells were isolated using an alternative technique now commonly employed for 
murine cells which negatively selects against CD11b (Kopen et al., 1999, Baddoo et al., 
2003, Tropel et al., 2004). The resultant mouse cell population will therefore not be a 
direct reflection of MSCs isolated in the traditional way and this may allow for the 




This study highlights the differences seen in MSC populations. Species differences, site 
of MSC isolation, technique for isolation and passage number can all have an influence 
upon variation within MSCs. This study demonstrates the need for further work in 
characterising individual MSC populations including more global marker expression 
profiling studies and highlights the dangers in extrapolating successful differentiation 
based upon marker expression alone.  
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CHAPTER 7 
Canii ne Mesenchymall  Stem Cell ll s and 
Cartii ll age Dii fferentii atii on 
 
Abstt rr actt   
 
Mesenchymal stem cells (MSCs) have a capacity for multi-lineage differentiation thus 
providing a promising source of stem cells for regeneration.  Due to the poor cardiac 
differentiation discussed in Chapter 5, it was decid to differentiate canine MSCs 
toward a connective tissue lineage, given that thisis a key determinant of MSC 
characterisation, thus confirming that a true MSC population has been isolated. In this 
chapter primary canine MSCs isolated from the bone marrow were differentiated toward 
cartilage using standard 3D pellet culture and exposure to transforming growth factor β 
(TGFβ) and dexamethasone. The differentiated pellets were analysed for their 
expression of the chondrocyte marker SOX9, the cartilage markers collagen type I and 
II, and examined for the development of proteoglycan matrices indicative of functional 
cartilage. SOX9 was found expressed more widely in differentiated pellets compared to 
undifferentiated and collagen type II expression was seen to increase in differentiated 
pellets compared to undifferentiated with a decrease in collagen type I. Furthermore 
evidence of the development of proteoglycan matrix was seen in differentiated pellets. 
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This data suggests that successful formation of articular type cartilage from primary 
canine MSCs in vitro has occurred and that primary canine MSCs are therefor  capable 




Cartilage disease and osteoarthritis (OA), a degenerativ  joint disease, are associated 
with high morbidity in pet dogs. Current treatment regimes rely on pain management, 
weight control and slowing of disease progression, however the development of new 
therapies is sorely required. MSCs have been postulated as a possible cell source for 
direct therapy. However, little baseline in vitro study of canine MSCs prior to their use 
therapeutically has been performed and therefore more research in this area is required. 
Furthermore, MSCs may offer the ability to study these progressive diseases in vitro 
allowing for the development of targeted novel therap utics.  
 
7.1.1 Mesenchymal Stem Cell Differentiation Toward Connective Tissue 
 
By definition true MSCs must be capable of differentiation along multiple connective 
tissue routes (Dominici et al., 2006). The three routes of differentiation are 
predetermined by development factors; early in embryogenesis mesodermal cells 
develop to form mesenchyme, the precursor of all connective tissue, which has an  
inherent ability to migrate, a key factor required for normal embryonic development 
(Caplan, 1991). These mesodermal cells are the precursor to many structures within the 
body, and therefore MSCs have been isolated from several locations including bone 
marrow, adipose tissue and umbilical cord blood (Kern et al., 2006).  
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7.1.1.1 Osteogenic, Adipogenic and Chondrogenic In Vitro Differentiation  
 
Studies across several species have shown that MSCs are readily capable of 
differentiating into osteoblast, adipocyte, and chondr cyte cell types in vitro (Gronthos 
et al., 1994, Yoo et al., 1998, Pittenger et al., 1999, Dennis et al., 2002, Suzdal'tseva et 
al., 2007). The techniques employed are standardized in the literature (Table 7.1); 
 
Table 7.1. Techniques for MSC differentiation toward bone, fat and cartilage 
Target  Technique 
Osteoblast Monolayer culture in DMEM media plus 10% FBS and 
dexamethasone, ascorbic acid and  β-glycerophosphate 
Adipocyte Monolayer culture in DMEM plus 10% FBS and insulin, 
dexamethasone, isobutylmethylxanthine and indomethacin 
Chondrocyte Pellet (aggregate) culture in serum free DMEM in the presence 
of  insulin-transferrin-selenium, sodium pyruvate, transforming 
growth factor β (TGFβ) and dexamethasone 
  
Interestingly, initial site of MSC isolation can affect efficiency of differentiation: 
Umbilical cord derived MSCs are less able to differentiate into adipocytes (Kern et al., 
2006) and bone marrow derived MSCs have superior potential for chondrogenic and 




7.1.1.2 Canine Mesenchymal Stem Cells and Connective Tissue Differentiation 
 
Canine MSCs have been isolated from the bone marrow and differentiated toward 
osteogenic lineages successfully using both in vitro exposure to dexamethasone and also 
co-culture with primary autologous osteoblasts. Demonstration of an increased uptake of 
alkaline phosphatase and evidence of mineralisation implied formation of bone 
(Kadiyala et al., 1997, Csaki et al., 2009). Furthermore, canine MSCs have been isolated 
from umbilical cord blood and found capable of differentiation to all three connective 
lineages, as well as neuronal lineages reinforcing the multipotent differentiation 
potential of canine MSCs (Kamishina et al., 2006, Seo et al., 2009).  
 
7.1.1.3 Pathways Controlling Mesenchymal Differentiation 
 
It is believed that Wnt signalling closely controls the differentiation fate of MSCs 
(Etheridge et al., 2004, Ling et al., 2009). However more recently new pathways have 
been found which closely control the three differentiation routes of MSCs including the 
TGFβ, platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) 
signaling pathways (Ng et al., 2008). Using genome wide transcription analysis, Liu et 
al described the key regulators involved in differentiation of both bone marrow derived 
and adipose derived MSCs during differentiation along the three standard lineages. 
Interestingly, little difference was seen in marker expression between adipose and bone 
marrow derived MSCs during differentiation. Furthermo e, a similar 
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early-differentiation pathway was seen for osteogenesis and adipogenesis, which was not 
seen for chondrogenesis. ZNF145 (a promyelotic zinc finger protein) and 
carboxypeptidase M (a cell membrane metalloprotease) were both upregulated in the 
osteogenic and adipogenic pathways whereas dermatopontin (an extracellular matrix 
protein) and collagen 10A1 were upregulated in chondr genic pathway. By late stage 
differentiation, each pathway had its own separate se  of signaling molecules, allowing 
for terminal differentiation; for osteogenesis Osteomodulin (OMD), Apolipoprotein D 
(APOD) and ZNF145; for adipogenesis Adiponectin (ACDC), Fatty Acid Binding 
Protein 5 (FABP5) and Low Density Lipoprotein (LDL). For cartilage differentiation, a 
further increase in the expression of the early stage markers at late differentiation 
triggered terminal differentiation suggesting the importance of this pair of markers in the 





Figure 7.1. Differentiation pathways for MSCs from both bone marrow and adipose 
sources along connective tissue routes. A close relationship between the control of 
differentiation of osteocytes and adipocytes is seen at early stages whereas chondrocytes 
breakaway early in differentiation and follow their own path (factors in blue). At late 
stage differentiation each cell type is influenced by its own signaling factors (factors in 
pink).  Carboxypeptidase M (CPM), Collagen 10A1 (Col10A1), Dermatopontin (DPT) 
Osteomodulin (OMD), Apolipoprotein D (APOD), Zinc Finger Protein 145 (ZNF145), 
Adiponectin (ACDC), Fatty Acid Binding Protein 5 (FABP5), Low Density Lipoprotein 
(LDL). Based upon Liu et al (Liu et al., 2007). 
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7.1.2 Articular Cartilage Defects and the Role of C ellular Therapy 
 
Articular cartilage is a tough connective tissue which protects articular surfaces, acts a 
shock absorber and participates in the fluid biomechanics of the joints associated with it. 
Damage to articular cartilage has long been known to be a precursor to the development 
of OA (Cox and Cordell, 1977, Ghosh et al., 1990, Berjon et al., 1991, Little et al., 1996, 
Lindhorst et al., 2000). Management of OA is based upon pain control and slowing of 
disease progression, however ultimately the condition always advances over time. This 
has led to the investigation of novel treatments and the use of cells as a source of 
therapy.  
 
7.1.2.1 Chondrocytes in Cartilage Repair 
 
Chondrocytes are the cells which are found within cartilage and secrete collagen and 
extracellular matrices. A loss of functional chondrocytes leads to the degeneration of 
cartilage and is a forerunner to the development of OA. Chondrocytes have been 
investigated as a direct source of treatment for damaged cartilage with some evidence of 
success in animal models (Ibarra et al., 1997, Peretti et al., 2004). Autologous 
chondrocytes have been used as treatment options in human knee joint disease since 
1987 and were found to improve damaged tissue. Research into improving this as a 
treatment option still continues (Brittberg et al.,1994, Brittberg et al., 2001). 
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Use of chondrocytes for therapeutics is limited by the difficulty in isolating the cells in 
significant numbers. Furthermore, it has been shown that cultured articular chondrocytes 
de-differentiate in long term monolayer culture toward fibrochondrocytes, the cells 
which contribute to the formation of scar cartilage. This alters both expression of 
collagen class from II toward I and the balance of the proteoglycan matrix, which has 
major ramifications in the scale up of these cells in culture prior to their use 
therapeutically (Benya et al., 1978, Stokes et al., 2002). 
 
7.1.2.2 Mesenchymal Stem Cells in Cartilage Repair 
 
Using animal models it has been suggested that MSCs may offer an alternative cellular 
therapy to chondrocytes when injected into damaged cartilage. However, based on 
current research improvement in healing is seen at short time points, and with as yet no 
evidence of long term repair (Wakitani et al., 1994, Wilke et al., 2007). Black et al from 
Vet-Stem, California, performed two studies injecting adipose derived MSCs directly 
into the coxofemoral or elbow joints of dogs suffering from chronic osteoarthritis and 
found that in both diseases a significant improvement was seen in lameness, range of 
motion and pain on manipulation over time, when compared with baseline values (Black 
et al., 2007, Black et al., 2008). However little characterization was performed prior to 
the implantation of these MSCs, and due to the isolation technique a mixed population 
of cells was likely to have been injected, therefor although these results are promising, 
more basic science needs to be performed to support this data.  
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It is not yet known how MSCs exert their effect when used therapeutically; they may act 
via a paracrine signaling mechanism or direct cell r placement, or a combination of 
both. This is currently a highly researched field, but it can be seen from the literature 
that there is commonly an improvement when MSCs are used. MSCs can be used in 
their primary form, or pre-differentiated into chondrocytes before implantation. 
Comparison between injection of MSCs versus MSC derived chondrocytes 
demonstrated an improved repair in MSC treated populations which was not seen in the 
MSC derived chondrocyte treated populations. This may indicate that prior 
differentiation of the MSC population limits tissue incorporation or alternatively a 
paracrine effect induced by released factors from MSCs may be responsible which is lost 
upon terminal differentiation of the cells (Meirelles Lda et al., 2009, Pabbruwe et al., 
2010). Several clinical trials are now underway investigating the use of autologous 
MSCs for specific joint diseases in humans (Clinical Trials.gov) and the results of these 
trials are awaited with great expectation.  
 
7.1.2.3 Cell Laced Scaffolds for Cartilage Repair 
 
Therapeutics using both chondrocytes and MSCs often us  a scaffold as a method for 
inserting the cells into damaged tissue. Non-synthetic allogenic scaffolds were 
commonly used early in research. Peretti  al used devitalized allogenic meniscal 
cartilage to lace chondrocytes onto prior to implantation in pigs which showed bonding 
of the implant, and improved healing in treated joints versus controls (Peretti et al., 
2004). Synthetic scaffolds are now widely available and a huge variety are accessible in 
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the field (scaffolds reviewed in (Stella et al., 2010)). Efficiency of chondrocyte 
differentiation using MSCs within hydrogel or gelatin scaffolds shows no difference 
between substance used, however biomechanical properties of the subsequent cartilage 
can vary significantly (Awad et al., 2004).   Furthermore, it has been seen that type of 
scaffold used is significant in the migration and differentiation of MSCs in the in vivo 
environment (Pabbruwe et al., 2010). The use of scaffolds for MSC implantation is an 




In this Chapter we will take previously characterizd canine MSCs (first discussed in 
Chapter 5) and differentiate them towards cartilage using traditional techniques. The 
resultant cell population will be analysed using multiple techniques, and in particular for 
evidence of successful articular type cartilage differentiation.  
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7.2 Materials and Methods 
 
7.2.1 Isolation and Characterisation of Canine Mese nchymal Stem Cells, 
Chondrocytes and Fibroblasts 
 
7.2.1.1 Isolation of Canine Mesenchymal Stem Cells 
 
Canine MSCs were isolated from bone marrow and cultured and characterised as 
described previously (see Chapter 5; Canine Mesenchymal Stem Cells and the 
Cardiovascular System).  
 
7.2.1.2 Isolation of Canine Chondrocytes 
 
Articular cartilage from the femoral head of two recently euthanized dogs was dissected 
into shavings using a scalpel and placed into 10 mL DMEM media with 10% FBS and 
100 U/mL penicillin G and 100 µg/mL streptomycin (all Invitrogen, UK) and chilled on 
ice. These were then centrifuged at 1500 rpm for 5 minutes at room temperature to move 
shavings to the base of the Falcon tube. Medium was removed and a 0.2% trypsin/0.4% 
collagenase IV (Invitrogen, UK) digestion solution was added onto the shavings and 
incubated at 37 °C for 30 minutes in a water bath. The shavings were then centrifuged at 
1500 rpm for 5 minutes at room temperature and the original trypsin/collagenase 
removed and fresh added. The shavings were then incubated again at 37 °C for a further 
30 minutes, before a repeat centrifuge and trypsin/collagenase removed. Fresh 
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trypsin/collagenase was added and the shavings incubated for 180 minutes at 37 °C. The 
shavings were then centrifuged a final time and the trypsin/collagenase discarded and 
the shavings washed in chondrocyte media; DMEM Hams F12 (Invitrogen, UK), with 
10% FBS and 100 U/mL penicillin G and 100 µg/mL  streptomycin. A final centrifuge 
was performed and media discarded and the shavings resuspended in 5 mL of 
chondrocyte media. This was then passed through a 100 µm diameter filter membrane to 
release cells and the flow through collected. The filt r was washed through with a 
further 5 mL of chondrocyte media, and the flow through added to the suspension. The 
cell suspension was then centrifuged at 1500 rpm for 5 minutes to pellet the cells. Cells 
were resuspended in 1 mL of chondrocyte media and counted as previously described. A 
cell count of 1.5 x 105, and 2.2 x 106 was achieved for the first and second dog 
respectively and each was placed into a fibronectin coated T25 at 37 °C, 5% CO2. A 
partial media change was performed after 5 days, and at 7 days culture flasks for both 
dogs had become confluent and were passaged into T75 tissue culture flasks with media 
changes every 3-4 days. 
 
7.2.1.3 Isolation of Canine Fibroblasts 
 
1 cm sections of clipped full thickness skin was harvested from the lateral thoracic 
region from two recently euthanized dogs (as for chondrocytes) and placed into  10 mL  
chondrocyte media; DMEM low glucose media with 10% FBS and 100 U/mL  penicillin 
G and 100µg/mL  streptomycin and chilled on ice. Skin sections were then transferred 
into a digestion solution of 0.2% trypsin/ 0.4% collagenase and incubated at 37 °C for 
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30 minutes in a water bath. Sections were manually removed from the digestion solution 
using forceps and placed into PBS to wash the sections. Two washes were performed 
and hair was scraped away from the skin before a final PBS wash. The skin was then cut 
into small sections and placed into 7 mL chondrocyte media and transferred to 
fibronectin coated T25 flasks and incubated at 37 °C, 5% CO2. Following 4 days in 
culture 4 mL of chondrocyte medium was removed to allow skin sections to contact the 
base of the flask to stimulate attachment, and 48 hours later 4 mL of fresh chondrocyte 
medium was replaced. At 1 week post harvest skin sections were removed from T25 
culture flasks and discarded and 6 mL medium was remov d and replaced with fresh 
chondrocyte medium.  
 
7.2.2 Mesenchymal Stem Cell Differentiation Toward Cartilage 
 
Two techniques were employed to differentiate canine MSCs to cartilage. 
 
7.2.2.1 Cartilage Differentiation using Matrigel™  
 
Matrigel was purchased from BD Biosciences, UK and defrosted at 4 °C on ice 
overnight. Using pre-chilled pipettes 5 mL of matrigel were transferred to 1.5 mL of 
DMEM low glucose media, to make a total of 6.5 mL. Canine mesenchymal stem cells 
(passage 1), chondrocytes (passage 2) and dermal fibroblasts (passage 1) were harvested 
from their respective flasks and counted as previously described. 1 x 105 cells/mL of 
each cell type were added to the matrigel solution and kept chilled. A plate plan using a 
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48-well tissue culture plate (Costar, UK) was set up as below (Figure 7.2) including 
wells for each cell type, with differentiated and undifferentiated MSCs, and 3 time 
points; 7, 14 and 21 days in triplicate. 175 µL of appropriate matrigel cell suspension 
(1.75 x 104 cells total) was added to the base of each appropriate well on the 48-well 
plate. The plate was then placed at 37 °C for 30 minutes to allow matrigel to set. 
Following this, 300 µL of appropriate media was added to each well. For MSC 
differentiation media consisted of; DMEM high glucose (Invitrogen), 1% ITS+ premix 
(BD Biosciences, UK), 10-7 M Dexamethasone (Autogen Bioclear, UK), 1 mmol/L Na 
Pyruvate (Gibco, UK), 10 ng/mL TGFβ1 (Peprotech) and 100 U/mL  penicillin G and 
100 µg/mL  streptomycin (both Invitrogen). For MSC undifferentiated wells standard 
MSC media was added consisting of; DMEM low glucose containing Glutamax-I 
(Invitrogen), with 10% FBS (Invitrogen) and 100 U/mL  penicillin G and 100 µg/mL  
streptomycin (both Invitrogen). For both chondrocyte and fibroblast wells chondrocyte 
media was added. The plate was then placed at 37 °C, 5% CO2. A media change for each 
well was performed at 3 days, and first harvest of cells collected at day 7. Day 0 pellets 




Figure 7.2. 48-well plate layout for MSC differentiation to chondrocyte using matrigel. 
Three cell types were used; MSCs, chondrocytes and fibroblasts from the same dog. 
Wells were run in triplicate. Harvests of cells were collected at days 7, 14 and 21.  
 
7.2.2.1.1 Harvest of Cells from Matrigel™  
 
Cells were harvested at each time point from matrigel using Matrigel Cell Recovery 
Solution (BD Biosciences, UK). Media was removed andiscarded and the cells washed 
three times with PBS. 700 µL of recovery solution was added to the surface of the 
matrigel and the cell/gel layer was scraped into an ice cold 50 mL Falcon tube. The well 
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was rinsed with a further 2 mL of cell recovery solution which was added to the Falcon 
tube. The tube was inverted several times and left on ice for 1 hour to dissolve matrigel 
completely. The cell suspension was then centrifuged at 300g for 5 minutes at 4 °C, and 
the resultant supernatant discarded. The cell pellet was washed with chilled PBS, and 
re-centrifuged. A second PBS wash was performed and the triplicate pellets pooled 
before a final centrifuge. Following this the PBS was removed and Falcon tube 
examined for the presence or absence of a cell pellet.  
 
7.2.2.2 Cartilage Differentiation using 3D Pellet Culture 
 
2 x 105 canine MSCs were placed into either standard MSC media or cartilage 
differentiation media in 15 mL Falcon tubes. Cells were spun at 500g for 2 minutes, and 
placed at 37 °C, 5 % CO2 overnight. After 12 hours small pellets formed in the base of 
the Falcon tubes which were free floating in the media. These pellets were maintained 
over the period of the experiment, with media changes performed every 2-3 days with 
either standard MSC media or cartilage differentiation media. Pellets were harvested at 
days 7, 14 and 21 for RNA extraction and histopathology and immunohistochemistry, 
with each experiment run in duplicate. Day 0 MSCs were snap frozen and stored at -80 
°C at initial set up as a baseline control. Extracted RNA was used for quantitative 




A repeat experiment was performed using an initial h gher cell number input to create 
the 3D pellet. 2 x 106 MSCs were added to the Falcon tube prior to initial centrifuge in 
1 mL of appropriate media, followed by an exact copy f the original experiment. RNA 
was extracted from the final pellets and used for dwnstream quantitative RT-PCR 
reactions.  
 
7.2.2.2.1 Immunohistochemistry of Differentiated Pellets 
 
Cellular pellets were transferred from media to HistoGel (Thermo Scientific, UK) to fix 
prior to paraffin wax embedding, and then sectioned using microtome cutting. 
Immunohistochemistry staining was performed by Neil Macintyre, Laboratory Manager, 
Histology and Cytology, R(D)SVS, University of Edinburgh. 
 
7.2.2.2.1.1 Collagen Type II 
 
The sections were dewaxed using xylene (Table 7.2) and a stepwise protocol described 
in Table 7.3; 
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Table 7.2. Dewaxing stages for paraffin embedded sections. 
Xylene (De Wax solutions) 15 minutes 
100% ethanol 10 minutes 
95% ethanol 10 minutes 
90% ethanol 10 minutes 
70% ethanol 10 minutes 
water 10 minutes 
 
Antigen retrieval was performed using enzyme treatmnt; 2 mg/mL hyaluronidase 
(Sigma) with 0.125 U/mL chondroitinase (Sigma) in Tris-buffered saline, pH 7.6. The 
enzyme solution was warmed at 37°C along with the sections for 30 minutes prior to 
enzyme treatment for 2 hours at 37 °C. Sections were subsequently placed into distilled 
water and then placed into Thermo Fisher Scientific Sequenza coverplates in TBST 
(50 mM Tris.HCl, 150 mM NaCl, 0.1% Tween 20) buffer pH 7.6. Collagen II rabbit 
polyclonal antibody (Abcam, UK. Catalogue number Ab34712) was diluted 1/50 using 
Dako antibody diluent (Dako, UK. Catalogue number S0809) and 100 µL applied to the 
slides and placed at 4 oC for 16 hours. The sections were then placed at 25 °C in an 
incubator for 30 minutes (and all reagents warmed to 25 °C for 30 minutes). The 
sections were then rinsed in TBST, pH 7.6 and then loaded onto the Thermo Fisher 
Scientific Autostainer 360 and rinsed again in TBST, pH 7.6, before staining using the 
UV Quanto protocol; 
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Table 7.3. UV Quanto protocol for immunohistochemistry 
 
Step Time 
Non specific peroxidase block (Dako, UK REAL blocking agent. 
Catalogue number S202386) 
10 minutes 
TBST rinse  
Antibody amplifier (Thermo Fisher Scientific, UK. Catalogue 
number TL-125-QHL) 
10 minutes 
TBST rinse  
HRP Polymer (Thermo Fisher Scientific, UK. Catalogue 
number TL-125-QHL) 
10 minutes 
TBST rinse  
DAB buffer substrate (Newmarket Scientific, UK. Monosan Dab 
substrate kit. Catalogue number. MON-APP177). 
2 minutes 
TBST rinse  
DAB buffer substrate 10 minutes 
TBST rinse  
Distilled water rinse  
DAB Enhancer (Newmarket Scientific, UK. DAB concentrate. 
Catalogue  number CO7-25). 
3 minutes 
TBST rinse  
Counterstain in Harris haematoxylin 30 seconds 
Wash in tap water 1 minute 
Blue up using Scott’s Tap water substitute 2 minutes 
Dehydrate and clear through ethanol and xylene (as above) 2 minutes each 
Mount in ClearVue mountant (Thermo Fisher Scientific, UK)  
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Positive controls were performed using canine articular cartilage. Negative controls were 




The sections were dewaxed as previously described. SOX9 antigen retrieval was 
performed using Heat Induced Epitope Retrieval (HIER), using Histos 5 microwave 
antigen retrieval system (Leica Microsytems, Germany). Sections were placed at 110 °C 
for 15 minutes in 0.01 mol/L citric acid, pH 6.0. Sections were allowed to cool then 
placed into distilled water. Sections were then placed into Thermo Fisher Scientific 
Sequenza coverplates in TBST.  SOX9 rabbit polyclonal (Abcam, UK. Catalogue 
number Ab3697) was diluted 1:50 with Dako antibody diluent and then added to the 
sections. The sections were then incubated at 25°C for 1 hour, with subsequent staining 
using the UltraVision Quanto Detection System (Thermo Fisher Scientific, UK) as 
above. Positive controls were performed using canine articular cartilage. Negative 
controls were performed using canine articular cartilage and antibody diluent only.  
 
7.2.2.2.2 Toluidine Blue Staining of Differentiated Pellets 
 
Cartilage sections were rinsed in distilled water, and then placed into 1% aqueous 
Toluidine Blue (Sigma, UK) for 30 minutes at room temperature. The sections were then 
rinsed in distilled water and de-colourised using acid alcohol (1% HCL in 70% ethanol), 
diluted 1:4 for 5 seconds. The slides were then rinsed in distilled water again, before air 
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drying and clearing in Xylene (as above). The slide were then mounted in DPX 
mounting media (VWR, UK). Toluidine blue staining of slides was performed by Neil 
Macintyre (as above).  
 
7.2.2.2.3 Quantitative RT-PCR Analysis of Cartilage Differentiation 
 
Primer and probe designs for collagen type I and II were generously donated by Dr 
Dylan Clements. Sequence details were aare described in Table 7.4; 
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Table 7.4. Primer sequences and product information for collagen type I (Col1A2b) and II (Col2A1). 
 
Target Forward 5’-3’ Tm 
(°C) 






Col1A2b CTA TCA ATG GTG GTA CCC 
AGT TT 
 
59 TGT TTT GAG AGG CAT GGT 
TG 
59 111 40 
Col2A1 CTG GTG AAC CTG GAC GAG 
AG 
 
60 ACC ACG ATC ACC CTT GAC 
TC 
59 86 53 
 





7.2.2.2.3.1 cDNA synthesis 
 
RNA extracted from cartilage differentiation pellets was reverse transcribed as described 
in Chapter 2; Materials and Methods. 
 
7.2.2.2.3.2 PCR Master mix 
 
A master mix was prepared for the target genes and 18s rRNA are described in Tables 
7.5 and 7.6 below; 
 
Table 7.5. Target gene master mix for collagen typeI and II  
Master mix 1x (µL) (n x =number  of wells) 
Realtime Master mix 5 
10x Primer/Probe (FAM) 0.3 
 
 A master mix was also prepared for the 18s rRNA housekeeping control gene: 
 
Table 7.6. 18s rRNA control gene master mix 
Master mix 1x (µL) (n x =number of wells) 
Realtime Master mix 5 
20x 18s VIC Control 0.15 
Water 0.15 
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7.2.2.2.3.3 Primer Efficiency and Optimisation 
 
Real time plates and cover foils were ordered from Roche, UK. RNA was extracted from 
canine articular cartilage and 50 ng of total RNA was used for reverse transcription. 
Neat cDNA was serially diluted 1:5, 1:10, 1:50 and 1:100 and a plate plan was devised 
for primer pair optimisation (Figure 7.3).  
 
 
Figure 7.3. 96-well plate plan for collagen type I and II primer optimization. Wells were 
designed to allow for triplicates of articular cartil ge cDNA dilutions (1:5, 1:10, 1:50, 
1:100) run with primers for collagen type I (C1) and collage type II (C2). Triplicate 
wells of water negative controls were run for all primers, and –RT wells of articular 
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cartilage RNA were run with each primer. Primers for c llagen type I and II were bound 
to a FAM probe, and primers for 18s rRNA in-house gene positive control bound to a 
VIC probe.  
 
 5.3 µL of appropriate master mix (FAM - collagen I and II; VIC - 18s rRNA) and 4.7 
µL of appropriate cDNA dilution was added to each well. 4.7 µL of diluted sample RNA 
(-RT) or DEPC treated water was added to each control well. Wells were sealed shut 
using a foil and centrifuged at 1500g for 2 minutes to pool samples into base of wells. 
Plates were placed into the Roche Lightcycler 480 and run on a relative analysis 
programme (Table 7.7): 
 
Table 7.7. Programme data for Roche Lightcycler 480 
Programme Cycle Acquisition 
Pre-incubation 1 N 
Amplification 50 Quantify 
Cooling 1 N 
 
  
With individual cycles as described in Table 7.8: 
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Table 7.8. Temperature settings per cycle for Roche Lightcycler 480 
 Temperature °C Acquisition Hold (Time) Ramp 
Pre-Incubation 95 N 10 minutes 4.4 
Amplification (50x) 95 N 10 seconds 4.4 
 54 N 30 seconds 2.2 
 72 Single 1 second 4.4 
Cooling 40 N 10 seconds 1.5 
 
Data was exported to Microsoft® Excel and a primer efficiency curve was generated 
including an R2 value, which gave an indication of efficiency of reaction.  
 
7.2.2.2.3.4 Relative Gene Expression Analysis 
 
Following primer optimisation samples could be compared for relative expression of 
specific gene targets. A plate plan for relative expr ssion of collagen I and II is shown 
below (Figure 7.4): 
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Figure 7.4. 96-well plate plan for collagen type I and II gene expression analysis. Wells 
were designed to allow for triplicate technical replicates of sample cDNA dilutions with 
sample replicates run separately (1,2) for each time point (7, 14 and 21 days) for both 
differentiated (+) and undifferentiated (-) cells. Triplicate wells of Day 0 cDNA were 
run alongside with articular cartilage cDNA run as positive control. Primers for collagen 
type I and II were bound to a FAM probe, and primers for 18s rRNA positive control 
bound to a VIC probe.  
 
This plate design allows for comparison between day 0, 7, 14 and 21 differentiated and 
undifferentiated samples. Articular cartilage cDNA was added to allow for a reference 
control sample.  
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All negative controls were run on a separate plate, du  to plate space limitation, using 
the same master mix that was used for the sample plat thereby eliminating master mix 
error (Figure 7.5). 
 
 
Figure 7.5. Plate plan for negative control samples from MSC differentiation to 
cartilage. Water negative controls were run in triplicate, and –RT wells of each sample 
duplicate and articular cartilage control were run with each primer using the same master 




7.3.1 Canine Primary Cell Culture 
 
7.3.1.1 Canine Mesenchymal Stem Cell Behaviour in Culture 
 
Canine MSC behaviour in culture is discussed in Chapter 5; Canine Mesenchymal Stem 
Cells and the Cardiovascular System 
 
7.3.1.2 Canine Chondrocyte Behaviour in Culture 
 
Canine chondrocytes adhered to fibronectin coated tissue culture flasks readily, and cell 
replication was rapid. An adherent monolayer of cells morphologically similar to 
fibroblasts cells grew rapidly, and required passage by 1 week post harvest (Figure 7.6).  
 293 
 
Figure 7.6. Canine chondrocytes in culture. Morphologically chondrocytes assumed a 
fibroblast-type morphology. Magnification x 100 (left) and x 200 (right).   
 
At passage the trypsinised cells assumed a spherical morphology, which subjectively 
appeared green in colour. Following cell removal from the flask obvious cell secretions 
were present on the bare tissue culture plastic surface, suggestive of cellular secretion 
(Figure 7.7). Chondrocytes were readily passaged and adhered to new tissue culture 
flasks within 24 hours. 
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Figure 7.7. Chondrocyte secretions. Following passage adherent secretions could be seen 
attached to the base of the flask. Magnification x 400 (left) and x 200 (right). 
 
7.3.1.3 Canine Fibroblast Behaviour in Culture 
 
Canine dermal fibroblasts grew out from skin explants i  small patches. Explants were 
removed from culture after 1 week, following which dramatic cell replication occurred. 
The majority of the cells appeared morphologically like fibroblasts, with adherent, 
flattened elongated cells which were distinct from canine chondrocytes (Figure 7.8). 
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Figure 7.8 Canine dermal fibroblasts in culture. Morphologically dermal fibroblasts 
were adherent spindle shaped cells with long projecti ns contacting other cells. 
Magnification x 100 (left) and x 200 (right).   
 
However there was some heterogeneity in cell morphology, with some spheroid cells 
suggestive of adipocytes (Figure 7.9) 
 
Figure 7.9. Mixed population of cells from skin explant culture. Following skin explant 
culture a mixed population of cells was present, wih spherical globular cells similar to 
adipocytes surrounded by fibroblast like cells. Magnification x 100 (left) and x 200 
(right).   
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7.3.2 Canine Mesenchymal Stem Cell to Cartilage Dif ferentiation  
 
7.3.2.1 Cartilage Differentiation using Matrigel 
 
A differentiation experiment for MSCs was devised using the semi-solid growth 
substrate matrigel in differentiation media. Control wells were run using MSCs in 
standard MSC media, and chondrocytes as a positive control and dermal fibroblasts as a 
negative control. All three cell types were harvested from two dogs, however only cells 
from one dog became ready for experimentation at the same time. Cells were mixed into 
matrigel and plated up as described in materials and methods above. 24 hours after 
plating cells could be seen within the matrigel for all cell types and by 3 days post set-up 
MSCs, chondrocytes and fibroblasts all looked morphlogically similar. At day 7 the 
first harvest of cells was performed using matrigel c ll recovery solution. Following 
harvest no cell pellets could be seen in individual Falcon tubes, and therefore triplicates 
were pooled before a final centrifuge. However no cell pellet was present again, and 
therefore Falcon tubes discarded. Before day 14 harvest there was fungal contamination 
within the wells of the 48 well plate. The experiment was therefore abandoned due to 
technical difficulty.  
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7.3.2.2 Cartilage Differentiation using 3D Pellet Culture 
 
2 x 105 canine MSCs were placed into Falcon tubes and centrifuged to form pellet 
cultures. 24 hours following initiation spheroid pellets of approximately 0.5 mm were 
present in all differentiated and control Falcon tubes. Pellets remained present 
throughout the entirety of the experiment, however p llets cultured in standard MSC 
media tended to be less regular in shape, and showed some areas of cell breakaway and 
some cell growth present on the inner surface of the Falcon tube. Pellets grown in 
differentiated media appeared to shrink or contract and stayed spherical. At each time 
point pellets were taken for histological studies, and were used for RNA extraction. It 
was noted that over time the pellets in differentiation media became very hard, and were 
therefore difficult to break up to allow RNA extraction from cells. Those in standard 
MSC media were easily broken down and RNA extraction was therefore easier. This 
was reflected in total RNA extracted, with low levels of total RNA from pellets in 
differentiation media, particularly at later time points. Due to this difficulty in RNA 
extraction a repeat experiment was performed using 5 x 106 MSCs in the original start 




7.3.2.2.1 Quantitative RT-PCR Analysis of Cartilage Differentiation 
 
7.3.2.2.1.1 Primer Optimisation 
 
Primers for collagen Type I and II were optimized using RNA extracted from canine 
articular cartilage. R2 values were calculated for both primer sets and 18s rRNA in house  







Figure 7.10. Primer optimization graph demonstrating R2 values for collagen type I and 
II primers and their corresponding 18s rRNA primers using canine articular cartilage 
cDNA. 
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7.3.2.2.1.2 Relative Analysis of Collagen type I and II Expression 
 
Following primer optimization relative expression of collagen type I and II was 
examined in two dogs using canine articular cartilage s a reference gene. For final data 
analysis sample duplicates and technical replicates were combined for each dog (Figures 





Figure 7.11. Quantitative RT-PCR analysis of marker expression showing fold change compared to articular cartilage of collagen 








Figure 7.12. Quantitative RT-PCR analysis of marker expression showing fold change compared to articular cartilage of collagen 







In both dog A and B collagen type I expression was decreased approximately 50-60% in 
all samples compared to day 0 MSCs. Levels of collagen type I varied little across 
differentiated and undifferentiated samples across all time points. Dog A expression of 
collagen type II increased approximately 6 fold between day 0 and day 7 in 
differentiated pellets. In the undifferentiated pellets collagen type II remained at day 0 
levels. At day 14 differentiated pellets increased expression to 8 fold that of day 0, 
which then returned back to 7 fold by day 21. In undifferentiated pellets of dog A 
collagen type II expression decreased to half that of day 0 levels at day 14 and returned 
to day 0 levels by day 21. Dog B increased expression of collagen type II by 5 fold at 
day 7, to 8 fold at day 14 and approximately 10 fold f day 0 levels in differentiated 
pellets. In undifferentiated pellets collagen type II increased 2 fold at all time points 
compared to day 0.  
 
Pellet differentiation was repeated using an increase in MSC cell number at initiation. 
RNA was extracted and reverse transcribed and quantitative PCR performed as 
previously described (Figure 7.13). A small improvement was seen in total RNA 
extracted, allowing for 125 ng of total RNA to be used in reverse transcription to 




Figure 7.13. Quantitative RT-PCR demonstrating relative collagen expression in pellets with increased tarting cell number from 





Collagen type I expression appeared similar to that seen previously. Expression 
decreased in all samples by approximately 60% when compared to day 0. However 
Collagen type II expression demonstrated less comparable findings. Day 7 differentiated 
pellets increased expression 2 fold compared to day 0, whereas day 7 undifferentiated 
pellets increased 20 fold. From day 14 expression patterns returned to those seen 
previously with day 14 differentiated pellets demonstrating a 12 fold increase in 
expression compared to day 0, which increased to a 19 fold increase at day 21. In the 
undifferentiated pellets there was an increase to 5f ld and 7 fold at day 14 and 21 
respectively when compared to day 0.  
  
7.3.2.2.2 Immunohistochemistry for Collagen Type II Expression 
 
Cell pellets were examined for protein expression of c llagen type II following 
differentiation. Initially positive and negative controls were performed using canine 
articular cartilage sections to optimize antibody dilutions (Figure 7.14). 
 
Following optimization sections of differentiated and undifferentiated pellets were 
stained for collagen type II expression. Expression was seen extracellularly as would be 
expected and was seen in a diffuse pattern in differentiated pellets when compared to 




Figure 7.14. Collagen type II labelling of canine articular cartilage sections for antibody optimisation. Positive control (left) and 






Figure 7.15. Collagen type II expression in differentiated (A and C) and undifferentiated 
pellets (B and D) with a more diffuse staining seen in differentiated pellets. 
Magnification x 200 A and B, x 400 C and D.  
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7.3.2.2.3 Immunohistochemistry for SOX9 Expression 
 
Cell pellets were further examined for the expression of SOX9, a nuclear chondrocyte 
marker. Initially positive and negative controls were performed using canine articular 
tissue which demonstrated nuclear staining corresponding to SOX9 (Figure 7.16). 
 
Following optimization differentiated and undifferentiated pellets were examined for 
expression of SOX9. A higher proportion of positive staining nuclei were seen in 
differentiated pellets when compared to undifferentiated and positive nuclei appeared 





Figure 7.16. Nuclear SOX9 staining (black arrows) of canine articular cartilage sections for antibody optimisation. Positive 








Figure 7.17. SOX9 expression in differentiated (A and C) and undifferentiated pellets (B 
and D) with nuclear staining seen in differentiated p llets. Magnification x 200 A and B, 
x 400 C and D. 
 
7.3.2.2.4 Toluidine Blue Staining for Proteoglycan Matrices 
 
Pellets were examined for toluidine blue which labes proteoglycan matrix. A steady 
increase in the uptake of toluidine blue was seen in differentiated pellets over time, 





Figure 7.18. Toluidine blue staining of cartilage differentiation pellets. Pellets were 
examined for toluidine blue labeling at days 7, 14 and 21 for both differentiated and 




Following standardized MSC isolation described in the literature MSCs should be 
capable of differentiation into adipocyte, osteoblast nd chondrocyte lineages. Canine 
MSCs have previously been shown to be capable of differentiation into different 
mesodermal cell types (Kadiyala et al., 1997, Csaki et al., 2009) and we aimed to 
demonstrate the ability of our isolated canine MSC population to differentiate into 
cartilage. 
 
7.4.1 Isolation and Culture of Canine Chondrocytes and Dermal 
Fibroblasts 
 
Canine chondrocytes were easily cultured from isolated articular cartilage sections. 
These primary cells readily grew in culture and upon monolayer adherence lost their 
spherical shape and assumed a more fibroblast like morphology which may be 
suggestive of a switch from the articular type chondr cyte to a more fibrochondrocyte 
type which has been previously described (Benya et l., 1978, Stokes et al., 2002). 
Interestingly, evidence of extracellular matrix secretions were present on the surface of 
the flask during cell passage. This was a strong indicator of active chondrocyte presence, 
however given the morphological appearance of the chondrocytes in monolayer culture 
it would be likely that this secretion was predominantly collagen type I, plus 
extracellular matrix proteins (von der Mark et al.,1977, Kuettner et al., 1982). 
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Dermal fibroblasts were cultured as a negative control cell line for differentiation 
experiments. Following explant culture, cells of fibroblast morphology grew and 
replicated steadily. A mixed population of cells was present, with a predominant 
fibroblast phenotype and the indication of some adipocyte contamination. This is a 
common and likely occurrence with any primary sourced ell but must be taken into 
account when culturing cells for a particular cell type.  
 
7.4.2 Are Canine Mesenchymal Stem Cells Capable of Cartilage 
Differentiation?  
 
7.4.2.1 Differentiation of Canine Mesenchymal Stem Cells using Matrigel 
 
It is known that chondrocytes in monolayer culture de-differentiate into 
fibrochondrocytes as previously mentioned. It is believ d that chondrocytes cultured in 
suspension limits de-differentiation and therefore we aimed to differentiate canine MSCs 
within a semi-solid culture media using matrigel (Guo et al., 1989, Hauselmann et al., 
1994). We cultured autologous chondrocytes and fibroblasts alongside to act as positive 
and negative controls respectively. However this experiment suffered two major 
setbacks. Firstly, to achieve semi-solid matrigel it must be used in a near undiluted form 
and this limited the amount of matrigel available (due to expense) and the experiment 
was designed to allow for this, leading to use of a 48-well plate and therefore low cell 
numbers. Wells were run in triplicate to try and allow for any inter-well variation and 
also to allow end point pooling if required. However, at first harvest no cells were seen 
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following pelleting and pooling using the cell recovery system. The aim had been to 
continue the experiment, and try harvesting cells again to obtain day 14 and 21 harvests, 
with the expectation that cell numbers would be higher given that replication would have 
occurred. However between day 7 and 14 we had a second setback where the plate 
became contaminated with fungus and the experiment was abandoned.  
 
7.4.2.2 Differentiation of Canine Mesenchymal Stem Cells using 3D Pellet 
Culture 
 
Using previously published pellet 3-dimensional culture and differentiation media (Yoo 
et al., 1998, Pittenger et al., 1999, Suzdal'tseva et al., 2007) we demonstrated that canine 
MSCs could be successfully differentiated into articular type cartilage. A steady increase 
in the articular related collagen type II over the t ree weeks of differentiation with a 
decrease in the more fibrous collagen type I expression was seen in differentiated canine 
pellets. Furthermore staining for SOX9 (a definitive chondrocyte nuclear marker) was 
increased and there was evidence of increased extrac llul r matrix secretions in the 
differentiated pellets compared to controls. This work compares favourably with 
previous work performed in both mouse and human MSCs where collagen type II was 
seen to increase, and collagen type I decrease following chondrogenic differentiation. 
(Lisignoli et al., 2005). Further research is required to elucidate the mechanisms behind 
cartilage differentiation and to optimize cell number. Published literature inputs 2 x 105 
MSCs as a starting population (Yoo et al., 1998, Dennis et al., 2002) however this cell 
number is very small, leading to very small pellets and technical difficulties in RNA 
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extraction. When this cell number was raised a more irr gular collagen type II 
expression increase was seen in differentiated cells l ading to the conclusion that 
optimal cell number for successful differentiation is very small and this would be a 




This data demonstrates successful cartilage differentiation of primary sourced canine 
MSC, and furthermore that differentiation was selectiv ly toward articular cartilage. 
This may have key significance in the future applications of MSCs for the study of 
canine orthopaedic disease in vitro. The use of MSCs in rebuilding damaged cartilage in 
osteoarthritis and articular defects will need to be optimized to allow for increase in cell 
number and to specifically analyse cartilage type wh n starting cell numbers are higher. 
The differentiation of MSCs using scaffolds is an exciting future area of research and 
may allow for more clinical applications of MSCs. Furthermore, investigation into the 
paracrine effects of MSCs (as discussed in Chapter 5 fo  cardiac disease) in joint disease 
is a developing area and may produce novel anti-inflammatory therapeutics. 
 317 
CHAPTER 8  
Fii nall  Dii scussii on 
 
This thesis set out to answer several questions regarding adult stem cells in the dog. 
Adult stem cells are a readily accessible potential source of multipotent cells, which 
bypass the technical and ethical issues surrounding canine ES cells, and are also 
considered safer in terms of therapeutic applications.  Answers to the questions posed 
will have direct relevance to the field of stem cells and in particular veterinary disease 
study and therapeutics. 
 
8.1 Can Adult Stem Cells be Isolated from the Dog? 
 
We demonstrated successful isolation and culture of CSCs and MSCs from the heart and 
bone marrow respectively. The techniques used to obain and grow these cells were 
based upon published literature for both the human and mouse, and we found that canine 
cells behaved similarly and particularly closely to human adult stem cells.  
 
8.1.1 Cardiac Stem Cells 
 
Canine CSCs have rarely been described (Linke et al., 2005, Bartosh et al., 2008) and 
we therefore undertook extensive characterisation of this isolated cell population. CSCs 
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could be harvested from the same explant tissue over several weeks based upon a 
technique described by Messina et al (Messina et al., 2004); typically 3-4 harvests could 
be taken before explants had to be discarded. We found that CSCs were able to grow in 
harsh serum free conditions, forming cardiospheres as described in the literature. 
Furthermore we found them capable of clonal expansion indicating their self-replication 
ability. CSCs were never obtained in significant numbers. Although multiple harvests 
could be taken from an explant and CSCs did replicate in culture as demonstrated using 
clonal expansion and sphere formation, they were a technically demanding cell 
population to work with. Furthermore they could not be frozen down; all attempts to do 
this resulted in dying cells upon re-plating. This meant that isolation of CSCs was totally 
reliant on fresh explant tissue, which was occasionally difficult to obtain and will 
therefore be a limitation of use of these cells in the future.  
 
CSCs expressed key markers indicative of a cardiac progenitor line, such as c-Kit, 
GATA 4 and Flk-1 and were negative for cardiac lineag  markers. As discussed in this 
thesis, there is a belief that multiple stem cell populations reside within the adult heart 
defined by developmental markers such as islet 1, Nkx2.5 and Flk-1. We were unable to 
isolate an islet 1 positive cell line consistently, and this is an area of future research. 
Isolation of islet 1 populations has been performed in rodent models using cre-lox 
technology which enabled isolation of living cells which could then be used for 
downstream applications (Laugwitz et al., 2005). This is obviously not possible yet in 
the canine, and therefore novel techniques will need to be devised. Initially a study to 
examine presence and location of islet 1 in the myocardium should be performed, using 
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cardiac sections and techniques such as immunohistoc emistry or in situ hybridisation. 
This would be a laborious and time consuming project given the likelihood of low islet 1 
positive cell numbers, but would be rewarding should the data indicate a region of the 
heart where islet 1 cells predominate. In this project CSCs were found to be isolated in 
higher number from atrial explants than ventricular, and therefore early in the project a 
decision was made to work solely with atrial explants for CSC isolation. This subjective 
observation may have in fact been due to stem cell niche locations as discussed 
previously (Urbanek et al., 2006), but it must be acknowledged that this may have 
skewed the CSC population we isolated and experimented with.   
 
8.1.2 Mesenchymal Stem Cells 
 
Canine MSCs have been described in more detail than CSCs in the literature, however 
we still undertook extensive characterisation of our cells and again found that they 
compared favourably with human MSCs (Dominici et al., 2006). Canine MSCs were 
CD44 and STRO-1 positive, negative for CD45 and predominantly negative for CD34. 
They were readily isolated from the bone marrow using Ficoll separation, and were 
obtained in high number. Canine MSCs adhered naturally to tissue culture plastic flasks 
allowing for contaminating haematopoitic cells and debris to be removed using media 
washes. The cells replicated rapidly, and could be harvested and frozen down and used 
for later experiments. This meant that canine MSCs were easily expanded and multiple 
experiments could be performed using cells from the same dog if required. Canine 
MSCs did however senesce between passage 4-6, with significant slowing of cellular 
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replication and alteration of morphology with increas d size. No late passage cells were 
used for experiments, and this senescence compared f vourably with primary human 
MSCs (Banfi et al., 2000, Sekiya et al., 2002). However, this behaviour does bring into 
question the stem-like properties of canine and human MSCs, and whether ‘stemness’ is 
lost over time in culture. The long term culture characteristics and marker expression of 
canine MSCs were not analysed in this thesis, and would be something worthy of 
investigation. Based upon that, further research to prolong the replicative capacity and 
maintain primary MSC expression profiles would be us f l.  
 
Using Ficoll separation and tissue culture plastic adherence allows for a more 
heterogeneous MSC population to be isolated initially. We acknowledge this, and 
allowed for it to occur to therefore not select against a population of cells which may in 
fact be more stem-like than another. It is likely that several different MSC populations 
reside within the bone marrow, each with their own characteristics and differentiation 
potential and future work could investigate cell sorting for isolation of individual MSC 
populations and analysis of their characteristics. Magnetic Activated Cell Sorting 
(MACS®) and Fluorescent Activated Cell Sorting (FACS) would be ideal techniques to 
do this, but would rely upon cell surface markers for sorting. Care must be taken when 
performing these experiments due to marker expression changes during cell isolation 
and processing; for instance certain cell surface receptor epitopes may be blocked by 
proteins when in serum which could skew results and ffect sorting efficiency. MACS 
and FACS are also reliant upon antibody selection, and as discussed in this thesis dog 
specific antibodies are rare and therefore specificity must be validated.  
 321 
 
Alternative MSCs populations were demonstrated in th s hesis by the discovery of a 
CD34 positive MSC population from the canine bone marrow. Up until that point all 
MSCs had been CD34 negative, which corresponded to standard MSC characterisation 
profiles. CD34 is a cell surface adhesion marker, but can also be used to indicate 
haematopoietic lineages (Nielsen and McNagny, 2008). Given these CD34 positive cells 
were CD45 negative it may indicate an MSC population with both mesodermal and 
haematopoietic differentiation potential. These cells were discovered late on in the 
project, and therefore time did not allow for extensive work upon them. However, this is 
certainly an area for future research, either with the specific cells isolated (which have 
been frozen down as stocks) or by selecting for CD34 from the original bone marrow 
harvest.  
 
8.1.3 VEGF Splice Variation in Stem Cell Populations 
 
VEGF gene expression was seen with a multiple banding pattern representing splice 
variation. This difference in banding is representative of the production of the different 
VEGF isoforms, and as discussed these isoforms are known to have different functions 
(Poltorak et al., 1997). Interestingly both MSCs and CSCs had the same banding pattern, 
which may indicate that this pattern is stem cell specific. Furthermore, this pattern was 
different to that seen with differentiated tissues such as the whole heart tissue used as a 
control sample. The relevance of the banding pattern and the role of the individual 
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isoforms in stem cells and somatic tissues in the dog is an area which will need further 
investigation.  
 
8.2 Can Canine Adult Stem Cells be Differentiated T oward Somatic Cells? 
 
8.2.1 Cardiac Directed Differentiation 
 
This project focussed heavily upon cardiac aspects of adult stem cells due to the need for 
more veterinary research in this area. We therefore t ok both CSCs and MSCs and 
differentiated them toward cardiac lineages using techniques described in the literature 
(Oh et al., 2003, Kruglyakov et al., 2006, Smits et al., 2009b).  
 
CSCs appeared to differentiate toward a cardiomyocyte lineage, with upregulation of the 
cardiac specific transcription factor Nkx2.5 and the cardiac functional gene CTT. We 
defined this differentiation as partial. No other cardiomyocyte specific markers were 
upregulated such as CTI, the ryanodine receptor and the β1-adrenergic receptor. 
Furthermore no evidence of spontaneous rhythmical beating was seen. This was 
frustrating, and further work will need to be performed to improve on the current 
differentiation techniques. Co-culture with RNCM may be a valid option, and one we 
investigated as a possibility. However, due to the technical difficulties in obtaining 
CSCs in terms of timing, it was difficult to obtain RNCM at the precise time CSCs were 
ready for harvest. Also this technique would require direct co-culture which would 
therefore make analysis more challenging, although not impossible; for instance, 
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RT-PCR primers could be designed specifically for the canine, thereby not picking up 
rat transcript, and translational analysis such IFA could use antibodies specific for 
canine protein. Should techniques to isolate specific ardiac progenitor populations be 
developed as discussed above, it would be interesting to repeat cardiac differentiation 
with the individual progenitor cell types to see if more efficient differentiation occurs 
with one particular line more than another.  
 
Canine MSCs showed no evidence of cardiac directed differentiation, even when using 
techniques claiming successful differentiation in the literature. MSCs are from the 
mesodermal lineage, as are cardiomyocytes, and therefor  it was hypothesised that there 
is an inherent nature of MSCs to move toward cardiac lineages. Minor morphological 
changes were seen in differentiated cells, with suggestion of lining up. We propose that 
this may indicate some level of cellular organisation, however no evidence in terms of 
marker expression supports this and therefore this result is subjective. Nkx2.5 expression 
was seen to increase, similar to the CSCs but this marker in isolation cannot be used to 
determine cardiac differentiation. The combination f morphological changes and 
increase in Nkx2.5 may indicate a very early stage of differentiation, and may warrant 
the investigation of improving the current differentiation techniques.  
 
Flk-1 expression was seen to decrease in CSCs and increase in MSCs following cardiac 
differentiation. Flk-1 is both a cardiac developmental marker, and also an endothelial 
marker due to its nature as a VEGF receptor. This difference in Flk-1 expression may 
represent a movement away from endothelial lineages when reduced, and vice versa. It 
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would be interesting to follow this result up further, and examine whether MSCs are in 
fact moving toward a cardiac endothelial lineage rather than cardiomyocyte as we have 
proposed for CSCs.  
 
8.2.2 Cartilage Directed Differentiation 
 
Canine MSCs were differentiated toward cartilage based upon the literature stating that 
MSCs should be capable of multiple connective tissue type differentiation (Dominici et 
al., 2006). Canine MSCs were found to differentiate to articular type cartilage, using 
standard techniques, thereby validating that we were isolating the correct cellular 
population from the bone marrow. This positive result is exciting for future orthopaedic 
applications of MSCs and could be used for the development of in vitro disease 
modelling. However, we found that very small cell numbers were optimum for 
differentiation to succeed and therefore investigations into maximising cell number 
needs to be performed to allow for further downstream applications and even clinical 
applications. An interesting area of research is the development of scaffolds for cartilage 
differentiation, particularly those which can be used therapeutically and the investigation 
of our canine MSC populations and their differentiation capability on these scaffolds 
would be worthwhile.  
 
 325 
8.3 Do Rodent Models Compare Favourably with the Do g? 
 
Due to the poor cardiac directed differentiation of canine MSCs and given that the 
literature claiming successful differentiation was based upon rodent models (Makino et 
al., 1999, Fukuda, 2001, Kruglyakov et al., 2006), it was deemed worthwhile to purchase 
murine MSCs to run alongside the dog cells as a positive control. We designed mouse 
specific primers, and analysed the cells extensively for our full panel of MSC and 
cardiac markers. At initial characterisation mouse and canine MSCs appeared 
morphologically similar. However striking differences appeared between culture 
behaviour and marker expression, with murine MSCs capable of long term passage and 
expressing several cardiac lineage markers such as CTT, CTI and the ryanodine 
receptor. This immediately brought into question the similarities between canine and 
murine MSCs. Furthermore, differences in marker expr ssion seen during cardiac 
differentiation appeared to be explained by time in culture alone. Based upon that, we 
analysed early and late passage mouse MSCs for our marker panel and found an increase 
in the expression of the cardiac markers CTT, CTI, islet 1 and GATA 4 and a 
downregulation of SMA. These results taken in isolati n could infer cardiac 
differentiation, however no significant morphological changes or rhythmical beating 
were observed, therefore cardiac differentiation is unlikely to have occurred. It may be 
that the expression of these markers indicates a pre-determined cardiac lineage potential 
which is greater than that of the canine MSCs. However techniques to improve 
differentiation need to optimised and the results seen here reiterate the importance of 
extensive baseline analysis of cells prior to differentiation.  
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8.4 Does Stem Cell Co-Culture Influence Cellular Ex pression? 
 
We devised a novel indirect co-culture experiment between autologous CSCs and MSCs 
to investigate the role of released factors upon each cell population. The paracrine 
effects of stem cells, and in particular MSCs is an exciting new area of research, and 
investigates whether adult stem cells may be useful not only for cellular replacement and 
in vitro studies but also for their released factors modulating tissue environments.  The 
co-culture experiment was technically challenging due to the need for both CSCs and 
MSCs to be ready for experimentation at the same tiwhen harvested from the same 
dog. We ensured no cellular crossover could occur by using small diameter transwell 
inserts, and analysed marker expression from both cell populations. Interestingly the 
CSCs appeared to show a morphological change toward an endothelial cobblestone 
appearance, which was combined with an apparent increase in Flk-1 and vWF 
expression. This may imply that MSCs release factors which direct CSCs toward the 
endothelial lineage and not toward the cardiomyocyte. In the reverse experiment there 
was no significant alteration in MSC expression toward any of the cardiac lineages. The 
affect of the MSCs upon the CSCs will need to be investigated further, in particular 
protein analysis of soluble released factors in the media and their function. 
 
During the co-culture experiment we discovered the canine CD34 positive MSC line.  
CD34 was seen to switch off in MSCs co-cultured with CSCs. The cells in the 
co-cultured wells peeled off into 3D pellets at early stages, which was not seen in 
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control wells even though cell numbers where the same t input. CD34 is a cell adhesion 
molecule, so the downregulation of this marker may h ve triggered the cellular release 
from the base of the well thus forming the free floating pellet. Furthermore CD34 in 
mice has been found important for angiogenesis althoug  the importance of that here is 
unknown. The results do suggest that CD34 was downregulated in response to the 
co-culture environment with CSCs and this interesting finding is an area of future 
research, again looking at the soluble released factors from CSCs and relevance of both 




This thesis demonstrates the isolation and characterisa ion of two adult stem cell sources 
from the dog. These cells conformed to stem cell criteria and were capable of 
differentiation along different routes and offer a potential new source of cells to study 
veterinary diseases in vitro. The results obtained have answered the initial questions 
posed, and several others which became evident during the research. The results have 
also led to the development of new questions which will require future investigations 
and the beginning of new projects. The field of stem cell research is constantly 
developing and evolving, and the hope is that the data produced here will contribute to 
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Cardiac disease is one of the most significant causes of morbidity and mortality in dogs, 
cats and humans. Until relatively recently the heart was considered a terminally 
differentiated organ, however it is now thought that t e heart has a resident population of 
adult stem cells (ASCs) which may be capable of some degree of self-repair. 
ASCs are capable of multipotent differentiation, and are lower in the stem hierarchy.  
They have been isolated from several organ systems, and described in multiple species. 
The dog may act as a large animal disease model, and is also a clinical subject in its own 
right. Development of organ specific stem cell culture may act as an animal sparing 
procedure for pharmaceutical testing. Therefore we have aimed to isolate and 
characterise adult stem cells from the dog.  
Materials and Methods 
Atrial cardiac explants and bone marrow aspirates wre taken from dogs post mortem 
and cultured using previously published techniques. Putative stem cell harvests were 
collected from these tissues, and cardiac lineage directed differentiation was performed. 
Gene expression profiles of stem cell markers, mid-differentiation markers and cardiac 
differentiated markers were investigated at both the RNA and protein level to determine 
outcome of the differentiation procedure. 
Results 
Phase bright cells isolated from cardiac explants demonstrated similar behaviour to those 
described in the literature for cardiac stem cell populations. These cells were able to 
survive successive passages in serum free media and often formed large spherical cell 
clusters, termed ‘cardiospheres’. These cells were capable of clonal expansion under 
controlled culture conditions, demonstrating their ability for self-renewal. Cells cultured 
from the bone marrow behaved typically as mesenchymal stem cells, and following 
cardiac differentiation appeared morphologically altered, with cells forming alignments 
when compared to controls.  
Conclusions 
Our results suggest that it is possible to isolate adult stem cells in the dog from both the 
mesenchyme and the heart itself. These cells are capable of clonal expansion, and 
directed differentiation. The combination of clonal expansion and gene expression 
profiles supports and justifies further characterisation of these cell populations. 
Characterisation of these cells is crucial in furthe ing our understanding of their biology 
and potential; adult stem cells have provided great hope in the development of 
regenerative medicine and tissue engineering. 
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Canine adult stem cells as a model for human cardia c stem cell research 
 
 
Problem : Cardiac disease is a significant cause of morbidity and mortality in humans 
and dogs. Although rodent modelling systems allow fr cost effective and rapid analysis 
the results obtained rarely directly translate into human disease systems. Larger animal 
models are required to study cardiac stem cell biology. 
 
Background : The dog is a species which develops naturally occurring cardiac disease; 
including clinical syndromes seen in humans. Moreover the pet dog is a close human 
companion, and therefore shares common environmental fac ors of disease.  
 
Hypothesis : Adult stem cells have been isolated from the heart in both mice and 
humans, which have been found to be multipotent and clonogenic. We propose that the 
dog also has a resident cardiac stem cell population, which can be isolated, characterized 
in terms of marker expression profiles and behaviour following cardiac directed 
differentiation allowing direct comparisons with human cardiac stem cell populations.    
 
Research : Using published techniques, atrial cardiac explants were taken from dogs 
post-mortem and cultured to isolate putative adult stem cells. These cells were 
characterized using an extended panel of markers, and compared to those expressed in 
human populations. The canine cells were subsequently placed into cardiac lineage 
differentiation protocols, and the expression profiles analyzed.  
 
Observations : Following isolation from cardiac explants, large round phase bright 
cells were harvested and placed into stem cell culture. These cells were able to survive 
successive passages in serum free media and formed larg  spherical cell clusters, termed 
‘cardiospheres’. These cells were capable of clonal expansion under controlled culture 
conditions, demonstrating their ability for self-renewal. Characterization of marker 
profiles demonstrated c-kit, GATA 4 and flk-1 positive cells which were Nkx2.5 and 
cardiac lineage marker negative. Following cardiac directed differentiation marker 
profiles altered with upregulation of cardiac troponin T and Nkx2.5 and a down-
regulation of c-kit and endothelial lineage markers.   
 
Conclusions : From our observations we have found a cell population hat can be 
isolated from the canine heart and which behaves similarly to previously described 
human cardiac stem cells. Furthermore, we have demonstrated a change in marker 
expression consistent with cardiac directed differentiation. Further work will target 
isolating and characterising further adult stem cell populations from the dog, and 
exploring their differentiation potential. We conclude that canine adult stem cells are 
directly comparable to human stem cells, and are therefore an appropriate large animal 
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